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Abstract 
Efavirenz is an antiretroviral drug used in the treatment of HIV-positive patients as part of first 
line triple-highly active antiretroviral therapy. Treatment response varies among individuals and 
adverse drug reactions tend to occur, as a result of the variation in the rate of efavirenz 
metabolism among individuals. This is partly caused by genetic variation; therefore the study of 
genes involved in the metabolism of efavirenz, such as CYP2B6, could potentially enhance 
treatment success. The effect of CYP2B6 SNP 516G>T (part of the CYP2B6*6 allele) is 
particularly important, as individuals homozygous for the minor allele of this SNP have 
significantly increased efavirenz levels. Furthermore, nuclear receptors, specifically constitutive 
androstane receptor, encoded by NR1I3, and pregnane X receptor, encoded by NR1I2, are 
involved in the regulation of the genes responsible for efavirenz metabolism and could therefore 
indirectly influence the pharmacokinetics of efavirenz.  
 
The current study identified variants in the NR1I3 and NR1I2 genes through in silico analysis, bi-
directional sequencing and literature searches. A total of nine NR1I3 and ten NR1I2 target 
variants were subsequently genotyped in 132 HIV-positive female patients from the Xhosa and 
Cape Mixed Ancestry populations. The resulting genotype and allele frequencies were 
statistically analysed to search for correlations between genetic variations and available efavirenz 
levels in hair samples, treatment outcome as measured by viral load, and the occurrence of 
adverse drug reactions. The minor allele of a NR1I2 5’-upstream SNP, rs1523128 (6334A>G), 
was significantly associated with decreased efavirenz levels. From analysis of the effect of 
composite SNPs, NR1I3 5’-upstream SNP rs55802895 (258G>A) in conjunction with 
CYP2B6*6, was significantly associated with efavirenz-levels. It was found that the minor allele 
of rs55802895 inhibited the effect of CYP2B6*6, resulting in normal efavirenz levels for 
individuals homozygous for the minor allele of both SNPs. Additionally, when the target NR1I3 
and NR1I2 variants were analysed in conjunction with six SNPs from CYP1A2, CYP2A6, 
CYP3A4 and CYP3A5, 11 compound genotypes were shown to be statistically associated with 
mean EFV plasma levels. The study emphasises the complexity of efavirenz metabolism, and the 
importance of transcriptional regulation in xenobiotic metabolism. 
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Opsomming 
Efavirenz is ‘n antiretrovirale middel wat gebruik word in die behandeling van HIV-positiewe 
pasiënte as deel van drievoudige hoogs-aktiewe antiretrovirale terapie. Reaksie op behandeling 
verskil tussen individue en nadelige newe-effekte, wat veroorsaak word deur die verskil in tempo 
waarteen efavirenz gemetaboliseer word, neig om voor te kom. Hierdie verskille word gedeeltelik 
veroorsaak deur genetiese variasie; dus kan die studie van gene betrokke by die metabolisme van 
efavirenz, soos CYP2B6, moontlik die sukses van behandeling verhoog. Die effek van CYP2B6 
SNP 516G>T (deel van die CYP2B6*6-alleel) is veral belangrik, want individue wat 
homosigoties is vir die minderheids-alleel het betekenisvol hoë efavirenz-vlakke. Nukleêre 
reseptore, spesifiek konstitutiewe androstane reseptor, deur NR1I3 gekodeer, en pregnane X 
reseptor, deur NR1I2 gekodeer, is betrokke by die regulering van die gene verantwoordelik vir 
efavirenz-metabolisme en kan dus die farmakokinetika van efavirenz beïnvloed. 
 
Die huidige studie het variante in NR1I3 en NR1I2 identifiseer deur in silico-analise, bi-
direksionele volgordebepaling en ’n literatuurstudie. Nege NR1I3 en tien NR1I2-variante in totaal 
is vervolglik gegenotipeer in 132 HIV-positiewe vroulike pasiënte van Xhosa en Kaapse 
Gemengde Afkoms populasies. Die gevolglike genotipe- en alleelfrekwensies is statisties 
geanaliseer om vir korrelasies tussen genetiese variasies en beskikbare efavirenz-vlakke in 
haarmonsters, uitkoms van behandeling gemeet in virale lading en die voorkoms van nadelige 
newe-effekte te soek. Daar is gevind dat die minderheids-alleel van ’n NR1I2 5’-stroomop SNP, 
rs1523128 (6334A>G), betekenisvol geassosieer is met ’n daling in efavirenz-vlakke. Vanuit die 
saamgestelde SNPs, is die NR1I3 5’-stroomop SNP rs55802895 (258G>A), tesame met 
CYP2B6*6, betekenisvol geassosieer met efavirenz-vlakke. Daar is gevind dat die minderheids-
alleel van rs55802895 die effek van CYP2B6*6 demp, en gevolglik normale efavirenz-vlakke in 
individue homosigoties vir die minderheids-allele van albei SNPs veroorsaak. Addisioneel is die 
teiken NR1I3 en NR1I2 variante gemeenskaplik met ses SNPs van CYP1A2, CYP2A6, CYP3A4 
en CYP3A5 geanaliseer en 11 gekombineerde genotipes is statisties geassosieer met gemiddelde 
EFV plasma vlakke. Hierdie studie beklemtoon die kompleksiteit van efavirenz-metabolisme en 
die belangrikheid van transkripsionele regulering in xenobiotiese metabolisme. 
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CHAPTER 1  Introduction 
1 
 
CHAPTER 1 
1. Introduction 
Access to antiretroviral therapy (ART) has vastly improved over a period of ten years. ART is 
now accessible to an increased number of people in 2014 (12.9 million) compared to 2003 
(400,000) (World Health Organization, 2004; World Health Organization, 2014). This has greatly 
increased the problem of inter-individual variation in patient response to antiretroviral (ARV) 
drugs, and the difficulty of measuring this variation through viral load (VL), cluster of 
differentiation 4 (CD4) cell count and clinical outcome. 
Alternative strategies including therapeutic drug monitoring (TDM) and pharmacogenetic 
analysis can aid in measuring and managing individual response to treatment through the 
alteration of ARV dosage. These two methods have already been proven to play a significant role 
in studies analysing treatment response (Marzolini et al., 2001; Fellay et al., 2002; Haas et al., 
2004). TDM is the measurement and monitoring of ARV levels in the body in order to evaluate 
patient treatment response. ARV levels in the body indicate the rate at which the ARV is broken 
down. Sub-optimal ARV levels, the possible result of a fast metabolism rate, can cause a negative 
treatment response, as indicated by persistently high VLs and low CD4 counts. Super-optimal 
ARV levels, the possible result of a slow metabolism rate, can cause a high occurrence of adverse 
drug reactions (ADRs). 
Efavirenz (EFV), an ARV drug classified as a non-nucleoside reverse transcriptase inhibitor 
(NNRTI), is prescribed as part of a standardised, first-line, triple-ART regimen in South Africa 
(National Department of Health, 2010). The inter-individual differences in HIV-positive patient 
response to EFV treatment can in part be attributed to the variable rate of EFV metabolism 
among patients, and subsequently, variable long-term EFV levels present in the bodies of 
different patients (Haas et al., 2004). This drug is a significant case to consider, because of its 
narrow therapeutic range and vast inter-individual pharmacokinetic variation. EFV plasma levels 
have been associated with VL parameters and the occurrence of EFV-specific ADRs (Marzolini  
et al. 2001; Figueroa et al., 2010). Importantly Cytochrome P450 (CYP) 2B6 SNPs 516G>T (part 
of the CYP2B6*6 allele) and 983T>C (part of the CYP2B6*16 and *18 alleles)  have consistently 
been associated with an increase in EFV levels (Haas et al., 2004; Gandhi et al., 2012; Ngaimisi 
et al., 2013). 
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EFV metabolism is a complex process involving not only the enzymes (CYP2B6, CYP3A, 
CYP1A2, CYP2A6, and UGT2B7) directly responsible for EFV breakdown into its metabolites, 
but also the nuclear receptors responsible for the transcriptional regulation of the genes encoding 
the metabolisers (constitutive androstane receptor, CAR and pregnane X receptor, PXR). These 
two nuclear receptors play a role in the transcriptional regulation of genes responsible for 
xenobiotic metabolism, among others. The activity of these two nuclear receptors is, in turn, 
activated by a range of ligands, of which xenobiotic compounds are the majority. Genetic variants 
in NR1I3 and NR1I2, encoding for CAR and PXR respectively, have been associated with altered 
regulatory activity of CAR and PXR (Zhang et al., 2001; Ikeda et al., 2005), as well as altered 
EFV levels and the occurrence of EFV-specific ADRs (Wyen et al., 2011; Swart et al., 2012). 
It would therefore be advantageous to investigate whether NR1I3 and NR1I2 genotypes affect 
EFV levels and treatment outcome in South African HIV patients. 
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CHAPTER 2 
2. Literature Review 
2.1. Antiretroviral therapy and treatment outcome 
2.1.1. Antiretroviral accessibility and management on an international scale 
Since the official implementation of the first effective ART in 1996, many HIV/AIDS-infected 
individuals have experienced significant improvements in both their life expectancy and quality 
of life (Palella et al., 2003; World Health Organization & UNAIDS, 2003). However, most of the 
patients who received ART were from first world countries, primarily because ARV drugs were 
more easily available and affordable in these resource-rich, developed countries (World Health 
Organization, 2004).  
In 2003, an estimated 400,000, out of six million patients in developing countries, were receiving 
ART; 100,000 of these patients were from African countries (World Health Organization, 2004, 
2006a). The World Health Organization (WHO) and the United Nations Programme on 
HIV/AIDS (UNAIDS) thus formed the “3 by 5” Initiative to address the huge demand for ARV 
drugs in developing countries (World Health Organization, 2004). This joint venture worked 
towards making ART available for three million people by the year 2005, through the creation of 
documents to provide healthcare departments, particularly in developing, resource-poor countries, 
with guidelines on how to implement national ART programmes (World Health Organization, 
2004). 
Even though the target of providing access to ART for three million people was not achieved by 
2005, the number of people on ART tripled from 2003 to the end of 2005 (approximately 1.3 
million patients; of which 800,000 were from Africa) (World Health Organization & UNAIDS, 
2006). The “3 by 5” Initiative was a success in that it highlighted the huge demand, as well as the 
limited access to ART, worldwide. Today the WHO, UNAIDS and other important organisations 
continue to provide guidance for the management of ART in all countries. 
The latest global HIV statistics revealed that more than 35 million people are HIV positive, with 
70% residing in sub-Saharan Africa (World Health Organization, 2013b; World Health 
Organization, 2014). A decade after the launch of the 3 by 5 Initiative, approximately 12.9 
million people in developing countries are being treated with ARV drugs (World Health 
Organization, 2014). The number of people eligible for ART currently stands at 17.6 million 
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according to the WHO 2010 guidelines on antiretroviral therapy and will be extended to 28 
million, pending the implementation of the latest recommendations made in 2013 by the WHO 
(World Health Organization, 2010a; World Health Organization, 2013b; Stover et al., 2014; 
World Health Organization, 2014). By the end of 2013, two million new patients have started 
receiving ART, the highest number to date, signifying that the rate of access to ART therapy is 
growing rapidly (World Health Organization, 2014). With the latest revised guidelines released in 
2013, the goal of 15 million people receiving ART by the end of 2015 does appear to be 
achievable (World Health Organization, 2013b; Stover et al., 2014). 
The WHO ARV guidelines recommend using WHO clinical stage and the CD4 cell count of 
patients to determine eligibility for ART.  The WHO clinical stages represent a classification 
system for the severity of symptoms associated with AIDS, with the least severe at stage I (nearly 
asymptomatic) and the most severe at stage IV (critical bacterial, viral and/or fungal infection) 
(World Health Organization, 2004).  
Table 1 lists the current recommended criteria for asymptomatic and symptomatic HIV-positive 
patients that are eligible for ART, in comparison to previous criteria. These criteria are 
periodically updated as new evidence from clinical studies emerges, ART coverage goals are 
reached and new goals, with regards to ART coverage, are set. Compared to the 2006 guideline, 
the CD4 cut-off value is less stringent in the 2010 guidelines (≤ 350 cells/ml), and even more so 
in the 2013 edition that is currently being implemented (≤ 500 cells/ml) (World Health 
Organization, 2010a; 2013b; World Health Organization, 2014). These instructions are in 
agreement with guidelines from the United States of America (USA) Department of Health and 
Human Services (DHHS) (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2014). 
Patients with tuberculosis (TB)- or hepatitis B virus (HBV)-infections combined with HIV 
infections are automatically enlisted for ART (World Health Organization, 2013b). 
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Table 1: WHO criteria for eligibility for ART, adapted from (World Health Organization, 
2010a). 
Target group 2013 ART guidelines 2010 ART guidelines 2006 ART guidelines 
Asymptomatic 
patients (stage I) 
 CD4 ≤ 500 cells/ml  CD4 ≤ 350 cells/ml  CD4 ≤ 200 cells/ml 
Symptomatic 
patients 
 CD4 ≤ 500 cells/ml 
 Priority given to: 
▬ Stage III or 
IV 
▬ Or CD4 
count ≤ 350 
cells/ml 
 Stage II with CD4 ≤ 
350 cells/ml 
 Or stage III or IV 
irrespective of CD4 
count 
 Stage II or III with 
CD4 ≤ 200 cells/ml 
 Or stage III with 
CD4 200 – 350 
cells/ml 
 Or stage IV 
irrespective of CD4 
count 
Adapted from: World Health Organization, 2010a. 
2.1.2. Current ARV drugs and ART regimens 
There are currently 26 ARV drugs approved for clinical use, and these drugs are divided into six 
groups: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), 
fusion inhibitors (FIs) and co-receptor inhibitors (CRIs) (Kumari & Singh, 2012; Panel on 
Antiretroviral Guidelines for Adults and Adolescents, 2014). Tenofovir disoproxil fumarate 
(TDF) may be grouped separately as a nucleotide reverse transcriptase inhibitor (NtRTI) (Kumari 
& Singh, 2012). 
The majority of HIV-positive patients receiving ART are prescribed a first-line ART regimen 
(World Health Organization, 2013a). The strategy for first-line ART in adults and adolescents is 
to prescribe a combination of three ARV drugs, as part of the triple-highly active antiretroviral 
therapy (HAART) (World Health Organization, 2006). This regimen usually consists of one 
NNRTI and two NRTIs, because it is effective in terms of cost, viral suppression and 
immunological regeneration, and can be prescribed as a fixed dosage, which can improve patient 
adherence (Martín et al., 2010; World Health Organization, 2010a; Panel on Antiretroviral 
Guidelines for Adults and Adolescents, 2014, World Health Organization, 2014). Other 
recommended regimens can include two NRTIs and either one PI (especially for children less 
than three years of age) or one INSTI (Panel on Antiretroviral Guidelines for Adults and 
Adolescents, 2014).  
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Specialised regimens are prescribed for pregnant women, although discrepancies exist among 
leading countries and organisations. The DHHS recommends the use of nevirapine (NVP), as 
opposed to EFV, as the most appropriate NNRTI for pregnant and breastfeeding women (Panel 
on Antiretroviral Guidelines for Adults and Adolescents, 2014). Primate and human studies have 
reported growth and neuronal deformities in fetuses exposed to EFV in the first three months of 
pregnancy (Jeantils et al., 2006; Bristol-Myers Squibb Pharma Company, 2013). This stance was 
supported by the 2006 WHO Guidelines; however, since 2010, the guidelines were altered in 
favour of EFV prescription for pregnant women (World Health Organization, 2006; 2010a). The 
motivation for this alteration was the increasing number of studies and review articles supporting 
the stability of EFV use and the increased risk for toxicity in pregnant women due to exposure to 
NVP (Ford et al., 2011; Ekouevi et al., 2011; Bera & Mia, 2012), as well as the WHO’s aim of 
simplifying its ART guidelines. The British HIV Association (BHIVA) in 2012 and in the DHHS 
in 2013 also added the use of EFV as alternative NNRTI for HIV-infected pregnant women 
(Taylor et al., 2012; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2014). 
The treatment prescribed for patients with TB-HIV and/or HBV-HIV co-infections should be 
carefully considered, due to ARV drug-drug interactions with the TB drug rifampicin, the 
common occurrence of immune reconstitution inflammatory syndrome (IRIS), the increase in 
progression of liver-disease in HBV-chronic patients and problems with drug toxicities. The 
WHO Guidelines recommend a standard regimen of one NNRTI and two NRTIs for TB-HIV- 
and/or HBV-HIV-infected patients. The NRTIs TDF and lamivudine (3TC) are preferred for 
HBV-HIV-infected patients, because of the antiviral activity against both HIV- and HBV-
infections (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2014; World Health 
Organization, 2014). 
The recommended second-line ARV-regimen consists of one PI (enhanced with ritonavir (RTV)) 
and two NRTIs, providing that first-line therapy did not include a PI (World Health Organization, 
2013b). PIs are preferentially used in second-line treatment because they differ substantially from 
NRTIs and NNRTIs in terms of structure, target viral receptor, and half-life, and are therefore 
suitable for combating viral resistance to first-line therapy (World Health Organization, 2006; 
Martín et al., 2010). It is important to select three active drugs for second-line therapy to aim for 
complete viral suppression, thus NRTIs are not re-prescribed (World Health Organization, 
2013b). According to Hamers et al. (2012), tenofovir (TDF) and stavudine (d4T) should not be 
interchanged, as the same pattern of viral resistance is observed in patients taking both NRTIs, 
and thereby reducing the activity of the second-line regimen. New and second-generation ARVs, 
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e.g. etravirine, (an NNRTI), raltegravir (RAL) (an INSTI) and enfuvirtide (a FI) are examined in 
past, recent and on-going studies for use in second-line regimens (Lazzarin et al., 2003; Gatell et 
al., 2010; Katlama et al., 2010). The second-generation NNRTIs etravirine and rilpivirine are 
already considered for second-line treatment in the DHHS guidelines (Panel on Antiretroviral 
Guidelines for Adults and Adolescents, 2014). However, in the Hamers et al. (2012) study, 
patients failing first-line NNRTI-based therapy showed a rapid increase in viral mutations, which 
suggests that second-line NNRTIs will have decreased efficiency when used as second-line 
treatment. 
The introduction of rilpivirine, an alternative NNRTI to EFV and NVP, has recently received 
attention from the public and health sector (James et al., 2012). Clinical trials report no 
significant difference between rilpivirine and EFV with regards to virological response and CD4 
cell count, but rilpivirine resulted in fewer ADRs, with the associated reduction in treatment 
discontinuation. However, patients with higher viral load (VL) (> 10,000 copies/ml) presented an 
increase in the frequency of viral failure and, subsequently, an increase in ARV resistance (James 
et al., 2012). 
2.1.3. Evaluation of treatment outcome 
ART theoretically suppresses all viral replication; however, treatment outcome differs among 
individuals and is dependent on a number of variables. Treatment outcome can be measured by 
CD4 cell count (immunological outcome), VL, clinical outcome and TDM (Woldemedhin & 
Wabe, 2012). The occurrence of adverse drug reactions (ADRs) in response to treatment is also 
an important aspect to consider when monitoring treatment outcome. 
Patients will experience varying responses to treatment during the first few weeks that would not 
necessarily be indicative of treatment outcome, as the body is still adjusting to the treatment 
(World Health Organization, 2006; Lima et al., 2012). These responses can manifest in different 
ways, for example sudden increases in VL and short-lived instances of ADRs (Havlir et al., 
2001). The onset of IRIS, the occurrence of symptoms of preceding diseases in patients because 
of an improving immune system in HIV patients, is also not an indicator of treatment failure 
(World Health Organization, 2006; Steele et al., 2011). TB and cryptococcal disease are most 
common diseases that present as IRIS (World Health Organization, 2006). Accurate 
measurements of treatment outcomes are further complicated by the co-prescription of other 
medications for additional diseases. These drugs usually have their own set of adverse effects, 
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and can also interact with ARV medication to decrease the effectiveness of the ARV treatment 
(Panel on Antiretroviral Guidelines for Adults and Adolescents, 2014). 
2.1.3.1. CD4 cell count 
CD4 cell count is an indication of the immunological outcomes of a patient and can be used as a 
measurement of treatment response. According to the DHHS, it is also the best predictor for 
determining treatment response in a clinical environment (Panel on Antiretroviral Guidelines for 
Adults and Adolescents, 2014). A CD4-count of below-baseline or on-going counts below 100 
cells/ml suggests immunological failure (World Health Organization, 2013b). However, a CD4 
count increase of 50-150 cells/ml per year is considered to be a good immunological response 
(Panel on Antiretroviral Guidelines for Adults and Adolescents, 2014). 
2.1.3.2. Viral load 
Since 2010, HIV treatment studies using VL as measurement of treatment outcome have become 
more prevalent, and have shown that VL is a more sensitive measurement than CD4 count to 
identify treatment failure (Laurent et al., 2011; Loutfy et al., 2013). By 2013, VL was considered 
by the WHO to be the most important method of measuring treatment response (World Health 
Organization, 2013b).  
Treatment response can range from successful viral suppression to virologic failure and viral 
resistance to drugs (Rodríguez-Nóvoa et al., 2006). The cut-off value for virologic failure is still 
under discussion, and different values are being used by different studies. Currently, the WHO 
defines virologic failure as the occurrence of at least two sequential measures of VL above 1,000 
copies/ml. In the 2010 guidelines, the cut-off value was 5,000 copies/ml (World Health 
Organization, 2010a). Alternatively, the DHHS differentiates between virologic failure (< 200 
copies/ml) and persistent low-level viremia (< 1,000 copies/ml) (Panel on Antiretroviral 
Guidelines for Adults and Adolescents, 2014). One reason for the amended 1,000 copies/ml cut-
off-value, is that viral transmission is significantly reduced in patients with VL below this value 
(Loutfy et al., 2013). Some studies have reported that sporadic occurrences of VL levels between 
50 and 1,000 copies/ml are not statistically associated with an increased risk of treatment failure, 
however, other studies claim that when these VL values occur consistently, they indicate 
treatment failure (Havlir et al., 2001; Castelnuovo et al., 2011; Lima et al., 2012). Unfortunately, 
due to the high cost of scheduled VL measurements in patients (i.e. every three to six months), it 
is difficult to implement more frequent measurements in clinics. 
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 2  Literature Review 
9 
 
2.1.3.3. Clinical outcome 
The clinical results of a patient also indicate treatment response. Recent, new and on-going 
clinical complications, for example TB, pneumonia, fungal infections, and HBV-infections 
reported six months after ART initiation, can indicate viral failure (World Health Organization, 
2013b). However, a problem with relying only on clinical outcome to identify treatment outcome, 
is that high viral loads can remain undetected, and, by the time patients are switched to another 
treatment regimen, viral resistance can already be present (World Health Organization, 2006). 
2.1.3.4. Therapeutic Drug Monitoring 
Therapeutic Drug Monitoring (TDM), the use of drug levels in the body to determine and 
regulate treatment outcome, is a possible additional approach to monitor ART (Panel on 
Antiretroviral Guidelines for Adults and Adolescents, 2014). TDM has been proven effective for 
the observation of plasma drug levels for PIs saquinavir (SQV), RTV, indinavir (IDV) and 
nelfinavir (NFV) in a research capacity (Schapiro et al., 1996; Durant et al., 2000). The use of 
TDM to trace the patient’s reaction to treatment is especially useful for ARVs with a narrow 
therapeutic range and wide inter-patient variability, like NNRTIs EFV and NVP and the NRTI 
zidovudine (AZT) (Marzolini et al. 2001; Ståhle et al., 2004; Antonelli & Turriziani, 2012; 
Zanger & Schwab, 2013).  
Plasma ARV levels are measured from blood samples collected from patients at regular intervals 
(every one to three months) using variations of high-performance liquid chromatography (HPLC) 
(Durant et al., 2000; Marzolini et al., 2001; Ståhle et al., 2004; Figueroa et al., 2010). These 
plasma ARV levels are then used, in conjunction with other evaluation methods, as an indication 
of patient response to treatment (Durant et al., 2000; Figueroa et al., 2010). ARV drug levels 
above the specific treatment range are an indication of the risk of occurrence of adverse effects 
(Haas et al., 2004; Huang et al., 2008; Gutiérrez et al., 2013; Menezes et al., 2013), while, sub-
therapeutic drug levels may be an indication of decreased drug activity, treatment failure and the 
development of viral resistance (Marzolini et al., 2001; Huang et al., 2008). 
Some organisations discourage the use of TDM in the clinical environment (Thompson et al., 
2012). Measuring plasma ARV concentration can prove to be difficult, because of logistical 
barriers in obtaining a uniform sample in all patients. This is because of the varying 
pharmacokinetics of ARV drugs among patients, as well as varying time intervals between 
ingesting the drug and measuring plasma levels, differences in drug-drug interactions among 
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patients and differences in adherence among patients (Duval et al., 2007). This approach is also 
subject to confounding factors, such as patient diet and metabolism. 
Measuring ARV levels in hair, which represent drug levels in the body over a period of weeks or 
months, is an alternative method to consider (Huang et al., 2008). Duval et al. (2007) examined 
the effect of drug concentrations in plasma vs. hair levels for IDV, a protease inhibitor. After 
multivariate analysis, only hair samples were significantly associated with VL (Duval et al., 
2007). The practical advantages of hair samples are that they are easier and less invasive to 
collect and can be stored for longer periods of time. Huang et al. (2008) examined the available 
methods of extracting drug levels from hair samples and concluded that a technique combining 
liquid mass chromatography with gas spectrometry would most efficiently extract and measure 
EFV, lopinavir (LPV) and RTV levels in hair samples. A study by Gandhi et al. (2012) analysed 
the short-term effects of 230 polymorphisms on EFV levels by using plasma samples and the 
long-term effects by using patient hair samples. A total of 28 polymorphisms, including two 
important CYP2B6 SNPs (CYP2B6516G>T and CYP2B6983T>C), had a reduced, but still 
significant, effect on EFV hair levels compared to EFV plasma levels (Gandhi et al., 2012). In a 
study published in 2013, Gandhi et al. used the same strategy of plasma levels representing recent 
exposure and hair levels representing long-term exposure, to show that EFV was transferred from 
mother to infant both through the placenta while in the uterus and through breastfeeding after 
birth, but LPV and RTV were transferred from mother to infant only through the placenta. 
Another study by Gandhi et al., (2014) compared two methods of measuring ARV treatment 
adherence in Kenyan patients: ARV hair levels and self-reported adherence. The study suggested 
that ARV levels in hair are a more accurate representation of treatment adherence than adherence 
reported by the patients themselves. 
2.1.3.5. Adverse drug reactions 
Drug toxicity (the advent of adverse reactions) is one of the biggest reasons for changing to an 
alternative ARV regimen (Kumarasamy et al., 2006; Hart et al., 2007; Woldemedhin & Wabe, 
2012). Toxicity to ARV therapy is manifested in a wide range of ADRs, including 
hypersensitivity (caused by NRTIs and NNRTIs), central nervous system (CNS) side effects 
(caused by EFV), peripheral neuropathy (caused by d4T), nausea, anaemia, neutropenia (caused 
by AZT) back pain, double vision and, after long term exposure, hepatotoxicity (caused by NVP) 
and lipodystrophy (caused by d4T) (World Health Organization, 2006; Wyen et al., 2011; 
Woldmedhin  Wabe, 2012). These effects can occur within a week of treatment initiation, or at a 
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 2  Literature Review 
11 
 
later stage, and can continue for several months regardless of treatment regimen alteration or 
discontinuation (World Health Organization, 2006; Wyen et al., 2011).  
Studies disagree with regards to the most frequent cause of ART-related drug toxicity. 
Woldemedhin & Wabe (2012) studied patients who were prescribed a variety of treatment 
regimens, and identified peripheral neuropathy as the primary cause for altering treatment 
regimens. Alternatively, two other studies, one performed on Peruvian patients and one 
performed on North American patients, reported anaemia as the primary cause for altering 
treatment regimens (Bangsberg et al., 2006; Nevin et al., 2011). 
Usually the severity of the ADRs determines whether a change of regimen is needed (Wyen et 
al., 2011). An effective and timeous intervention is vital, because the occurrence of any of the 
potential ADRs may lead to treatment non-adherence or discontinuation and increase the risk of 
drug resistance and/or virologic failure (Panel on Antiretroviral Guidelines for Adults and 
Adolescents, 2014). Drug toxicity is monitored through physician- and patient-reported 
symptoms during clinical assessments and laboratory analysis of blood samples (World Health 
Organization, 2013b). Toxicities are not always carefully observed and recorded, and therefore it 
is difficult to determine the absolute effect of these adverse reactions on patient treatment 
response and adherence (World Health Organization, 2006). The presence of the symptoms of co-
occurring diseases (e.g. malaria or TB), as well as IRIS, also complicates the accurate annotation 
of ART-related adverse effects (World Health Organization, 2006). 
A change in drug regimen owing to adverse effects may, however, lead to a greater risk of viral 
resistance (Nevin et al., 2011). Viral resistance to ARVs results in poor treatment outcome, such 
as virologic failure and mortality (Nevin et al., 2011). Standardised genotypic tests for viral 
resistance are available, testing for mutations in the genes encoding the viral reverse transcriptase 
(RT) and protease enzymes (Panel on Antiretroviral Guidelines for Adults and Adolescents, 
2014). 
2.1.4. Antiretroviral therapy in a South African context 
A report by Statistics South Africa (ZA) (2013) shows a prevalence of HIV-infected individuals 
of 10% in the South African population (Statistics South Africa, 2013). The latest data collected 
by the WHO shows that by the end of 2012, 2.15 million South African citizens were receiving 
ART, with an additional 2.7 million citizens eligible for ART (World Health Organization, 
2013a). This amounts to a coverage of 83%, which is the third highest coverage of countries in 
Africa, following Botswana and Namibia (World Health Organization, 2013a). 
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Criteria for a South African HIV-positive patient to start ART are based on clinical as well as 
immunological assessments. National guidelines in 2010 were more stringent in terms of ART 
eligibility than the updated 2013 version (National Department of Health, 2010, 2013). Currently, 
all patients with a CD4 count of <350 cells/ml are eligible for ART; this correlates with current 
WHO standards. Priority is given to patients with a CD4-count below 200 cells/ml, co-infected 
with TB and who clinically present other WHO stage IV criteria (National Department of Health, 
2013). 
South African first- and second-line ART regimens are in accordance with WHO guidelines. The 
general first-line ARV-regimen prescribed for South African patients, is one NNRTI (EFV or 
NVP), along with two NNRTIs (TDF plus emtricitabine (FTC) or 3TC) (National Department of 
Health, 2013). Pregnant HIV-positive patients are currently also prescribed EFV, in contrast to 
2010 South African guidelines that promoted the use of NVP in pregnant patients. Prior to 2010, 
South African patients were commonly prescribed d4T as part of the first-line regimen, however 
this drug was phased out because of severe adverse effects such as peripheral neuropathy, 
lipodystrophy, and pancreatitis (World Health Organization, 2010a). A second-line regimen 
consists of a RTV-boosted PI-based regimen (including LPV or atazanavir as the PI), and patients 
with a VL above 1,000 copies/ml are eligible for this regimen (National Department of Health, 
2013). A third-line ART option exists that includes new ARV drugs such as darunavir and RAL.  
South Africa first implemented a national ART-plan in 2004 and even though this was an 
important achievement, there are still some problems in the clinical environment and also in the 
patients’ living environment that need to be addressed to access the full potential of ART (World 
Health Organization, 2010b). The limited number of doctors and nurses available to treat and 
monitor the vast number of HIV-infected patients in South Africa is of primary concern (Fairall 
et al., 2012), thereby limiting the  potential improvement in the quality of patient support, 
counselling and care that are required (Harries et al., 2001). In addition, the regulation of access 
to ARVs for eligible and non-eligible patients is compromised, potentially leading to death for 
eligible patients that do not start ART treatment early enough or drug resistance in treated 
patients who are not yet eligible (Harries et al., 2001; Fairall et al., 2012). A strategy has been 
proposed and tested in some South African clinics in which the workload is shared between 
doctors and nurses, with nurses being assigned to prescribe ARV medication, while doctors deal 
primarily with patients displaying severe disease symptoms (Fairall et al., 2012). This strategy 
proved to be successful, and is currently being implemented in other South African clinics. 
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Another challenge specific to sub-Saharan African countries, including South Africa, is the 
regulation of eligibility for second-line treatment regimens and controlling the emergence of viral 
drug resistance. Although South African Guidelines state that VL should be used as a 
measurement of eligibility for second-line ART, this is not yet fully implemented in South Africa 
and VL is not yet efficiently monitored, according to WHO standards (Harries et al., 2010; World 
Health Organization, 2013b). Some clinical studies in sub-Saharan Africa reported that 24% of 
HIV patients have a median VL of 400-500 copies/ml after six to 36 months on ART (Wester et 
al., 2005; Ferradini et al., 2006; Boulle, 2008). However, these findings tend to include the 
presence of viral blips (short occurrences of high VL), which are not necessarily indicative of 
viral failure. 
Patients’ living environments can also complicate treatment. The vast majority of South African 
HIV-positive patients live in poverty, which may result in a lack of nutrition, clean drinking 
water, sanitation and shelter (United Nations, 1995; Evans et al., 2012). Only malnutrition, 
however, has been associated with an increase in the severity of HIV disease (Macallan, 1999; 
Bates et al., 2004; Evans et al., 2012). Evans et al. (2012) recruited patients from Johannesburg 
in South Africa that were prescribed an ARV regimen as suggested in national guidelines and 
reported that a low body mass index (BMI), as a result of malnutrition, was significantly 
associated with increased VL, an increased chance of developing TB, increased onset of 
oropharyngeal candidiasis (OC), an HIV-disease-related symptom, and an increased  risk of 
death. 
2.1.5. Efavirenz 
EFV is an ARV drug used in the treatment of HIV-1 positive patients. It is an NNRTI, the group 
of ARVs that inhibit the activity of the RT enzyme of HIV-1, thereby hindering the conversion of 
viral RNA into DNA for integration into the host DNA (Ward et al., 2003; WHO Collaborating 
Centre, 2011). Reverse transcriptase (RT) gene mutations, most commonly K103N in the HIV-1 
strain, are responsible for EFV drug resistance, in that it reduces viral susceptibility to the drug 
(Adkins & Noble, 1998; Mollan et al., 2012; Thiam et al., 2013). 
2.1.5.1. The pharmacokinetics of EFV and the factors influencing EFV metabolism 
EFV (C14H9ClF3NO2) has a molecular mass of 315.68 and is ingested orally by patients in tablet 
form (600 mg), or in capsule form (50 mg or 200 mg) (Bristol-Myers Squibb, 2013). EFV, like 
most types of xenobiotic substances, is lipophilic and can enter intestinal cells through the cell 
membrane (Lindenberg et al., 2004; Bristol-Meyers Squibb, 2013). In plasma, EFV binds 
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predominantly to albumin (Bristol-Myers Squibb, 2013), with a very small percentage (0.4 to 
1.5%) unbound to proteins (Almond et al., 2005; Avery et al., 2013). In contrast to PIs, EFV’s 
small molecular mass enables the drug to cross the blood-brain barrier and enter the cerebrospinal 
fluid (CSF), with a plasma-CSF-gradient of 150 (Best et al., 2011). Although the EFV-
concentration in the CSF is much lower than in plasma, it is still higher than the EFV IC50-value 
(26 times higher), and is therefore sufficient for treatment success (Tashima et al., 1999; Best et 
al., 2011). 
EFV is primarily metabolised in the liver by CYP2B6 with assistance from CYP3A4, CYP3A5, 
CYP2A6, CYP1A2 and UGT2B7 to its inactive and conjugated forms, 8-hydroxyEFV, 7-
hydroxyEFV, 7,8-dihydroxyEFV and EFV-N-glucuronide (Figure 1) (Mutlib et al., 1999; Bristol-
Myers Squibb, 2013). CYP2B6 is also responsible for the secondary metabolism of EFV to 8,14-
dihydroxyefavirenz (Ward et al., 2003). Hepatocytes make use of these oxidative pathways to 
metabolise EFV into hydrophilic compounds, which facilitates excretion via urine (Lee, 2003). 
EFV has a plasma half-life of approximately 40 to 76 hours and has a plasma therapeutic range of 
1 to 4 μg/ml (Marzolini et al., 2001; Castillo et al., 2002; Haas et al., 2004; Bristol-Myers 
Squibb, 2013). The long half-life of EFV provides sufficient time for the drug be effective, but 
the narrow therapeutic range of EFV reduces the chance of good treatment outcome. Low, or sub-
therapeutic EFV plasma levels (< 1 μg/ml) are associated with a higher risk of treatment failure 
and drug resistance and may be due to an increased EFV clearance rate in certain individuals 
(Ward et al., 2003; Tsuchiya et al., 2004; Rodríguez-Nóvoa et al., 2006). High, or super-
therapeutic EFV plasma levels (> 4 μg/ml) may be the result of a slow EFV clearance rate and 
increases the probability of adverse effects, especially those that impact the CNS, including 
headaches, dizziness, insomnia and fatigue (Marzolini et al., 2001; Haas et al., 2004; World 
Health Organization, 2014). Additional adverse effects of EFV include hepatotoxicity, rash, 
hypersensitivity, dyslipidaemia, nausea, heartburn and diarrhoea (Adkins & Noble, 1998; 
Shubber et al., 2013; World Health Organization, 2013c). There is substantial inter-individual 
variability in EFV levels, which results in different toxicity patterns, further complicating the 
research aim of optimising EFV treatment (Haas et al., 2004).  
Figure 1 illustrates the various factors that can influence EFV metabolism. HIV-infected patients 
taking EFV is often prescribed additional medication for other diseases, therefore the effects of 
drug-drug interactions must be taken into account. The enzymes responsible for EFV metabolism 
are also involved in the metabolism of other drugs, including IDV and SQV (PIs), AZT (an 
NRTI) rifampicin (anti-TB drug), clarithromycin (antibiotic), pethidine (pain relieving drug) and 
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artemisin (antimalarial drug) (Ramírez et al., 2004; Asimus & Ashton, 2009; Belanger et al., 
2009; Gengiah et al., 2012; Hasegawa et al., 2012; Huang et al., 2012). In some cases, the co-
administration of these drugs results in impaired metabolism of EFV or the other drugs involved 
(Belanger et al., 2009; Gengiah et al., 2012; Hasegawa et al., 2012; Huang et al., 2012).  
Several xenobiotics have also been reported to inhibit the activity of EFV-metabolising enzymes 
either through direct binding or through indirect activation of nuclear receptors (NRs) and other 
transcription factors (TFs). These xenobiotics include clopidogrel (antiplatelet drug), methadone 
(pain relieving drug) and tamoxifen (hormone therapy drug) (Richter et al., 2004; Amunugama et 
al., 2012; Sridar et al., 2012). 
 
Figure 1: Diagram representing the metabolism of EFV and the factors that influence the 
rate of EFV metabolism. 
The red arrows indicate the influence of EFV on the regulation of its metabolising enzymes. The 
green arrows indicate the influence of other drugs on EFV metabolism and vice versa. The blue 
arrows indicate the influence of nuclear receptors and other transcription factors on EFV 
metabolism through the binding of EFV itself and other drugs. Adapted from Di Iulio et al., 2009, 
with publisher’s permission. 
EFV also influences the activity and transcription of its metabolising enzymes, CYP2B6 and 
CYP3A4, through an indirect mechanism by binding to NRs (Hariparsad et al., 2004; Habtewold 
et al., 2012). Therefore, EFV induces its own metabolism. The above-mentioned factors show 
that further studies are required in order to completely understand all the complexities involved in 
EFV metabolism. 
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2.1.5.2. The pharmacogenomics of EFV 
Genetic variants in all genes playing important roles in EFV metabolism (Figure 1), as well as the 
genes encoding potential transporters for EFV, have been implicated in pharmacogenomic studies 
on EFV. 
Genetic variants in the gene encoding CYP2B6, the main metaboliser of EFV, influence EFV 
levels in the body, treatment outcome and the occurrence of ADRs (Haas et al., 2004; Motsinger 
et al., 2006; Habtewold et al., 2011; Gandhi et al., 2012; Arab-Alameddine et al., 2013; Martín et 
al., 2013). Haas et al. (2004) assessed the interaction between genetic variation, EFV plasma 
levels and CNS-specific ADRs in a multicultural cohort of African American, Latin-American 
and Caucasian HIV-positive patients receiving EFV treatment and identified an association 
between the T-allele of CYP2B6 SNP 516G>T (part of the CYP2B6*6 allele) and higher EFV 
plasma exposure over a period of six months. This association was replicated in studies that 
utilised different methods of measuring EFV levels, including long-term EFV plasma exposure, 
EFV plasma clearance after a single dose, EFV levels in hair, and intracellular EFV levels in 
peripheral blood mononuclear cells (PBMCs) (Haas et al., 2005; Wang et al., 2006; Haas et al., 
2009; Habtewold et al., 2011; Gandhi et al., 2012). An association was also found between the C-
allele of another CYP2B6 SNP, 983T>C, (part of the CYP2B6*16 and *18 alleles) that have only 
been identified in individuals of African or admixed-African ethnicity, and elevated EFV plasma 
levels (Wyen et al., 2008; Gandhi et al., 2012; Maimbo et al., 2012; Mutwa et al., 2012; Johnson 
et al., 2013; Swart et al., 2013). 
Arab-Alameddine et al. (2009) developed a pharmacokinetic model for EFV clearance that 
identified two CYP3A4 SNPs, namely rs274057 (4713G>A) and rs4646437 (21726C>T), 
associated with decreased EFV clearance in combination with CYP2B6*6. CYP3A4 rs4646437 
was also associated with an increase in the occurrence of EFV discontinuation as a result of 
treatment failure or ADRs (Lubomirov et al., 2011).  
ABCB1 encodes the transporter protein p-glycoprotein (P-gp), and although studies report that P-
gp does not play a direct role in the transportation of EFV (Burhenne et al., 2010), the influence 
of variants in ABCB1 on EFV plasma levels warrants further investigation. Several studies 
identified an association between an ABCB1-SNP, 3435C>T, and a decreased chance of virologic 
failure, viral resistance, drug toxicity and ADRs in patients receiving EFV (Fellay et al., 2002; 
Haas et al., 2005; Motsinger et al., 2006; Ritchie et al., 2006; Yimer et al., 2011). 
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Other genes that have also indicated correlations among genomic variation, EFV levels and 
treatment outcome are CYP1A2, CYP2A6, UGT2B7, and two NR genes, NR1I3 and NR1I2 
(Kwara et al., 2009; Habtewold et al., 2011; Wyen et al., 2011; Swart et al., 2012; Cortes et al., 
2013; Martín et al., 2013). 
2.2. Nuclear hormone receptors 
2.2.1. Structure and organisation of the nuclear receptor superfamily 
Nuclear hormone receptors (NRs) form a family of TFs that regulate the transcription of genes 
involved in the metabolism of xenobiotic compounds as well as various endogenous compounds 
(Lamba et al., 2008; Ihunnah et al., 2011). NRs are also involved in vital cellular processes such 
as cell growth and differentiation, chromatin condensation, gene silencing, physiological 
homeostasis and metamorphosis (Mangelsdorf et al., 1995; Mckenna & O’Malley, 2002; 
Bertrand et al., 2004). 
NRs are only found in metazoans and are phylogenetically separated into six subfamilies (NR1 to 
NR6) (Giguère, 1999; Nuclear Receptors Nomenclature Committee, 1999). The number of NRs 
differs greatly among species, although trends can be observed in closely related species. For 
example, humans and mice have 48 and 49 NRs respectively, whereas the mosquito and the fruit 
fly have 21 NRs each, and nematodes Caenorhabditis elegans and C. briggsae both have more 
than 250 NRs (Bertrand et al., 2004). The diversity in total number of NRs among species can be 
explained by gene duplication periods as well as a loss of irrelevant genes with the passing of 
time (Maglich et al., 2001; Bertrand et al, 2004).   
Maglich et al. (2001) investigated the phylogenetic differences among nuclear receptor genes of 
two invertebrate and one vertebrate species using genome information obtained from the 
nematode (C. elegans), the fruit fly (Drosophila melanogaster) and humans. They reported 
several NRs present in humans that are absent in invertebrates, including thyroid hormone 
receptors, androgen receptors and steroid receptors. Additionally, 24 NRs of C. elegans and three 
NRs of D. melanogaster could not be classified according to any of the existing six subfamilies. 
The NR3 class contains no representatives of C. elegans and only one of the D. melanogaster, 
whereas the human NRs are represented in all six NR-subfamilies. 
NRs can also be separated into two groups based on their method of identification and ligand 
binding affinity. NRs that have an affinity for specific physiological ligands and were identified 
through protein and hormone binding studies are called ligand-dependent nuclear receptors. A 
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large number of NRs were identified through hybridisation and cloning studies using probes from 
the highly conserved DNA binding domain of other NRs. These NRs are termed orphan nuclear 
receptors and are named as such either because they do not require binding ligands for activation 
(constitutive expression) or because their specific ligands have not yet been determined (Giguère, 
1999). Orphan nuclear receptors account for 60% of all mammalian NRs and include the 
hepatocyte nuclear factor-4α (HNF4α), CAR and PXR (Mangelsdorf et al., 1995; Giguère, 1999; 
Chen et al., 2012). 
The important structural features of nuclear receptors are the DNA binding domain (DBD), the 
ligand binding domain (LBD), and two transactivation domains (AF-1 and AF-2) (Mangelsdorf 
& Evans, 1995; Wang & LeCluyse, 2003; Chen et al., 2012). The DBD is generally a highly 
conserved module among different species and plays a role in identifying and binding to 
xenobiotic response elements (XREs) or hormone response elements (HREs) on target genes 
(Mangelsdorf & Evans, 1995; Wang & LeCluyse, 2003; Lamba et al., 2008). The LBD is less 
conserved than the DBD and is involved in the binding of lipophilic ligands to the NR, which 
regulates the activity of NRs (Maglich et al., 2001). The LBD also plays a role in the interaction 
with co-repressors or co-activators, dimerisation and nuclear localisation (Wang & LeCluyse, 
2003; Lamba et al., 2008). The binding of a ligand induces a conformational change within the 
LBD, aided by AF-2, allowing the affinity of NRs for co-activators that aid in transcriptional 
regulation of target genes (Mangelsdorf et al., 1995; Giguère, 1999). Some NRs, mostly from the 
NR1-subfamily, form heterodimers with the retinoid X receptor (RXR) when binding to XREs on 
their target genes (Mangelsdorf & Evans, 1995; Wang & LeCluyse, 2003). 
In terms of species conservation of the DBD and LBD in NRs, CAR and PXR are among the 
exceptions. The DBD and LBD of PXR and, to a lesser extent, CAR, are less conserved among 
species than other NRs, on a protein as well as a genetic level. This explains the ability of human 
CAR and PXR to bind to a wider range of ligands than their homologs in other species (Reschly 
& Krasowski, 2006). 
2.2.2. The role of CAR and PXR as transcriptional regulators in xenobiotic 
metabolism 
CAR, encoded by NR1I3, and PXR, encoded by NR1I2, are the focus of this study, and overlap 
extensively in ligand specificity and target genes. CAR and PXR are involved in the 
transcriptional regulation of genes encoding for Phase I and II drug metabolising enzymes, genes 
involved in drug transport, steroid metabolism and bile acid and bilirubin detoxification, among 
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others (Xie et al., 2001; Handschin & Meyer, 2003; Lamba et al., 2008; Ihunnah et al., 2011). 
CAR and PXR are both expressed mainly in the liver (Wang & LeCluyse, 2003), which 
correlates with the expression of the key genes responsible for xenobiotic metabolism, including 
CYP2B6, CYP3A4, CYP3A5 and CYP2A6 (Chang et al., 2003; Lamba et al., 2003). 
The enzymes in the CYP1, CYP2 and CYP3-subfamilies are responsible for the phase I 
metabolism of approximately 70 to 80% of xenobiotic substances metabolised in the liver (Figure 
2) (Zanger et al, 2008). Maglich et al. (2002) reported that CAR and PXR enhance the expression 
of CYP1A2 through ligand activation (Maglich et al., 2002). However, recent studies only 
observe the ability of CAR to influence CYP1A2 expression (Yoshinari et al. 2010; Tojima et al., 
2012)  In vitro reporter assays by Yoshinari et al. (2010) showed that CAR plays a role in the 
activation of CYP1A2 expression by binding to a XRE approximately 300 bp upstream from the 
start of the CYP1A2 gene. PXR, however, is an important contributor to the transcriptional 
regulation of CYP3A4 and CYP3A5 enzymes, which play a role in the metabolism of 37% of 
xenobiotic substances (Zanger et al., 2008). Burk et al. (2004) observed that PXR induces 
CYP3A4 and CYP3A5 transcription in liver tissue by means of activation by the anti-TB drug, 
rifampicin (Burk et al., 2004). The study also reported that CAR, in cooperation with HNF4α, 
plays a role in the basal expression of CYP3A genes. 
CYP2B6 is an important enzyme with respect to the metabolism of medical and environmental 
chemicals. Tissue culture studies demonstrate the phenobarbital-mediated activation of CYP2B6 
through a CAR-RXR-heterodimer binding to a 5’upstream region of the gene, called the 
phenobarbital-responsive enhancer module (PBREM) (Sueyoshi et al., 1999). Wang et al. (2003) 
also reported the influence of PXR on CYP2B6 regulation through the discovery of yet another 
response element 5’upstream of the PBREM element that is capable of binding to both CAR and 
PXR. Using cultured liver cells, both CAR and PXR were shown to induce CYP2B6 expression 
through binding to both response elements, PBREM and the novel response element. 
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Figure 2: Representation of the Cytochrome P450 enzymes involved in drug metabolism 
and the factors that influence their activity 
The percentage values indicate the proportion of drugs that are metabolised by the specific 
enzyme. ↑ indicates increased enzyme activity. ↓ indicates decreased enzyme activity. Taken 
from Zanger & Schwab, 2013, with publisher’s permission. 
Additional CYP-enzymes that are regulated by CAR and PXR include CYP2A6, CYP2C9, 
CYP2C19 and CYP4F12 (Chen et al., 2005; Tolson et al., 2009). Other phase I enzymes that are 
regulated by PXR include aldo-keto reductases (AKRs), enzymes that break down toxic 
aldehydes and ketones, and carboxylesterases (CESs), enzymes that break down esters, amides 
and thioesters (Rosenfeld et al., 2003). 
UGT-enzymes are involved in the glucuronidation of xenobiotics and endobiotics as part of phase 
II metabolism. A member of this family of enzymes, UGT1A1, is responsible for the metabolism 
and clearance of bilirubin in the body. Xie et al. (2002), using transgenic mice, observed that 
PXR activated by rifampicin increased the transcription and expression of UGT1A1. Sugatani et 
al. (2005), using cultured oncogenic liver cells, also observed that CAR and PXR induce 
UGT1A1 transcription through dexamethasone activation and co-activation through the 
glucocorticoid receptor (GR). CAR and PXR also regulate other UGTs such as UGT1A4 and 
UGT1A9 (Ji et al., 2012). 
Other Phase II enzymes that CAR and PXR regulate, include sulfotransferases (SULTs), enzymes 
that are responsible for the conjugation of substances through the addition of a sulfonyl group, 
and glutathione S-transferases (GSTs), enzymes that catalyses the addition of glutathione 
substances (Xie et al., 2002; Sugatani et al., 2005; Duret et al., 2006; Alnouti & Klaassen, 2008; 
Sueyoshi et al., 2011). 
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Transporter proteins play a significant role in controlling homeostasis for both xenobiotic and 
endobiotic compounds in a cell. Geick et al. (2001) used a cultured colon cancer cell line to show 
that ABCB1 expression is induced by rifampicin through the direct binding of PXR to a response 
element in the ABCB1 upstream region. CAR is also capable of binding to ABCB1 and 
influencing its expression in colon cancer cell lines (Burk et al., 2005). 
Some of the ligands that are recognised by CAR and PXR include steroids (e.g. pregnane), 
catabolites (e.g. bilirubin), herbal xenobiotics (e.g. hyperforin) and drugs used in various clinical 
treatment regimens (e.g. rifampicin) (Di Masi et al., 2009). Various ARVs are also ligands of 
CAR and PXR, including the PIs, IDV and RTV, and NNRTIs, NVP and EFV (Sinz et al., 2006; 
Faucette et al., 2007). However, the affinity of PXR for EFV is weak, as observed in the analysis 
of PXR-activity using reporter assays. PXR-activity in the presence of EFV was only 30% when 
measured as a percentage of total PXR-activity in the presence of rifampicin (Faucette et al., 
2007). CAR has a strong affinity for EFV and is up-regulated by EFV by as much as ten times the 
basal expression  (P < 0.05) (Faucette et al., 2007). 
Both NR1I3 and NR1I2 undergo alternative splicing to form different isoforms of CAR and PXR, 
resulting in different structural and functional characteristics, which might help to explain why 
CAR and PXR can recognise such a variety of ligands and target genes. Di Masi et al. (2009) 
suggested that SNPs in the critical splice areas of these genes could affect protein activity, and 
therefore also affect the biological pathways containing CAR and PXR. 
2.2.3. CAR encoded by NR1I3 
NR1I3 is 8,600 base pairs (bp) in length and is located on chromosome 1, region q23.3 (Lamba et 
al., 2004; Ensembl Genome Browser). The gene consists of nine exons, the first of which forms 
part of the 5’-untranslated region (UTR). The remaining eight exons can undergo alternative 
splicing to form the wild type CAR and 26 different isoforms (Arnold et al., 2004; Lamba et al., 
2004). The wild-type CAR-protein, CAR.1, is translated from a mRNA molecule, 1,153 
nucleotides (nt) in length, that contains the transcription product of all nine exons (Lamba et al., 
2004). CAR.1 consists of 348 amino acids (aa) and has the highest ligand binding affinity of all 
the CAR isoforms (Lamba et al., 2004). There are some CAR-isoforms that incorporate 
premature stop-codons, and are therefore translated to form non-functional proteins that are 
rapidly degraded (Lamba et al., 2004; Di Masi et al., 2009). CAR is constitutively expressed, 
because it allows nuclear co-activators to bind without the necessity for concurrent ligand binding 
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(Xiao et al., 2010), however, the activity of CAR can be up- and down-regulated through the 
binding of specific ligands and TFs (Pascussi et al., 2003; Assenat et al., 2004).  
2.2.3.1. Population distribution and function of genetic variation in NR1I3 
Until recently, only three main studies provided data for genetic variation in the gene (Ikeda et 
al., 2003, 2005; Thompson et al., 2005). Ikeda et al. (2003) reported 26 novel SNPs in a Japanese 
cohort of 253 subjects. Most SNPs were intronic and upstream variants, however, three SNPs 
were located in exons 4, 5, and 9 respectively; one was non-synonymous (V133G) and two were 
synonymous (P180P and Q344Q). However, no functional studies were performed. A follow-up 
study by Ikeda et al. (2005), involving functional studies as well as sequencing of NR1I3 in 334 
Japanese cancer patients, reported three novel exonic SNPs (H246A, L308P and N323S) with 
low allele frequencies (0.5%, 0.3% and 0.3% respectively). This study identified an association 
between the H246A and L308P variants and a decrease in CYP3A4-activation. Because this 
reduction was not due to reduced CAR expression, it was suggested that the two variants 
potentially cause a functional alteration of the protein.  
Thompson et al. (2005) sequenced the NR1I3 gene in 24 Caucasian, 23 African American and 23 
Chinese Han individuals. The majority of variants that were identified occurred at a low 
frequency and were unique to each population, with the minor allele frequency (MAF) greater 
than 0.2 for only five of the 21 SNPs, and only five of the 21 SNPs occurred in all three ethnic 
groups. Four novel exonic variants were identified, including a non-synonymous SNP, R97W. In 
silico analysis reported that R97W disrupts a predicted exonic splicing enhancer (ESE).  
The results published by two large-scale population genetic projects, the HapMap Project (The 
International HapMap 3 Consortium, 2010) and the 1000 Genomes Project (The 1000 Genomes 
Consortium, 2012), greatly increased the available variant data for most genes in the human 
genome, including NR1I3. To date, the Ensembl database, containing SNP data from both the 
HapMap Project and the 1000 Genomes Project, lists approximately 40 non-synonymous and 18 
synonymous SNPs in NR1I3, a frequency of one variant per 18 nucleotides in the coding region.  
When compared to the characteristics of an average human gene, the SNP frequency of NR1I3 is 
much higher. The E2F2 gene is representative of the average characteristics of 213 genes 
investigated in the Environmental Genome Project (Livingston et al., 2004). This gene has a SNP 
frequency of one variant per 24 nucleotides in the coding region, which is 33% lower than the 
NR1I3 SNP frequency (Ensembl Genomes Browser). These facts indicate that sequence 
conservation is lower in the coding region of human NR1I3 than previously thought (Ikeda et al., 
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2003; Thompson et al., 2005; Reschly & Krasowski, 2006). However, when investigating genetic 
conservation, a distinction should be made between common and rare variants, and differences 
among ethnic groups should be taken into account. 
2.2.3.2. The role of NR1I3 variants in EFV metabolism and treatment outcome 
CAR plays a role in the transcriptional regulation of most enzymes involved in EFV metabolism; 
it is therefore hypothesised that some genetic variation in NR1I3 may influence the rate of EFV 
metabolism (Wang et al., 2003; Burk et al., 2004; Yoshinari et al. 2010). This could influence 
EFV levels in vivo and, subsequently, could have downstream implications, such as altered 
clinical outcome. Two NR1I3 SNPs, rs2307424 and rs3003596, have been implicated in altered 
EFV levels or treatment outcome in previous studies.  Table 2 lists the MAFs for these two SNPs 
in Caucasian, Asian, African and African American patients, taken from 1000 Genome data. Both 
SNPs occur frequently in all four ethnic groups, however, rs2307424 occurs at a lower frequency 
in African populations (MAF = 0.108). In addition, the minor allele for the Asian population (C) 
differs from the minor alleles in the other ethnic groups (T). 
Wyen et al. (2011) investigated associations between CYP2B6 and NR1I3 polymorphisms and 
early EFV treatment default and discontinuation (< three months). The study used a cohort of 373 
patients, the majority of which were of Caucasian ethnicity and the remainder were of African 
ethnicity. Out of the total cohort, 131 patients discontinued EFV-based therapy within the first 
three months (35%), for various reported reasons, including CNS-specific ADRs (55%). Other 
reasons for discontinuation include viral failure and hepatotoxicity, but a large percentage of 
patients (42%) defaulted for unknown reasons. After logistic regression analysis correcting for 
confounding factors, CYP2B6 516G>T and NR1I3 rs2307424 were significantly associated with 
early EFV default (P = 0.006 and 0.007 respectively). Results also indicated that patients with 
composite genotypes for both SNPs were at a significantly higher risk of early default and 
discontinuation (P = 0.02). The confounding effects that were significantly associated with early 
EFV default are ethnicity and smoking habits (P < 0.05 in both cases). This is the only EFV-
based study that analysed direct genotype-to-treatment outcome correlation, without using EFV 
levels as a transitional measurement.  
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Table 2: Population and functional details of NR1I3 SNPs associated with EFV levels and 
treatment outcome in populations of Caucasian (Cau), Asian (Asn), African (Afr) and 
African American (AA) ethnicities. 
Location 
rs 
number 
Genomic 
identifier 
MAF 
Functional 
Relevance 
Reference Cau 
(CEU) 
Asn 
(CHB) 
Afr 
(YRI) 
AA 
(ASW) 
Intron 4 rs3003596 8784T>C 
0.453 
(T) 
0.420 
(C) 
0.386 
(T) 
0.492 
(T) 
Risk of CNS-ADRs, 
EFV plasma levels 
Swart et al., 2012; 
Mukonzo et al., 2013 
Exon 5 rs2307424 10396C>T 
0.300 
(T) 
0.485 
(C) 
0.108 
(T) 
0.213 
(T) 
EFV discontinuation, 
EFV plasma levels 
Wyen et al., 2011; 
Swart et al., 2012; 
Cortes et al., 2013 
CEU, CHB, YRI and ASW, represent four respective ethnic groups that form part of the 1000 
Genomes Project. CEU, Residents in Utah, USA, of Northern and Western European ancestry. 
CHB, Han Chinese in Bejing, China. YRI, Yoruba in Ibadan, Nigeria. ASW, Americans of 
African Ancestry in South West, USA.  
The rs2307424 SNP was also associated with EFV plasma levels in a Latin American cohort of 
208 HIV-positive individuals (Cortes et al., 2013). Patients with the rs2307424 T/T genotype had 
significantly decreased EFV plasma levels in comparison with the C/C (P < 0.05) and C/T (P < 
0.01) genotype. 
Swart et al. (2012), studying South African Bantu HIV-positive individuals (n = 464), also 
reported that rs2307424 is associated with increased risk of EFV discontinuation. In this study, 
32% of the patients with the rs2307424 C/T genotype experienced discontinuation of EFV 
treatment within one year, as opposed to 21% of patients with the wild type (C/C) genotype. 
However rs2307424 was not significantly associated with EFV plasma levels in this study. 
A SNP located in intron 4 of NR1I3, rs3003596 (8784T>C), was associated with EFV plasma 
levels in the Swart et al. (2012) study. Patients with the C/C and C/T genotypes had significantly 
lower EFV plasma levels than patients with the T/T genotype (P = 0.015 and 0.010 respectively). 
This significant association was not replicated in Mukonzo et al. (2013), a study of 197 patients 
living in Uganda. However, a trend was found between the rs3003596T/T and C/T genotypes and 
an increased risk of developing CNS-specific ADRs (P = 0.06). This corroborates previous 
studies that suggest that higher EFV levels lead to an increased occurrence of ADRs.  
These results suggest that EFV plasma levels are not always a direct indication of treatment 
outcome and that the addition of other measurements of treatment outcome is needed in ARV 
pharmacokinetic studies. It is also suggested that the assessment of the influence of confounding 
factors on EFV levels is important, such as age, ethnicity and treatment adherence. 
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2.2.4. PXR encoded by NR1I2 
NR1I2 is 34,500 bp in length and is located on human chromosome 3, region q13.33 (Hustert et 
al., 2001; Ensembl Genomes Browser). The gene contains ten exons, which are alternatively 
spliced to form the wild type PXR protein and nine other isoforms of PXR (Hustert et al., 2001). 
The wild-type protein, hPXR, contains translated material from all ten NR1I2-exons and is 434 aa 
in length (Lehmann et al., 1998; Hustert et al., 2001). The DBD consists of exons 3 and 4, while 
the LBD spans over exons 5 to 10 (Di Masi et al., 2009). The translation of an important isoform 
of PXR, hPXR.2, differs from the wild-type PXR in that the 37 aa in the ligand binding domain is 
lost, resulting in decreased PXR activity (Hustert et al., 2001). 
Even though it is not constitutively expressed, and various physiological compounds have been 
identified as ligands, PXR is still classified as an orphan nuclear receptor (Kliewer et al., 1998; 
Pondugula & Mani, 2013). Northern blot and reverse transcriptase-PCR (RT-PCR) assays report 
that PXR is expressed predominantly in the liver, and at a lower level in the colon and small 
intestine (Bertilsson et al., 1998; Lehmann et al., 1998). This differs from the expression patterns 
of PXR in mice (mPXR), where PXR is also expressed in stomach and kidney tissues, albeit at a 
much lower level (Kliewer et al., 1998).  
The ligand characteristics also differ between human and mouse or rat PXR homologs. For 
example, the affinity for rifampicin is much higher in human PXR than mouse PXR (Jones et al., 
2000; LeCluyse, 2001). This complicates the use of mouse models in PXR expression and 
association studies. However, Hasegawa et al. (2012) was able to circumvent this problem by 
using humanised mice to investigate the influence of PXR in the expression of CYP3A and 
CYP2C. 
2.2.4.1. Population distribution and function of genetic variation in NR1I2 
NR1I2 is less conserved among humans than NR1I3. The Ensembl-database, including data from 
the HapMap Project and the 1000 Genomes Project, currently lists approximately 65 non-
synonymous and 31 synonymous SNPs in NR1I2, a rate of one variant per 15 nucleotides in the 
coding region. Table 3 compares NR1I2 SNPs among four different ethnic groups from the 1000 
Genomes Project and literature.  
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Table 3: MAF of NR1I2 SNPs in populations of Caucasian (Cau), Asian (Asn), African 
(Afr) and African American (AA) ethnicities.  
Location rs number 
Genomic 
identifier 
Amino acid 
change, allele 
MAF 
Cau 
(CEU) 
Asn 
(CHB) 
Afr    
(YRI) 
AA 
(ASW) 
5’-upstream rs1523130  5177T>C n/a 
0.359 
(T) 
0.268 
(T) 
0.040 
(C) 
0.139 
(C) 
5’-upstream rs3814055  5705C>T n/a 0.341 0.268 0.301 0.238 
5’-UTR rs1523127 6709C>A n/a 
0.341 
(C) 
0.268 
(C) 
0.097 
(A) 
0.230 
(A) 
Intron 1 rs13085558 18885T>C n/a 0.188 0.178 0.023 0.066 
Intron 1 rs2472679 30120A>T n/a 0.188 0.077 0.489 0.418 
Intron 1 rs2472677 24087C>T n/a 0.359 0.371 0.352 0.361 
Exon 2 rs12721613 31846C>T P27S, PXR*2 0.000 0.000 0.188 0.107 
Exon 2 rs12721607  31873G>A G36R, PXR*3 0.000 0.000 0.000 0.016 
Exon 4 rs12721608
1 
36089G>A R122Q, PXR*4 0.010 n/a n/a 0.000 
Exon 4 rs72551372
2 
36142G>A V140M, PXR*10 0.001 n/a 0.002 n/a 
Exon 4 rs72551374
3 
36212A>G D163G, PXR*11 0.000 n/a 0.014 n/a 
Exon 8 rs35761343  40296G>A A370T 0.000 0.000 0.023 0.016 
1
2001 Zhang et al. 
2
Svärd et al., 2010. 
3
Hustert et al., 2001. MAFs for all other SNPs obtained 
from the 1000 Genomes Database. CEU, CHB, YRI and ASW, represent four respective ethnic 
groups that form part of the 1000 Genomes Project. CEU, Residents in Utah, USA, of Northern 
and Western European ancestry. CHB, Han Chinese in Bejing, China. YRI, Yoruba in Ibadan, 
Nigeria. ASW, Americans of African Ancestry in South West, USA. n/a, not applicable. 
Zang et al. (2001) first sequenced the NR1I2 gene in 150 Caucasian and 22 African American 
patients and reported 38 SNPs, including five 5’-upstream SNPs, two 5’-untranslated region 
(UTR) SNPs, three synonymous and three non-synonymous SNPs. One non-synonymous SNP, 
rs12721613 (P27S), was non-polymorphic in the Caucasian cohort and another SNP, rs12721607 
(G36R), was observed at a higher frequency in African Americans than in Caucasians. In the 
1000 Genomes data, P27S was detected in the Yoruban (YRI) and African American South West 
(ASW) populations (MAF = 0.188 and 0.107), but was non-polymorphic in the European 
Caucasian (CEU) and Chinese Han (CHB) population. G36R was present in the ASW population 
only (MAF = 0.016). The SNP rs12721608 (R122Q), polymorphic in only Caucasian individuals, 
was associated with a decrease in CYP3A4-promoter activation by PXR following in vitro PXR 
activity assays using reporter gene constructs. 
King et al. (2007) sequenced the NR1I2 gene including the 5’-UTR  and 3’-UTR in 120 
individuals of Caucasian, African American and Asian ancestry and identified 52 SNPs, of which 
14 (27%) were only polymorphic in the African American cohort. These SNPs included four non-
synonymous SNPs, three of which were unique to the African American cohort. One SNP in the 
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5’-UTR, rs1523127 (6709C>A), was associated with altered PXR activity. In this study, patients 
with the rs1523127 A-allele presented a significant increase in the PXR-induction of both 
CYP3A4 and ABCB1 transcription (P = 0.04 for both genes) (King et al. 2007). 
The sequencing of the 16 kb promoter region and intron 1 of NR1I2 by Lamba et al. (2008) in 24 
individuals resulted in the identification of 89 SNPs. Analysis of CYP3A4-activity in the 
presence of rifampicin identified five important SNPs. The T-alleles of two of these SNPs, 
rs13085558 (18885T>C) and rs2472679 (30120A>T), were significantly associated with 
decreased CYP3A4 induction by rifampicin (P = 0.010 and 0.023 respectively). Two other SNPs, 
rs2472677 (24087C>T) and rs1523130 (5177T>C), were significantly associated with increased 
basal CYP3A4 activity (P = 0.006 and 0.037) and one other SNP, rs3814055 (5705C>T), was 
significantly associated with increased induction of CYP3A4 by rifampicin (P = 0.046). After 
analysis of hepatic PXR expression, rs3814055, was also reported to be associated with decreased 
PXR expression in male individuals (P = 0.029). 
Even though these five studies present some overlap in SNP identification and selection, none of 
the significant functional findings was replicated in any of the studies. For example, the non-
synonymous SNP rs72551372 (V140M) was detected by both Hustert et al. (2001) and Svärd et 
al (2010), however, only the latter study was able to find significant statistical evidence of the 
influence of the SNP on PXR activity. 
2.2.4.2. The role of NR1I2 variants in EFV metabolism and treatment outcome 
There is little evidence that directly links NR1I2 genetic variation with EFV pharmacokinetics 
and treatment outcome. The T-allele of the rs2472677 SNP, as discussed above, was associated 
with higher CYP3A4 activity. In the study by Wyen et al. (2011), this SNP bordered on 
significance in EFV treatment outcome, as patients with the T-allele experienced a higher 
instance of EFV discontinuation (P = 0.072). It can therefore be hypothesised that an increase in 
CYP3A4 activity may result in a more rapid breakdown of EFV in the body and subsequent sub-
therapeutic EFV levels. 
Patients with the G/G-genotype for the rs3732356 (34783G>T) SNP experienced the lowest 
instance of EFV discontinuation after one year (0%), compared to patients with the T/G genotype 
(24%) and the T/T genotype (21%) (Swart et al., 2012). However, no indication of statistical 
significance was given, and the sample size of patients with the G/G-genotype was small (n = 9). 
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Table 4 lists the MAF of the rs2472677 and rs3732356 SNPs. SNP rs2472677 is well distributed 
across all the ethnic groups, however, the minor allele for the African and African American 
populations differ from the Caucasian and Asian populations. SNP rs3732356 occurs at a low 
MAF in Caucasian and Asian populations. 
Table 4: Population and functional details of NR1I2 SNPs associated with EFV SNPs in 
populations of Caucasian (Cau), Asian (Asn), African (Afr) and African American (AA) 
ethnicities.  
Location 
rs 
number 
Genomic 
identifier 
MAF 
Relevance Reference Cau 
(CEU) 
Asn 
(CHB) 
Afr 
(YRI) 
AA 
(ASW) 
Intron 1 rs2472677  24087C>T 
0.359 
(C) 
0.371 
(C) 
0.352 
(T) 
0.361 
(T) 
EFV discontinuation 
Wyen et al., 2011; 
Swart et al., 2012 
Intron 3 rs3732356  34783G>T 0.071 0.072 0.295 0.279 EFV discontinuation Swart et al., 2012 
CEU, CHB, YRI and ASW, represent four respective ethnic groups that form part of the 1000 
Genomes Project. CEU, Residents in Utah, USA, of Northern and Western European ancestry. 
CHB, Han Chinese in Bejing, China. YRI, Yoruba in Ibadan, Nigeria. ASW, Americans of 
African Ancestry in South West, USA. 
2.3. The Cape Mixed Ancestry population 
The ethnic group known as Cape Mixed Ancestry (CMA), or South African Coloured, forms 9% 
of the South African population, and 54% of the Western Cape population (De Wit et al., 2010; 
Statistics South Africa, 2013). The use of individuals from an admixed population, such as CMA, 
in pharmacological association studies, holds certain advantages and disadvantages. Depending 
on the length of time since the original ancestries were combined, admixture results in the 
inheritance of longer sequence regions in linkage disequilibrium (LD), which reduces the number 
of variants or markers needed to cover a certain region to analyse effects on phenotype (Baye & 
Wilke, 2010). However, an admixed population presents a higher risk of stratification and the 
presence of genetically similar sub-groups within the study cohort,  which can lead to results that 
are mistakenly reported as significant (Baye & Wilke, 2010). Knowledge of the ancestries that 
contribute to the genetic composition of a specific admixed cohort is therefore advantageous in 
association studies. 
The genetic profile of an admixed population can be analysed using microsatellites, SNPs and 
indels (insertions and deletions) to form structural and variance patterns that differ among 
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ancestries, as graphically illustrated in the CMA population in figure 3. The prediction power of 
these patterns is enhanced through analysis of LD among variants (De Wit et al., 2010).  
Two studies examined the major ancestries contributing to CMA genetic composition. Tishkoff et 
al. (2009) reported genetic contributions to CMA by Khoisan ancestry (25%), Niger-Kordofanian 
(N-K) ancestry (19%), which is shared by groups from Central and Western Africa, Indian 
ancestry (20%) and European ancestry (19%) (Figure 3A). De Wit et al. (2010), accounting for 
LD, reported genetic components from Khoisan (32%), African Bantu (36%), European 
Caucasian (21%) and Indian (11%) ancestries (Figure 3B) in the CMA population. The De Wit et 
al. (2010) study reports that two geographically separate CMA cohorts are genetically 
compatible; however, further studies are needed to investigate the possible genetic differences in 
CMA sub-groups.  
 
Figure 3: Structural and genetic patterns that contribute to the genetic contents of the CMA 
population in two studies, arranged in four different ways according to the major 
contributing ancestries.  
Each individual is represented as one bar and divided into four colours according to the 
proportion of European, Indian, Khoisan and Niger-Kordofanian ancestry present. A. Adapted 
from Tishkoff et al. 2009, with publisher’s permission. B. Adapted with De Wit et al., 2010, with 
publisher’s permission. 
2.4. The Xhosa population 
The Xhosa-speaking population constitutes 17.6% of the South African population and 24.7% of 
the Western Cape population (Statistics South Africa, 2012). Despite the large population size, 
limited population genetic information was available for the Xhosa population until 2009, when a 
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comprehensive study investigating the genetic variation among African populations, highlighted 
the need for further analysis of these populations (Tishkoff et al., 2009). 
When analysing the genetic composition of the Xhosa population, which form part of the 
Southern African Bantu population, the main contributing populations are from N-K (populations 
from Central and Western Africa, including the Yoruban population), and Khoisan populations 
(Tishkoff et al., 2009). The genetic constituency of the Xhosa population thus forms a separate 
group from the Khoisan and N-K populations, as presented through principal component analysis 
using 174,272 SNPs (Figure 4) (Schuster et al., 2010). 
 
Figure 4: Representation of the genetic structure of the Xhosa population to illustrate their 
separation from West African and Khoisan populations. 
Data obtained from principal component analysis using approximately 170,000 SNPs. The Xhosa 
population forms part of the Southern African (Bantu Niger Congo) population group. JHO, MD8 
and NOH, Khoisan individuals. SAN, Bushmen. YRI, Yoruban individuals. XHO, Xhosa 
individuals. ABT, Xhosa/Tshwana Bantu individual. Taken from: Schuster et al., 2010, with 
publisher’s permission. 
2.5. Significance of the study 
The validity of this study is proven through a summary of some of the discussion points in the 
literature review above. These points illustrate how this study can contribute to the understanding 
of the scope of genetic variance influencing EFV pharmacokinetics and treatment outcome, as 
well as describing the central role that NRs CAR and PXR play in the complex system of 
xenobiotic metabolism. 
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 The vast number of people who are HIV-positive and enrolled for ART globally and in 
South Africa, reveal the gravity of this pandemic, both on a global and national scale. 
(Sections 2.1.1 and 2.1.4) 
 The annual rapid increase of patients enrolled for ART indicate the necessity for effective 
management of ART on a global and national scale. (Section 2.1.1) 
 Ineffective management of ART leads to viral resistance and treatment failure highlights 
the need to measure individual treatment outcome accurately and to establish a global 
consensus on the definition of good and poor treatment outcome. (Sections 2.1.2 and 
2.1.3) 
 The roles of CYP1-, CYP2-, and CYP3-genes in EFV metabolism have been the focus of 
several studies; however, a more thorough understanding of the activation and 
transcriptional regulation of the CYP-genes is needed. (Section 2.1.5.1) 
 The overwhelming evidence for the influence of the CYP2B6 516G>T SNP, and its 
composite genotypes, on EFV metabolism warrants further investigation into other 
variants that cooperate with the 516T-allele. (Section 2.1.5.2) 
 The ability of CAR and PXR to regulate the transcription of various genes involved in the 
breakdown of xenobiotic substances show that these NRs play an integral role in 
xenobiotic metabolism, including EFV metabolism. (Section 2.2.2) 
 The promiscuous nature of the ligand binding domains of CAR and PXR reveals that the 
transcription of these NRs are influenced by various xenobiotic substances, which could 
ultimately influence the rate of EFV metabolism. (Section 2.2.2) 
 The influence of intronic, exonic and upstream variants in NR1I3 and NR1I2 on gene 
transcription and protein activity demonstrated in previous studies warrant further 
analyses of the effects of variants in these genes on EFV metabolism and treatment 
outcome, especially in the diverse South African populations (Sections 2.2.3 and 2.2.4). 
2.6. Research aim and objectives 
This study aims to analyse variation in NR1I3 and NR1I2, encoding CAR and PXR respectively, 
in female South African HIV-positive Xhosa and Cape Mixed Ancestry patients and, in 
conjunction with variations in CYP2B6, CYP3A, CYP1A2 and CYP2A6 to investigate correlations 
with EFV levels, treatment outcome, and adverse effects. 
This aim will be achieved by the following objectives: 
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1. Identify target variants in NR1I3 and NR1I2 through bi-directional sequencing, data-mining of 
the HapMap Project and 1000 Genomes Project databases and a comprehensive literature 
search.  
2. Genotype these target variants in 132 Xhosa and Mixed Ancestry HIV-infected female 
patients.  
3. Utilise statistical analyses to search for correlations among the target variants, EFV levels in 
hair samples, and treatment outcome, by means of VL and the occurrence of adverse effects 
as data parameters.  
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CHAPTER 3 
3. Materials and Methodology 
The current study can be divided into four components, following each other chronologically: 
Sample and clinical data collection; target variant identification; target variant genotyping; and 
variant genotype analysis and statistical analysis (Figure 5). The project started with the 
recruitment of eligible study participants at the TC Newman HIV clinic in Paarl and the 
subsequent collection of hair and saliva specimens and clinical data. The hair specimens were 
used to determine long term EFV levels, and the saliva specimens were used to extract genomic 
DNA.  
Following recruitment and sample collection, target variants were identified in NR1I3 through bi-
directional sequencing and in NR1I2 through a survey of the HapMap and 1000 Genomes 
databases and literature. The identified target variants were then genotyped in the cohort of 79 
Xhosa and 53 CMA HIV positive patients using an assortment of genotyping techniques. The 
genotyping results were then analysed in conjunction with measured EFV levels and clinical data 
in order to find any statistically significant correlations. 
3.1. Study participants 
A total of 136 patients were initially recruited for this study, but only 132, consisting of 79 
patients of Xhosa (Xh) ethnicity and 53 patients of CMA ethnicity, were included for genetic 
studies. Ethnicity was verbally reported by the patients themselves. All patients were above the 
age of 18, female and HIV-positive. The patients were recruited at the TC Newman HIV Clinic in 
Paarl, Western Cape. All patients were prescribed an EFV-containing first-line ART regimen as 
directed by the South African Treatment Guidelines (National Department of Health, 2004) for a 
minimum period of three months. Other ARV drugs taken with efavirenz include d4T, 
lamivudine (3TC), tenofovir (TDF) and AZT. Consent were given by the patients for the 
participation in this study, and ethical approval was obtained by the Committee for Human 
Research, Stellenbosch University (Reference Number: N08/08/225) and the Department of 
Health (DOH), Western Cape. 
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Figure 5: Flow diagram representing the chronological division of the current project into 
four sections, specifically, sample and clinical data collection, target variant identification, 
target variant genotyping and statistical analysis.  
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3.2. DNA sample collection and extraction 
A minimum of 2 ml saliva were collected in Oragene
®
 collection units (DNA Genotek Inc., 
Kanata, Canada) from each patient (Röhrich, 2012) and labelled with individual patient 
identification (ID) numbers. The samples were prepared for storage following the protocol 
provided by the supplier (Appendix A) and stored at -20°C. DNA was extracted as needed from 
the samples following the Oragene
®
 protocol (Appendix A). The extracted DNA stock 
concentrations were measured for each sample using the NanoDrop
®
 ND-100 spectrophotometer 
(Thermo Fisher Scientific Inc., Waltham, USA). From the stock DNA, diluted aliquots with a 
concentration of 15 ng/μl were prepared with the addition of Sabax water (Adcock Ingram Pty. 
Ltd., Midrand, ZA). 
3.3. Hair sample collection and EFV measurement 
Hair samples were collected from each patient as reported in Röhrich (2012). Roughly 20 strands 
of hair were cut off close to the scalp at the back of the head from each patient and labelled with 
patient ID number and hair colour. Samples were covered in foil and sent to the Department of 
Clinical Pharmacy, University of California, San Francisco (UCSF) in the USA for analysis. The 
technique used for EFV measurement was liquid chromatography tandem mass spectrometry 
(LC/MS/MS), the protocol of which is described in Huang et al. (2008). The average weight of 
the hair samples were 2 mg and EFV levels were measured in ng EFV per mg of hair sample 
(ng/mg). 
3.4. Clinical data collection 
The TC Newman HIV clinic supplied clinical data for 131 patients from clinical folders and from 
an electronic database. Basic personal information was obtained, consisting of date of birth, 
hospital ID, alcohol consumption and smoking habits. Important dates were recorded including 
date of HIV diagnosis, start of ART, start of EFV-based ART and date of sample collection. 
Clinical baseline information was obtained at the start of treatment, which included height, 
weight, WHO disease stage and CD4 count. The level of adherence was described through a 
range of pill-count percentages: When 70 – 100% of medication was taken it was considered 
good adherence, acceptable adherence was considered as 50 – 70% and bad adherence was 
considered as 0 – 50%.  The list of adverse drug reactions obtained consisted of CNS-ADRs 
(headaches, dizziness, dreams, insomnia, depression and psychosis), liver toxicity, lactic acidosis, 
anaemia, lipodystrophy, peripheral neuropathy and work impairment. Adverse drug reactions 
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were reported through patient verbal communication, clinical examination and blood tests. 
Records of patient default of treatment, changes in regimen and the accompanying reasons were 
obtained. Measurements of CD4 count, VL and weight were recorded every six months. The list 
of additional medication collected consisted of medication for TB (primarily rifampicin), 
diabetes, hypertension, asthma, hypercholesterolemia, epilepsy, as well as anticoagulants and 
chemotherapeutic agents. Additionally, the genotypes of patients for the CYP2B6*6 allele was 
available from a previous study (Röhrich, 2012). 
3.5. In silico analysis of NR1I3 
In order to identify upstream amplicons (UAs) in the promoter and 5’-upstream area of the NR1I3 
gene, two strategies were followed. One strategy followed the claim that regions of high sequence 
conservation among orthologs of the human NR1I3 gene could be important to gene function. 
Therefore the promoter region of NR1I3 was searched for conserved regions. Another strategy 
followed the idea that possible transcription factor binding sites (TFBSs) in the gene promoter 
could be important for transcriptional regulation of the gene. Therefore, the promoter area of 
NR1I3 was scanned for putative TFBS. 
3.5.1. Analysis of sequence conservation using mVISTA 
Areas of genetic conservation in the NR1I3 promoter and 5’-upstream region were analysed using 
mVISTA (VISTA Tools for Comparative Genomics, Frazer, et al., 2004). Orthologs for the 
human NR1I3 gene was identified using the Ensembl Genomes Browser and HomoloGene. The 
orthologs selected and their respective percentage identities to the human NR1I3 gene are listed in 
Table 5. Sequences for the 5kb-upstream region, the first two exons and the first intron for each 
gene were obtained from the Ensembl Genomes Browser. The mVISTA software was used to 
find areas of sequence conservation among these homologous genes. 
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Table 5: List of orthologs used in the sequence conservation analysis using mVISTA and 
their percentage identity to the NR1I3 human sequence. 
Gene Species Ensembl identifier % identity 
NR1I3 Homo sapiens (human) ENST00000367983.4 100 
NR1I3_PANTR Pan troglodytes (chimpanzee) ENSPTRT00000002884 100 
NR1I3 Gorilla gorilla (gorilla) ENSGGOT00000005750 99 
A2T809_PONPY Pongo abelii (orangutan) ENSPPYT00000000729 98 
Q38IV5_CANFA Canis familiaris (dog) ENSCAFT00000014526 85 
Q2KIF4_BOVIN Bos Taurus (cow) ENSBTAT00000012145 84 
NR1I3 Rattus norvegicus (rat) ENSRNOT00000049873  77 
NR1I3 Mus musculus (mouse) ENSMUST00000005820  73 
NR1I3 Felis catus (cat) ENSFCAT00000000496  71 
3.5.2.  Identification of putative transcription factor binding sites using 
freeware prediction programs 
Further analysis of the promoter area of NR1I3 prompted the search for putative TFBSs. Free 
prediction software programs were used to find putative TFBSs in the 5 kb upstream area, exon 1 
and intron 1 of NR1I3. NR1I3 gene and transcript sequences were taken from the Ensembl 
Genomes Browser (Ensembl identifiers ENSG00000143257, ENST00000367983.4) and analysed 
using the default settings in six programs, Match, AliBaba, Patch, P-Match, Jaspar and rVISTA 
(Grabe, 2002; Loots et al., 2002; Kel, 2003; Sandelin et al., 2004; Chekmenev et al., 2005). 
Results were compiled in Microsoft Office Excel 2010 and compared to functional TFBSs in 
NR1I3 identified in literature. 
3.6. Identification of target variants in NR1I3 through bi-directional 
Sanger sequencing 
3.6.1. Primer design 
Sequences for a total of 10 amplicons were obtained from the Ensembl Genomes Browser 
(Ensembl identifier ENST00000367983.4). The amplicons include the areas encoding the DNA 
binding domain (DBD) and parts of the ligand binding domain (LBD) of NR1I3. Figure 6 
presents the location of the primer sets, as well as the regions amplified in NR1I3. Primers were 
either designed using PrimerQuest (Integrated DNA Technologies Inc., Coralville, USA) or 
obtained from literature (Ikeda et al., 2003; Thompson et al., 2005). Evaluation of primer melting 
temperature (TM), GC-content, dimer-formation and hairpin-formation was performed using 
OligoAnalyzer (Integrated DNA Technologies Inc., Coralville, USA) and evaluation of primer 
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specificity was performed using primer-BLAST (pBLAST) (Ye et al., 2012). Primers for 
amplifying the exonic regions were designed to allow a flanking region of +/- 50 bp both sides of 
the exons where possible in order to incorporate potential splice sites. All primers used for the 
amplification of the target regions for bi-directional sequencing are listed in Appendix B. Primers 
were supplied by Integrated DNA Technologies (IDT) (Integrated DNA Technologies Inc., 
Coralville, USA). 
 
Figure 6: Regions of NR1I3 amplified for sequencing, consisting of 10 amplicons. 
UA1 (red box) is located 4.2 kb from the start of exon 1. UA2 and UA3 (green boxes) are located 
just upstream of exon 1. The region in the blue boxes includes the 5’-UTR present in exon 1 and 
a part of exon 2, and also the rest of the coding region (a total region of 8.9 kb). 
3.6.2. PCR amplification 
Following optimisation, all 10 amplicons in NR1I3 were amplified using 15 ng of each diluted 
DNA sample for 15 Xhosa individuals and 15 CMA individuals, resulting in a total of 300 
polymerase chain reactions (PCRs). PCR amplification was performed on either GeneAmp 9700 
or GeneAmp2700 thermocyclers (Life Technologies
TM
 Corporation, Carlsbad, USA) using the 
following general cycle conditions: 94°C for three min, one cycle; 94°C for 15 sec, TA for 15 sec, 
72°C for 30 sec, 35 cycles; 72°C for five min, one cycle. Annealing temperatures (TA) of 64°C 
(for UA1 and UA3), 60°C (for Exon 1 and Exon 2), 54°C (for Exon 3), 58°C (for Exon 4/5) and 
62°C (for Exon 6/7) were used.  
Exons 8 and 9 were amplified through hotstart-PCR with the following cycle conditions: 94°C 
for three min, one cycle; 94°C for 15 sec, T1 for 15 sec, 72°C for 30 sec, 10 cycles; 94°C for 15 
sec, T2 for 15 sec, 72°C for 15 sec, 12 cycles; 72°C for five min.  Annealing temperatures (T1 and 
T2) of 58°C and 54°C (Exon 8); and 66°C and 60°C (Exon 9) were used. 
The total reaction mixture of 25 μl used for all amplicons consisted of 1x ammonium (NH4) 
reaction buffer, 1.5 mM magnesium chloride (MgCl2), 0.4 mM deoxynucleotide triphosphate 
molecules (dNTPs), the primers discussed above (forward and reverse primers for each PCR), 0.5 
U BIOTAQ
TM
 DNA polymerase, and Sabax water. All reagents in the reaction mixture were 
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supplied by Bioline
TM 
(London, UK), except for the primers (Integrated DNA Technologies Inc., 
Coralville, USA) and the Sabax water (Adcock Ingram Pty. Ltd., Midrand, ZA). The amount of 
each primer used was 10 pmol from a 10 pmol/μl stock solution for all amplicons except UA1 
and Exon 4/5, where 8 pmol of each primer was used. 
Electrophoresis was performed for the amplified PCR products on 1.0% (w/v) agarose gels 
(Lonza Group Ltd., Rockland, USA) prepared with a 1x TBE buffer solution (Appendix C) and 
stained with 2.5 μl ethidium bromide (Sigma-Aldrich Co. LLC, St. Louis, USA). A volume of 5 
μl of PCR product, mixed with 5 μl cresol loading dye (Appendix C) was loaded onto the agarose 
gel, along with a Hyperladder IV (Bioline
TM
, London, UK) molecular marker. The gels were 
exposed to an electric current for 30-45 min at 120 V and visualised under ultraviolet (UV) light 
at a wavelength of A260 nm using the  MultiGenius bio-imaging system (Syngene, Synoptics Ltd., 
Cambridge, UK). 
3.6.3. Sequencing reaction and capillary electrophoresis 
PCR products were subjected to a cleaning protocol (SureClean, Bioline
TM
, London, UK) 
(Appendix A) and cleaned product concentrations were determined using the NanoDrop
®
 ND-
100 spectrophotometer (Thermo Fisher Scientific Inc., Waltham, USA). Bi-directional 
sequencing reactions were performed using 3-20 ng of the cleaned PCR product, 3.3 pmol of a 
1.1 pmol/μl primer dilution (forward and reverse primers were used in separate reactions), 2.7 μl 
of Half-Dye Mix (Bioline
TM
, London, UK), 1.3 μl of BigDye® Terminator v1.1 Ready Reaction 
Mix (Life Technologies
TM
 Corporation, Carlsbad, USA) in a final reaction volume of 10 μl. The 
sequencing reaction was performed on a GeneAmp 9700 thermocycler (Life Technologies
TM
 
Corporation, Carlsbad, USA) and the following cycle conditions were used: 94°C for five min, 1 
cycle; 94°C for 10 sec, 55°C for 10 sec, 60°C for four min, 25 cycles. Following the sequencing 
reaction, 1 μl of a 2.2% (w/v) sodium dodecyl sulphate (SDS) solution (Appendix C) was added 
to the products, which were then subjected to a thermal cycle of 98°C for five min and 25°C for 
10 min. Following SDS clean-up, the products were sent to the DNA Sequencing Central 
Analytical Facility (CAF, Stellenbosch, ZA) for visualisation through capillary electrophoresis 
using a 3130XI Genetic Analyzer (Life Technologies
TM
 Corporation, Carlsbad, USA). 
3.6.4. Evaluation of sequencing results and identification of sequence variants 
Chromatograms for each patient were visualised in BioEdit Sequence Alignment Editor (Hall, 
1999) and aligned to reference sequences from the Ensembl Genomes Browser. Only variants 
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that were present in the sequencing results of both directions were accepted and used in further 
analysis. The identified variations were then evaluated in order to select target variants for 
genotyping. Priority was given to variants with functional importance in literature, the disruption  
of putative TFBSs as predicted by AliBaba (Grabe, 2002), the possible effect of non-synonymous 
variants on protein activity as predicted by SIFT and PolyPhen (Ramensky et al., 2002; Ng, 
2003), and the possible effect of variants on the folding of single-strand (ss) DNA and mRNA as 
predicted by mFOLD (Zuker, 2003). 
3.7. Identification of target NR1I2 variants through a survey of literature 
and genotype databases 
During this study, online accessible databases for the HapMap and 1000 Genomes projects were 
established (The International HapMap 3 Consortium, 2010; The 1000 Genomes Consortium, 
2012). These databases are easy to access, have a large amount of variation data available and use 
diverse populations (including African populations). Therefore it was decided to use these 
databases, in combination with a literature analysis, to find target variants for genotyping in the 
NR1I2 gene. Through the use of databases PubMed (http://www.ncbi.nlm.nih.gov/pubmed) and 
ScienceDirect (http://sciencedirect.com) and the search engine Google Scholar 
(http://scholar.google.co.za), suitable research journal articles were identified which focussed on 
NR1I2 SNP population frequencies, and their impact on drug pharmacokinetics as well as other 
medically relevant phenotypes. Functional importance and allele frequency were used as 
benchmarks for selecting variants. A minimum MAF of 0.05 was considered as a cut-off value 
for selecting variants, with priority given to variants with a high MAF in African or African 
American populations. Functional characteristics of variants that were considered included the 1) 
disruption of putative or confirmed TFBS, 2) the influence on the transcription and activity of 
PXR and downstream proteins, and 3) influence on phenotypic outcomes including drug levels, 
clinical disease outcome and clinical treatment outcome. 
3.8. Genotyping of target variants in NR1I3 and NR1I2 
A total of 19 variants were genotyped in the study cohort: Nine variants from NR1I3, nine 
variants from NR1I2 and one short deletion from NR1I2. Various genotyping techniques were 
used, namely PCR restriction fragment length polymorphism assays (PCR-RFLP) (14 SNPs), 
temperature switch PCR assays (TSP) (Tabone et al., 2009) (three SNPs) and Taqman
®
 SNP 
Genotyping assays (Life Technologies
TM
 Corporation, Carlsbad, USA) (one SNP). A 6-bp-
deletion (rs3842689) was characterised through PCR amplification and subsequent visualisation 
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of fragment size differences. The specific characteristics (TA, MgCl2 concentration and primer 
concentration) for each SNP assay are listed in Table 6. 
Table 6: PCR cycle characteristics for genotyping assays for all SNPs, consisting of 
annealing temperature, MgCl2 concentration and the amount of primer used per reaction. 
Gene SNP Genotyping assay 
TA  or T1, 
T2, T3 
(°C) 
[MgCl2] 
in mM 
Primer amount 
in pmol
1
 or 
μM2 
NR1I3 rs55802895 PCR-RFLP
 
60 1.5 10 
NR1I3 rs35709078 PCR-RFLP 54 1.5 10 
NR1I3 rs3003596
 
PCR-RFLP 60 1.5 10 
NR1I3 rs2502815 TSP 60, 47, 53 1.5 0.1, 0.5 
NR1I3 rs35205211 PCR-RFLP 58 1.5 8 
NR1I3 rs34161743 PCR-RFLP 58 1.5 8 
NR1I3 rs2307424 TSP 64, 51, 53 2.0 0.1, 0.4 
NR1I3 rs2307420 PCR-RFLP 60 1.5 10 
NR1I3 rs113800307 PCR-RFLP 62 1.5 10 
NR1I2 rs1523130 Taqman® analysis N/A N/A N/A 
NR1I2  rs3814055 PCR-RFLP 60
3
, 55
4 
1.5 10 
NR1I2 rs1523128 PCR-RFLP 60 1.5 10 
NR1I2 rs1523127 TSP 60, 43, 53 2.0 0.1, 0.5 
NR1I2 rs3842689 6-bp deletion 60 1.5 8 
NR1I2 rs2472677 PCR-RFLP 60 1.0 10 
NR1I2 rs12721613 (PXR*2) PCR-RFLP 60 1.5 10 
NR1I2 rs1464603 PCR-RFLP 60 1.5 10 
NR1I2 rs1464602 PCR-RFLP 60 1.5 10 
NR1I2 rs2276707 PCR-RFLP 60 1.5 10 
1
For PCR-RFLP and deletion assays: Primer amount as taken from a 10 pmol/μ stock solution. 
2
For TSP assays: LS primer TM and NLS primer TM.  
3
TM for the first amplification of the 
assay. 
4
TM for the nested amplification of the assay. 
3.8.1. Primer design 
Primers used for PCR-RFLP, TSP or deletion assays for NR1I3 and nine variants are given in 
Appendix B.  Primers were either designed with the use of PrimerQuest (Integrated DNA 
Technologies Inc., Coralville, USA), or taken from literature (Ikeda et al., 2003; Thompson et al., 
2005; Andrews et al., 2010), and analysed using OligoAnalyzer (Integrated DNA Technologies 
Inc., Coralville, USA). The template sequences used for primer design, ENST00000367983.4 
(NR1I3) and ENST00000393716 (NR1I2), were obtained from the Ensembl Genomes Browser. 
All primers were supplied by IDT. 
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Primers that best fit the following criteria were selected for the PCR-RFLP assays and deletion-
assay: Primer size between 22 bp and 26 bp, a TM between 55°C and 65°C, GC-content of 50% to 
60%, minimum primer dimer formation and minimum hairpin formation. Primer specificity was 
analysed through pBLAST (Ye et al., 2012). The assay for one SNP, rs3814055, required a 
nested PCR assay and primers were designed accordingly. 
For the TSP-assays, two sets of primers were designed for each SNP, a locus-specific (LS) primer 
set and a nested locus-specific (NLS) primer set with TM the key difference between the two sets. 
The LS primers required a TM between 60°C and 65°C and the resulting amplicon size exceeded 
400 bp. The NLS primers required a TM between 43°C and 47°C and the resulting amplicon size 
was between 200 bp and 300 bp. A non-complementary 5’-tail was added to all NLS-primers in 
order to increase the TM once annealing has taken place. 
3.8.2. Restriction fragment length polymorphism analysis 
PCRs for PCR-RFLP assays were performed on either GeneAmp 9700 or GeneAmp 2700 
thermocyclers using a reactant mix with a total volume of 25 μl consisting of 1x NH4 reaction 
buffer, MgCl2, 0.4 mM dNTPs, forward and reverse primers, 0.5 U BIOTAQ
TM
 DNA polymerase 
and Sabax water. Each reaction contained 15 ng of DNA (1 μl). The general cycle conditions 
used for amplification were: 94°C for three min, one cycle; 94°C for 15 sec, TA for 15 sec, 72°C 
for 30 sec, 35 cycles; 72°C for five min, one cycle.  
Ampified DNA products were visualised through electrophoresis using ethidium bromide-stained 
1.0% agarose gels prepared with 1X TBE buffer and a voltage of 120 V for 30 minutes (see 
Appendix C). A total loading volume of 10 μl consisting of 5 μl PCR product and 5 μl cresol 
loading dye for each sample was loaded onto the agarose gel and Hyperladder V (Bioline
TM
, 
London, UK) was used as the molecular marker. Following electrophoresis, the gels were 
visualised with the MultiGenius bioimaging system. 
PCR products were subjected to restriction enzyme digestion in a waterbath at specific 
temperatures as specified in Table 7, using enzymes supplied by New England Biolabs
®
, Inc. 
(NEB), Ipswitch, USA and Promega Corporation, Fitchburg, USA. The reactant mix for digestion 
consisted of 5μl PCR product, 1x reaction buffer, enzyme and Sabax water and amounted to a 
total volume of 20 μl. Table 7 lists the enzymes and amount of enzyme used, buffers, incubation 
time and additional reagents used for each SNP. 
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Table 7: Enzymes used for all SNPs genotyped using PCR-RFLP analysis. 
SNP Enzyme Buffer Supplier 
Amount 
in units 
(u) 
Incubation 
temperature 
(°C) and time 
Additional 
reactants 
rs113800307 Nco I NEBuffer 3 NEB® 3 u 37°C, 1 hr n/a 
rs2307420 Pst I NEBuffer 3 NEB® 5 u 37°C, overnight 100 μg/ml BSA 
rs34161743  MspA I NEBuffer 4 NEB® 3 u 37°C, 1-4 hrs 100 μg/ml BSA 
rs35205211 Hha I Buffer C Promega 3 u 37°C, 1-4 hrs n/a 
rs3003596
 
Hpy188 I NEBuffer 4 NEB® 3 u 37°C, overnight 100 μg/ml BSA 
rs35709078 Bfa I NEBuffer 4 NEB® 3 u 37°C, 1-4 hrs n/a 
rs55802895 Hph I NEBuffer 4 NEB® 3 u 37°C, 1 hr n/a 
 rs3814055 Mbo I NEBuffer 2 NEB® 3 u 37°C, 1 hr n/a 
rs1523128 Hha I NEBuffer 4 NEB® 3 u 37°C, 1 hr 100 μg/ml BSA 
rs2472677 Hpy188 I NEBuffer 4 NEB® 3 u 37°C, 1 hr n/a 
rs12721613 
(PXR*2) 
Bmr I 
NEBuffer 
2.1 
NEB® 3 u 37°C, 1 h n/a 
rs1464603 BsmB I NEBuffer 3 NEB® 5 u 37°C, overnight n/a 
rs1464602 BsmF I NEBuffer 4 NEB® 3 u 65°C, 1 hr 100 μg/ml BSA 
rs2276707 Bcc I NEBuffer 1 NEB® 3 u 37°C, 1 hr n/a 
NEB®, New England Biolabs®. BSA, bovine serum albumin. hr(s) hour(s). 
For SNP rs2276707, digested products were visualised using 15% (w/v) polyacrylamide gels (see 
Appendix C). All polyacrylamide gels were prepared using 5X TBE Buffer, prepared from a 10X 
TBE stock solution (see Appendix C).  A total loading volume of 15 μl consisted of 10 μl 
digested PCR product and 5 μl Bluejuice loading dye (Appendix C) for each sample. 
Additionally, a molecular marker (Hyperladder V, Bioline
TM
, London, UK) was loaded onto the 
gel. Electrophoresis was performed using a Mighty Small II S250 unit (Amersham Biosciences, 
GE Healthcare, Buckinghamshire, UK) at 150 V for 90 minutes. Following electrophoresis, the 
gels were stained using ethidium bromide and visualised with the MultiGenius bio-imaging 
system. For the remaining 13 SNPs, digested procucts were visualised through electrophoresis of 
agarose gels.  For each digested product,  7 μl digested product and 7 μl cresol loading dye was 
loaded onto a 3% (w/v) ethidium-bromide stained agarose gel, along with Hyperladder IV and V 
(Bioline
TM
, London, UK) as molecular markers. Gel electrophoresis was performed at a voltage 
of 80 V for +/- two hours, then visualised under UV light. 
3.8.3. Temperature switch PCR analysis 
All PCR-reactions for TSP genotyping assays were performed on a Veriti
TM
 thermocycler (Life 
Technologies
TM
 Corporation, Carlsbad, USA) with the following cycle conditions: 94°C for three 
min, 1 cycle; 94°C for 30 sec, T1 for 30 sec, 72°C for 1 min, 15 cycles; 94°C for 10 sec, T2 for 30 
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sec, five cycles; 94°C for 10 sec, T3 for 30 sec, 72°C for five sec, 15 cycles; 72°C for five min, 
one cycle. The reaction mix for each TSP reaction consisted of 1x NH4 reaction buffer, MgCl2, 
0.4 mM dNTPs, forward and reverse primers, 100 ng/μl bovine serum albumin (BSA) and 0.15 U 
BIOTAQ
TM
 DNA polymerase with a final total volume of 8 μl. All reagents were supplied by 
Bioline
TM
 (London, UK), except BSA (New England Biolabs
®
, Inc. (NEB), Ipswitch, USA) and 
Sabax water (Adcock Ingram Pty. Ltd., Midrand, ZA). Table 6 summarises the unique PCR-
characteristics of each TSP genotyping assay. 
Fragment size differences were visualised with electrophoresis of 1.5% (w/v) agarose gels 
prepared with 1X TBE at a voltage of 100 V for 45 minutes, and stained with ethidium bromide. 
An amount of 5 μl cresol solution was added to each TSP-product, after which 10 μl of the 
cresol-product mix was loaded onto the agarose gel along with a Hyperladder IV (Bioline
TM
, 
London, UK) molecular marker. The gels were visualised with the MultiGenius bioimaging 
system. 
3.8.4. Deletion analysis 
A 6 bp deletion, rs3842689, was genotyped through PCR amplification of the sequence flanking 
the deletion (Figure 7) and the subsequent visualisation of different fragment sizes of the 
resulting amplicon. The reactant mix with a total volume of 25 μl consisted of 15 ng of a 15 ng/μl 
DNA sample dilution, 1x NH4 reaction buffer, 1.5 mM MgCl2, 0.4 mM dNTPs, 8 pmol of 10 
pmol/μl forward and reverse primer dilutions, and 0.5 u BIOTAQTM. The fragment was amplified 
using a PCR cycle of: 94°C for three min, one cycle; 94°C for 15 sec, 60°C for 15 sec, 72°C for 
30 sec, 30 cycles, 72°C for five min, one cycle. 
 
Figure 7: Deletion rs3842689 (bold and in brackets) and its flanking sequence (in the 5’ to 
3’ direction). 
The arrows indicate the annealing sites of the forward and reverse primers. 
Resulting amplicons were visualised on a 15% polyacrylamide gel prepared with 5X TBE buffer 
(Appendix C). A Mighty Small II S250 unit (Amersham Biosciences, GE Healthcare, 
Buckinghamshire, UK) was used for electrophoresis. A total mixture of 15 μl consisting of 10 μl 
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PCR product and 5 μl Bluejuice (Appendix C) was loaded onto the gel, followed by 
electrophoresis at 120 V for 90 minutes. Gels were stained with ethidium bromide and fragments 
were visualised under UV light using the MultiGenius bioimaging system. 
3.8.5. Taqman® analysis 
One SNP, rs1523130, was genotyped using TaqMan
®
 Drug Metabolism Genotyping Assay 
(assay number C___9152783_20, Life Technologies
TM
 Corporation, Carlsbad, USA). A reaction 
mix with a total volume of 10 μl consisting of 15 ng sample DNA, 1x Taqman® Genotyping 
Master Mix, 1x TaqMan
®
 Drug Metabolism Genotyping Assay and Sabax water was pipetted 
onto a MicroAmp
®
 Fast Optical 96-well plate (Life Technologies
TM
 Corporation, Carlsbad, USA) 
and covered with a MicroAmp
®
 Optical Adhesive Film. After centrifuging, PCR amplification 
and probe incorporation was performed with the StepOne
TM
 Real-Time PCR System (Life 
Technologies
TM
 Corporation, Carlsbad, USA). The PCR cycle program was set using StepOne
TM
 
Software v2.2.2 and consisted of 60°C for 30 sec, 1 cycle; 95°C for 10 min, 1 cycle; 95°C for 15 
sec and 60°C for 1 min, 60 cycles. Results were analysed using StepOne
TM
 Software. 
3.9. Variant analysis 
3.9.1. Genotype and allele frequency analysis 
Allele frequencies for all variants were compared between the Xhosa cohort and the CMA cohort. 
The variant MAFs for both cohorts were also compared to MAFs of five population groups from 
the 1000 Genomes Project and one population group from the HapMap Project (The International 
HapMap 3 Consortium, 2010; The 1000 Genomes Consortium, 2012). Descriptions for all 
populations used are listed in Table 8. Genotype and allele information of all variants were 
collected from the 1000 Genomes Browser in Ensembl and from the HapMap database. 
Contingency tables (http://www.vassarstats.net) were used to search for significant differences in 
genotype and allele frequency between the study cohorts and the 1000 Genome and HapMap 
population groups. MAF information for the HapMap and 1000 Genomes populations were not 
available for variants rs113800307 and rs3842689, resulting in the omission of these two variants 
from the analysis. 
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Table 8: Description of HapMap (HM) and 1000 Genomes (1000 G) populations. 
Population Name Database Description 
LWK 1000 G Luhya in Webuye, Kenya 
YRI 1000 G Yoruba in Ibadan, Nigeria 
ASW 1000 G Americans of African Ancestry in South West, USA 
CEU 1000 G 
Utah Residents (CEPH) with Northern and 
Western European ancestry 
CHB 1000 G Han Chinese in Bejing, China 
GIH HM Gujarati Indian from Houston, Texas 
Adapted from: http://www.1000genomes.org/faq/which-populations-are-part-your-study. 
3.9.2. Hardy-Weinberg equilibrium analysis 
For both the Xhosa and CMA cohort, all genotyped variants were tested for compliance with 
Hardy-Weinberg equilibrium (HWE) using Tools For Population Genetic Analyses v1.3 
(TFPGA) (Miller, 1997). For variants for which less than five individuals were genotyped, an 
analogue to Fischer’s Exact test was used to evaluate deviation from HWE. For variants where all 
genotypes contained more than five individuals, a Pearson’s chi-square test (χ2) was used. 
Significant deviation from HWE in a population was indicated by a P-value (P) of less than or 
equal to 0.01. 
3.9.3. Testing variants for linkage disequilibrium 
Investigating the patterns of linkage disequilibrium (LD) in the Xhosa and CMA cohorts is 
important, as they might differ from other African populations. Testing for the level of LD among 
variants enables the differentiation between variants that have a unique effect on EFV levels and 
treatment outcome, and linked variants with a mutual effect. Genotype data for all genotyped 
variants in the Xhosa and CMA cohorts that complied with HWE and had a MAF of greater than 
0.01, were compiled and imported in Haploview v4.2 (Barrett et al., 2005), using default settings. 
The parameters used to indicate LD among variants, were correlation coefficient (r
2
) values of 
equal to or greater than 0.4 and logarithm of the odds (LOD) scores exceeding 2. 
3.10. Statistical analysis 
3.10.1. Analysing the effect of confounders 
Given the small sample size of the study, adjustments for large numbers of confounding factors 
can reduce the power of statistical analysis for the study. Therefore it was decided to minimise 
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the number of adjustments.  Using R statistical software (The R Development Core Team, 2010), 
the following confounding effects were tested for significant influence on the data generated: 
Ethnicity, time using EFV, baseline CD4, baseline VL, adherence, age at diagnosis, weight, 
smoking habits, alcohol consumption and WHO stage at treatment initiation. Confounding factors 
that showed significance (P ≤ 0.05) were adjusted for in all subsequent statistical analysis. 
3.10.2. Testing for correlations between genotype and EFV hair levels using 
linear regression models 
Using Microsoft Office Excel 2010, the preliminary effect of genotype on mean EFV levels was 
investigated, before statistical adjustments were made to the data. The two separate Xhosa and 
CMA cohorts were sorted into groups according to genotype for each variant. From the number 
of patients in each genotype group, the number and frequencies of each allele was calculated. The 
mean EFV level was calculated for each group (genotype and allele) and compared. 
Where possible, 2x2 and 3x2 contingency tables (www.vassarstats.net) were used to indicate 
significant differences in genotype frequency between groups. A P-value of ≤ 0.05 was an 
indication of possible significance. In each case where the individuals of one group were less than 
5, a Fisher’s exact test was used to test significance. In all other cases, a χ2 test was used. 
The linear effect of single variant genotype on EFV levels in the Xhosa and CMA cohorts were 
analysed using R statistical software (The R Development Core Team, 2010). The effects of 
statistically significant variants (P ≤ 0.05) were quantified through linear regression models.  All 
sequenced and genotyped variants that complied with HWE and had a MAF of ≥ 0.1 were 
included in the analysis.  
Additionally, the effect of composite variant genotypes on EFV levels were also analysed, using 
genotype data of CYP2B6*6 (CYP2B6 516G>T), as well as SNPs from CYP1A2, CYP2A6, 
CYP3A4 and CYP3A5 in the Xhosa and CMA cohort (Victor 2011; Röhrich 2012). NR1I3 and 
NR1I2 variants were analysed in combination with CYP2B6 516G>T in order to find out whether 
any of these variants either increase or diminish the elevated EFV levels caused by 
CYP2B6 516G>T. From previous results, it was found that in the current data, the CYP2B6*6 
allele has a recessive effect on EFV levels (Röhrich, 2012). Therefore, the two cohorts were 
separated into individuals that have two CYP2B6*6-alleles (indicated as *6*6), and individuals 
that have either no CYP2B6*6 alleles or one CYP2B6*6 allele (indicated as Non-*6*6). The 
NR1I2 and NR1I3 target SNPs were also analysed in conjunction with six SNPs from CYP1A2 
(CYP1A2*1F), CYP2A6 (CYP2A6*9B and CYP2A6*17), CYP3A4 (CYP3A4*1B) and CYP3A5 
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(CYP3A5*6 and CYP3A5*3). Frequency data for these SNPs for the study cohort were available 
from a prior study (Victor, 2011). The empirical influence of statistically significant composite 
genotypes on EFV levels (effect size) were calculated using additive allelic models. The effect of 
haplotypes as identified through LD analysis on EFV levels was also analysed. 
3.10.3. Testing for correlations between genotype and treatment outcome or 
adverse drug reactions using logistic regression models 
Patient response to treatment was dichotomised, as indicated by VL measurements on the date of 
sample collection or the last measurement prior to sample collection. Patients with a VL of < 80 
copies/ml were considered responders to treatment and patients with a VL of > 80 copies/ml were 
considered non-responders to treatment (Röhrich, 2012). The genotype and allele frequency for 
each variant for these two groups were compared, with a P-value of ≤ 0.05 as an indication of 
possible significance. 
Patients were also dichotomised according to the presence or absence of EFV-based ADRs.  The 
list of ADRs consisted of abnormal dreams, insomnia, depression and psychosis. Patients that had 
at least one clinical report of one or more of these ADRs were identified as “ADR-patients”. 
Patients with an absence of these ADRs were identified as “non-ADR patients”. The genotype 
and allele frequencies of each variant of these two groups were portrayed in column graphs. 
The effect of genotype on two outcomes, response to treatment and risk of ADRs, also 
dichotomised as explained in Section 3.10.1.2, was analysed using R statistical software (The R 
Development Core Team, 2010). All sequenced and genotyped variants were investigated for 
significant effect on one or both outcomes. The effect of statistically significant variants (P ≤ 
0.05) was quantified through logistic regression models. All variants that complied with HWE 
and had a MAF of ≥ 0.1 were included in the analysis. Xhosa and CMA cohorts were analysed 
separately. The additive effect of identified haplotypes on the two outcomes, treatment outcome 
and the occurrence of ADRs, was also analysed. 
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CHAPTER 4 
4. Results 
4.1. Characteristics of study participants 
A total of 136 female individuals were initially recruited, but only 132 participated in the current 
study. Participants were divided into two cohorts based on ethnicity as identified by the patients 
themselves. Participants that were excluded from the study included pregnant patients that were 
prescribed NVP instead of EFV (n = 1), according to the 2010 South African Guidelines 
(National Department of Health, 2010), patients providing insufficient DNA concentration (n = 
1), patients with missing clinical folders (n = 2) and patients that were not of Xhosa or CMA 
ancestry (n = 1). A total of 79 patients were identified as Xhosa ethnicity and 53 patients were 
identified as Cape Mixed Ancestry (CMA) ethnicity. All patients were HIV-positive and 
prescribed an ARV regimen that specifically included the NNRTI efavirenz (EFV). All patients 
were recruited at the TC Newman HIV Clinic in Paarl in the Western Cape.  
Table 9 presents the characteristics of the two cohorts used in this study. The Xhosa cohort had a 
median age of 39 years (inter-quartile range (IQR): 34 - 45) at the time of sample collection, 
which was slightly younger than the CMA cohort (median: 41 years, IQR: 37 - 46).  
Baseline height and weight was used to calculate the baseline BMI for each patient. The median 
BMI for both cohorts fall between the range as described by the WHO as “normal” (World 
Health Organization, 2000), with the Xhosa median BMI (23.38, IQR: 21-30) slightly higher than 
the CMA median BMI (21.46, IQR: 19-24). Figure 8 shows the percentage of each cohort 
characterised as “underweight”, “normal” and “overweight” according to WHO criteria (World 
Health Organization, 2000), compared to the national South African population average as 
described in the WHO Global Database on Body Mass Index (World Health Organization, 
2013c). Roughly half of the individuals in both cohorts have a normal BMI (Xhosa: 50.6%, 
CMA: 50.9%), which is slightly higher than the national South African percentage (46.2%) 
(World Health Organization, 2013c). 
Time using EFV differed for the two cohorts. The majority of Xhosa individuals were taking an 
ARV regimen containing EFV (median: 41 months, IQR: 24 – 57 months) longer than the 
majority of CMA individuals (median: 26 months, IQR: 10 – 41 months). 
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Table 9: Demographic and clinical characteristics of study participants  
 
Xhosa CMA 
Characteristic Median (IQR) Median (IQR) 
Age at sample collection (years) 39 (34 - 45) 41 (37 - 46) 
BMI Baseline 23.39 (21.06 - 29.66) 21.46 (18.69 - 24.39) 
CD4 Baseline (copies / ml) 159 (98 - 206) 147 (98 - 192) 
Time using EFV (months) 41 (24 - 57) 26 (10 - 41) 
Characteristic Number of pts (%) Number of pts (%) 
WHO Disease Stage: 
  
Stage I 3 (3.80) 3 (5.66) 
Stage II 16 (20.25) 12 (22.64) 
Stage III 39 (49.37) 21 (39.62) 
Stage IV 18 (22.78) 14 (26.42) 
n/a 3 (3.80) 3 (5.66) 
Smoking: 
  
yes 2 (2.53) 10 (18.87) 
no 47 (59.49) 24 (45.28) 
n/a 30 (37.97) 19 (35.85) 
Alcohol: 
  
yes 5 (6.33) 9 (16.98) 
no 48 (60.76) 26 (49.06) 
n/a 26 (32.91) 18 (33.96) 
Adherence 
  
good 70 (87.50) 43 (81.13) 
acceptable 6 (7.50) 7 (13.21) 
bad 3 (3.75) 2 (3.77) 
n/a 1 (1.25) 1 (1.89) 
Change in regimen   
No change 42 (53.16) 27 (50.94) 
Change 37 (46.84) 26 (49.06) 
More than once 9 (11.39) 7 (13.21) 
Regimen during sampling 
  
EFV/3TC/d4T 46 (58.23) 33 (62.26) 
EFV/3TC/AZT 21 (26.58) 9 (16.98) 
EFV/3TC/TDF 12 (15.19) 10 (18.87) 
n/a 0 (0.00) 1 (1.89) 
Occurrence of ADRs   
yes 11 (13.92) 5 (9.43) 
no 68 (86.08) 48 (90.57) 
Second-line therapy 
  
yes 6 (7.59) 1 (1.89) 
no 73 (92.41) 52 (98.11) 
n/a 0 (0.00) 1 (1.89) 
Additional medication 
  
yes 18 (22.78) 13 (24 53) 
no 61 (77.22) 40 (75.47) 
IQR, inter-quartile range. pts, patients. n/a, not applicable. BMI, body mass index. CD4, cluster 
of differentiation 4.  EFV, efavirenz. 3TC, lamivudine. d4T, stavudine. AZT, zidovudine. TDF, 
tenofovir disoproxil fumarate. 
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Figure 8: BMI distribution in the Xhosa and CMA cohorts compared to the nNational 
South African population as described in the WHO Global Database on Body Mass Index 
(World Health Organization, 2013c). 
CMA, Cape Mixed Ancestry cohort; ZA, South African population. 
4.2. In silico analysis of NR1I3 
4.2.1. Analysis of sequence conservation using mVISTA 
Sequence conservation in the human NR1I3 gene was analysed through the comparison of the 
gene to eight orthologs from different species using mVISTA software. Figure 9 shows the 
percentage sequence identity in the 5000 bp upstream region, exon 1, intron 1 and exon 2 of each 
ortholog to the human NR1I3 gene. Three important regions were conserved in all eight orthologs 
and were included in the regions used for bi-directional sequencing. The first region is a 260-bp 
region directly preceding the start of exon 1 and could play an important role in transcriptional 
regulation of the NR1I3 gene. The other two conserved regions are located at exons 1 and 2; this 
shows the functional relevance of these areas as part of the coding region. Both these two 
conserved regions also include parts of intron 1, which could indicate an important role of these 
regions in the regulation of intron splicing.  
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Figure 9: mVISTA sequence alignment of eight orthologs to the human NR1I3 gene.  
The pink areas indicate the % identity of the ortholog sequence to the human NR1I3 gene. The 
sequence starts 5000 kb before exon 1 and extends until the end of exon 2. The arrows indicate 
the location of functionally identified TFBSs on the human NR1I3 gene. Arrow A indicates a 
glucocorticoid receptor binding site as identified by Pascussi et al. 2003. Arrow B indicates an 
HNF4α2 binding site as identified by Pascussi et al. 2007. Arrow C indicates a serum response 
element binding site as identified by Osabe et al. 2009. 
4.2.2. Identification of putative transcription factor binding sites using 
freeware prediction programs 
Six prediction programs were used to find putative TFBSs in the 5 kb upstream region of NR1I3, 
as well as Exon 1 and Intron 1. All putative TFBSs detected in at least three of the six programs 
(n = 17) are listed in Table 10, as well as the three functionally identified TFBS from literature. 
Two of the three functional TFBSs, a glucocorticoid receptor (GR) and a hepatic nuclear factor 
4α (HNF-4α), were also detected by three or more prediction programmes. The third functional 
TFBS, a serum response element (SRE) was only detected in rVISTA. A 500-bp region located 
4.6 kb from the start of exon 1 contained five of the 17 identified putative TFBS, and included the 
functional GR. The high occurrence of putative TFBSs prompted the addition of this region into 
the list of amplicons used for bi-directional sequencing. Figure 9 shows the location of three 
functionally identified TFBS (arrows A, B and C). Only one TFBS, an HNF4α2 binding site 
(arrow B), is located in one of the conserved regions of the NR1I3 gene. 
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Table 10: Putative and functional TFBS in NR1I3 as identified in TFBS prediction software 
and literature. 
Position (bp) 
from start of 
exon 1 
TF 
TFBS prediction software 
Literature 
Match AliBaba Patch P-Match Jaspar rVista 
-4683 GR  x x   x Pascussi et al. 2003 
-4541 AP-1 x x x  x x n/a 
-4492 GATA-3 x x x  x x n/a 
-4429 GATA-3 x x x  x x n/a 
-4201 AP-1 x x x  x x n/a 
-3392 C/EBP x x  x x x n/a 
-2517 C/EBP x x x  x x n/a 
-1890 C/EBP x x  x x x n/a 
-1651 C/EBP x  x x x x n/a 
-1186 USF x x x  x x n/a 
-260 C/EBP x  x x x x n/a 
-61 AP-1 x x  x x x n/a 
+25 HNF-4α x  x  x x Pascussi et al. 2007 
+305 GATA-3 x x  x x x n/a 
+337 USF x x  x x x n/a 
+411 C/EBP x  x x x x n/a 
+622 C/EBP x  x x x x n/a 
+1611 SRF      x Osabe et al. 2009 
The symbol “x” signifies that this TFBS was predicted in the corresponding program. GR, 
glucocorticoid receptor. AP-1, activator protein 1. GATA-3, GATA-binding protein 3. C/EBP, 
CCAAT/enhancer-binding protein. USF, upstream stimulatory factor. HNF-4, hepatic nuclear 
factor 4. SRF, serum response factor. 
4.3. NR1I3 variants identified through bi-directional sequencing 
Bi-directional sequencing results of all amplicons of the 15 Xhosa and 15 CMA individuals were 
aligned to a reference sequence from the Ensembl Genomes Browser, and single nucleotide 
differences that occurred in both sequence directions were identified as variants.  The 
chromatograms for all identified variants are illustrated in Appendix F. 
4.3.1. Incidence of short tandem repeats (STRs) 
Sequencing results for Amplicons UA2, UA3 and Exon 6/7 showed the occurrence of enzyme 
slippage due to the presence of short tandem repeats (STRs) (Figure 10). Subsequently, an 
alternative forward primer was designed for Exon 6/7 in order to avoid the STR region.  The 
design of alternative primer sets for UA2 and UA3 was not viable, due to a high number of STR 
regions and poly T regions in these amplicons (see Appendix E). Therefore it was decided to 
exclude these two amplicons from the region used for bi-directional sequencing. 
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Figure 10: Chromatogram showing the occurrence of enzyme slippage in amplicon UA3 
due to a TC-allele repeat followed by a poly-T-allele repeat. 
4.3.2. Identification of target NR1I3 variants for genotyping 
Following alignment of all sequenced amplicons to the reference sequence ENST00000367983 
from the Ensembl Genomes Browser, a total of 12 SNPs were identified, three 5’-upstream SNPs, 
six intronic SNPs and three exonic synonymous SNPs. Table 11 lists these 12 SNPs and their 
MAFs in the sequenced Xhosa and CMA cohorts, as well as in the Yoruban population from the 
1000 Genomes Study, which contributes partially to the genetic constitution of the Xhosa 
population and, to a lesser extent, to the CMA population (Tishkoff et al., 2009). As mentioned 
previously, the DBD encoding region and parts of the LBD encoding region of NR1I3 was 
included in the sequenced amplicons (Section 3.6.1). Only one SNP was identified in the DBD 
region of NR1I3. The LBD region of NR1I3 is 3,458 bp long, however, because the LBD region 
also includes introns, only fragments amounting to a combined length of 1,646 bp were included 
in the sequencing amplicons. Five of the 12 identified SNPs fall within these fragments.  
From the 12 SNPs identified from sequencing, only six were selected for genotyping in the entire 
patient cohort. Three SNPs (rs55802895, rs2502815, rs2307424) were previously reported to 
have functional importance (Urano et al., 2009; Ikeda et al, 2010; Wyen et al., 2011; Swart et al., 
2012), of which one SNP (rs2307424) showed specific importance to EFV treatment outcome 
(Wyen et al., 2011; Swart et al., 2012). One of these SNPs (rs55802895) also disrupts a potential 
retinoic acid receptor-alpha (RAR-α) binding site, as predicted in AliBaba (Grabe, 2002). One 
SNP (rs35205211) was selected because it disrupts potential mRNA folding patterns, as predicted 
in mFOLD (Zuker, 2003). From the pool of intronic SNPs that showed no further importance in 
literature, SNPs rs35709078 and rs2307420 were also selected for genotyping due to their low 
MAF in the YRI population, which could indicate that they would also be present in the Xhosa 
and CMA cohorts.  
Three additional SNPs that were not identified in sequencing results were selected for genotyping 
based on their functional importance in literature and are indicated in bold in Table 11. The first 
of these SNPs, rs113800307 (Met265Val), was selected because of its identification in a whole-
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genome sequencing study using South African Khoisan and Bantu individuals (Schuster et al., 
2010). The second SNP, rs34161743 (R97W), potentially alters protein activity as predicted by 
both SIFT and PolyPhen, (Ramensky et al., 2002; Ng, 2003) and disrupts a potential ESE 
(Thompson et al. 2005). Lastly, rs3003596, an intronic SNP, was selected for genotyping as this 
SNP was previously significantly associated with decreased EFV plasma levels (Swart et al., 
2012). 
4.4. NR1I2 variants identified through a survey of literature and genotype 
databases 
From data obtained from previous studies and from the HapMap and 1000 Genomes database as 
described in Section 3.7 in Chapter 3, a total of ten variants were selected for genotyping, three 
5’-upstream variants (rs1523130, rs3814055, rs1523128), two 5’-UTR variants (rs1523127, 
rs38426891), four intronic variants (rs2472677, rs1464603, rs1464602, rs2276707) and one non-
synonymous variant (rs12721613). These identified variants are listed in Table 12. As no 
previous frequency data are available for these NR1I2 variants for the Xhosa and CMA cohorts, 
the MAF data for four other ethnic groups (CEU, CHB, YRI and ASW, respectively representing 
Caucasian, Asian, African and African American populations), obtained from the 1000 Genomes 
database and from literature, are displayed in Table 12 as guidelines. Based on the genetic 
contribution of each of the four populations to the Xhosa and CMA cohorts, frequency data for 
the Xhosa cohort are expected to be most similar to the Yoruban frequency data, and for the 
CMA cohort are expected to present as intermediate between either the Caucasian and Yoruban 
frequency data, or the Asian and Yoruban frequency data (Tishkoff et al., 2009). All variants 
except for two (rs1523130 and rs1464603) have MAFs greater than 0.05 in the YRI population, 
based on 1000 Genomes data. These two SNPs, however, have high MAFs in the other three 
populations (CEU, CHB and ASW), which could suggest that these SNPs could have a high 
MAF in the CMA population. 
The functional importance of the identified variants is indicated in Table 12. The six variants 
located in the 5’-upstream, 5’-UTR and Intron 1 region all disrupt putative TFBSs (Zhang et al., 
2001; Lamba et al., 2008). Five variants play a role in the regulation of CYP3A4. SNPs 
rs1523130 and rs1523127 are significantly associated with CYP3A4 expression (King et al., 
2007; Lamba et al., 2008); SNPs rs3814055, rs2472677 and rs12721613 are significantly 
associated with CYP3A4 induction (Lamba et al., 2008; Svärd et al., 2010); and rs1523130 and 
rs2472677 are significantly associated with CYP3A4 activity (Lamba et al., 2008).  
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Table 11: NR1I3 variants identified from bi-directional sequencing and literature, and their MAFs in the Xhosa, CMA and YRI populations 
Location rs number  
Genomic 
identifier 
Amino 
acid 
change 
Xhosa CMA YRI Putative 
TFBS 
(AliBaba) 
Functional Importance 
n MAF n MAF MAF 
5’-upstream rs55802895 258G>A n/a 3 0.100 3 0.100 0.034 RAR-α ↑ risk of hyperlipidemia1 
5’-upstream rs2501870 432C>T n/a 7 0.267 8 0.267 0.426 n/a n/a 
5’-upstream rs11584174 548G>A n/a 5 0.200 4 0.133 0.159 n/a n/a 
Intron 2 rs35709078 7145C>T n/a 1 0.033 1 0.033 0.023 n/a n/a 
Intron 3 rs141260451 7393C>G n/a 0 0.000 1 0.033 0.000 n/a n/a 
Intron 3 rs3003596 8784T>C n/a n/a* n/a* n/a* n/a* 0.386 n/a ↓ EFV plasma levels2 
Intron 3 rs2502815 9774C>T n/a 5 0.233 9 0.333 0.420 n/a ↓ bone mineral density3 
Exon 4 rs35205211 9892C>G n/a 1 0.033 1 0.033 0.006 n/a 
Disrupts putative ssDNA and mRNA folding patterns 
(mFOLD) 
Exon 4  rs34161743 9923C>T R97W 0 0.000 0 0.000 0.017 n/a 
Deleterious and probably damaging amino acid change 
(SIFT, PolyPhen) 
Exon 5 rs2307424 10396C>T n/a 1 0.033 3 0.100 0.108 n/a 
↓ EFV discontinuation2,4, ↓ EFV plasma levels2, ↑  risk of 
hyperlipidemia
1
 
Intron 5 rs2307420 10445A>G n/a 4 0.133 3 0.100 0.028 n/a n/a 
Exon 7 rs113800307 12076A>G M265V 0 0.000 0 0.000 n/a n/a Identified in Bantu (Xhosa/Venda) individuals
5
 
Intron 8 rs34859188 13196T>C n/a 3 0.133 3 0.100 0.023 n/a n/a 
Intron 8 rs35103872 13220G>A  3 0.100 3 0.100 0.017 n/a n/a 
Exon 9 rs36017137 13297G>A  1 0.033 0 0.000 0.006 n/a n/a 
SNP frequencies are displayed for the following groups: The Xhosa and Cape Mixed Ancestry cohorts of this study and the Yoruban population 
from the 1000 Genomes Project. The shaded regions are the SNPs selected from sequencing results for genotyping. The SNPs in bold are additional 
SNPs selected from literature for genotyping. ↑, increased. ↓, decreased. * No available Xhosa and CMA frequency data, as SNPs are outside the 
regions of NR1I3 selected for sequencing. n/a, not available. 
1
Ikeda et al., 2010. 
2
Swart  et al., 2012. 
3
Urano et al., 2009. 
4
Wyen et al., 2011. 
5
Schuster  et al., 2010. 
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Table 12: NR1I2 variants selected for genotyping, their MAFs in four population groups from the 1000 Genomes Project and their 
functional importance. 
Location rs number 
Genomic 
identifier 
Amno 
acid 
change 
MAF 
Putative 
TFBS
1,3 Functional importance 
Cau (CEU) Asn (CHB) Afr   (YRI) AA (ASW) 
5' upstream rs1523130 5177T>C n/a 0.359 (T) 0.268 (T) 0.04 (C) 0.139 (C) 
STAT1,3,6 
and NFAT 
↓ basal CYP3A4 activity, ↓ CYP3A4 and PXR expression1 
5' upstream rs3814055 5705C>T n/a 0.341 0.268 0.301 0.238 
NF-KB and 
ISGF-3 
↓ PXR expression, ↓ CYP3A4 induction1; ↑  cyclosporine 
bioavailabilty
4
 
5' upstream rs1523128 6334A>G n/a 0.000 0.000 0.432 0.270 
C/EBP and 
HNF-1α 
In LD with rs3814055, rs1523127 and rs2276707, ↑ 
susceptibility to Crohn’s Disease8 
5' UTR rs1523127 6709C>A n/a 0.341 (C) 0.268 (C) 0.097 (A) 0.230 (A) n/a ↓ ABCB1 and CYP3A4 expression5 
5'UTR rs3842689
1
 7070_7075del n/a 0.290
1
 n/a 0.173
2
 n/a HNF-1α ↓ PAR2 expression1; ↑ NVP clearance2 
Intron 1 rs2472677 24087C>T n/a 0.359 (C) 0.371 (C) 0.352 (T) 0.361 (T) HNF3β 
↑basal CYP3A4 activity, ↓ CYP3A4 induction, ↑ PAR2 
expression, ↑ PXR transcription1; ↓ plasma atazanavir levels6 
Exon 2 rs12721613 31846C>T P27S 0.000 0.000 0.188 0.107 n/a n/a 
Intron 2 rs1464603 32019G>A n/a 0.318 (G) 0.345 (G) 0.023 (A) 0.197 (A) n/a 
In LD with rs1464602 and rs3732357, ↓ plasma midazolam 
clearance
7
 
Intron 2 rs1464602 32042G>A n/a 0.318 (G) 0.345 (G) 0.233 (A) 0.369 (A) n/a 
In LD with rs 1464603 and rs3732357, ↓ plasma midazolam 
clearance
7
 
Intron 6 rs2276707 39823C>T n/a 0.118 0.459 0.386 0.352 n/a 
In LD with rs3814055, rs1523127, rs3842689 and rs6785049, 
↑ cyclosporine bioavailability4 
CEU, CHB, YRI and ASW, represent four respective ethnic groups from the 1000 Genomes Project. CEU, Residents in Utah, USA, of Northern and 
Western European ancestry. CHB, Han Chinese in Bejing, China. YRI, Yoruba in Ibadan, Nigeria. ASW, Americans of African Ancestry in South 
West, USA. n/a, not available. ↑, increased. ↓, decreased. 1Lamba et al. 2008. 2Brown et al. 2012, 3Zhang et al., 2001, 4 Fanta et al., 2010, 5 King et 
al., 2007, Siccardi et al., 2008, 
7
 He et al., 2006. 
8
Glas et al., 2011. 
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Six variants play a role in the regulation of NR1I2. SNPs rs1523130 and rs2472677 are associated 
with NR1I2 transcription (Lamba et al., 2008); and SNPs rs1523130, rs3814055 and rs2472677 
and deletion rs3842689 are associated with NR1I2 expression (Lamba et al., 2008). Five variants 
play a role in the pharmacokinetic characteristics of certain drugs. SNPs rs3814055 and 
rs2276707 are significantly associated with cyclosporine bioavailability (Fanta et al., 2010); 
deletion rs3842689 is significantly associated with nevirapine clearance (Brown et al., 2012); and 
SNPs rs1464603 and rs1464602 are significantly associated with midazolam clearance (He et al., 
2006). 
4.5. Variant genotyping results 
Following the selection of SNPs to be genotyped (Section 4.3.2 and 4.4), a total of 19 variants 
from NR1I3 and NR1I2 were genotyped for both cohorts (Xhosa n = 79 and CMA n = 53). 
Appendix G shows examples of gel photos for TSP, RFLP and deletion assays analysis of each 
variant for heterozygous individuals, individuals homozygous for the major allele and individuals 
homozygous for the minor allele, where applicable. Appendix H shows the allelic discrimination 
plots for Taqman analysis of rs1523130 (5177T>C) for all samples, and also amplification plots 
for one patient that is homozygous for the major allele (TT), one patient that is heterozygous 
(TC) and one patient that is homozygous for the minor allele (CC). 
4.5.1. Analysis of genotype and allele frequencies 
All variants genotyped were polymorphic in both the Xhosa and CMA cohorts, except for 
rs113800307, which was non-polymorphic in both cohorts. Table 13 lists the observed genotype 
frequencies and MAFs of all variants in the Xhosa and CMA cohorts. 
Four out of the 19 variants (21.05%), indicated in bold in Table 13, differed significantly between 
the cohorts with regards to allele frequency (a P-value of lower than or equal to 0.05). Of these 
four variants, one was located in NR1I3 (rs2307424) and three were located in NR1I2 (rs1523130, 
rs3814055, rs1523127). The MAF for rs3814055 was higher in the Xhosa cohort than in the 
CMA cohort, while the MAFs for rs2307424, rs1523130 and rs1523127 were higher in the CMA 
cohort. 
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Table 13: Genotype frequencies and MAFs for NR1I3 and NR1I2 variants in the Xhosa and 
CMA cohorts 
Gene Location rs name 
Genomic 
identifier 
Genotype 
Xhosa n = 79 1 
Cape Mixed Ancestry 
n = 53 1 P-
value3 
n (frequency) MAF n (frequency) MAF 
 
5’-upstream  rs55802895 258G>A 
GG 67 (0.848) 
0.082 
46 (0.868) 
0.066 0.624 NR1I3 GA 11 (0.139) 7 (0.132) 
 AA 1 (0.013) 0 (0.000) 
 
Intron 2  rs35709078 7145C>T 
CC 76 (0.962) 
0.019 
52 (0.981) 
0.009 0.651 NR1I3 CT 3 (0.038) 1 (0.019) 
 TT 0 (0.000) 0 (0.000) 
 
Intron 3 rs3003596 8784T>C 
TT 35 (0.449) 
0.340 
18 (0.340) 
0.415 0.215 NR1I3 TC 33 (0.423) 26 (0.491) 
 CC 10 (0.128) 9 (0.170) 
 
Intron 3  rs2502815 9774C>T 
CC 43 (0.551) 
0.269 
24 (0.462) 
0.317 0.403 NR1I3 CT 28 (0.359) 23 (0.442) 
 TT 7 (0.090) 5 (0.096) 
 
Exon 4  rs35205211 9892C>G 
CC 74 (0.974) 
0.013 
51 (0.981) 
0.010 1.000 NR1I3 CG 2 (0.026) 1 (0.019) 
 GG 0 (0.000) 0 (0.000) 
 
Exon 4  rs34161743 9923C>T 
CC 76 (0.962) 
0.019 
51 (0.981) 
0.010 0.654 NR1I3 CT 3 (0.038) 1 (0.019) 
 TT 0 (0.000) 0 (0.000) 
 
Exon 5  rs2307424 10396C>T 
CC 67 (0.848) 
0.076 
37 (0.698) 
0.179 0.011 NR1I3 CT 12 (0.152) 13 (0.245) 
 TT 0 (0.000) 3 (0.057) 
 
Intron 5  rs2307420 10445A>G 
AA 70 (0.886) 
0.057 
47 (0.887) 
0.066 0.796 NR1I3 AG 9 (0.114) 5 (0.094) 
 GG 0 (0.000) 1 (0.019) 
 
Exon 7 rs113800307 12076A>G 
AA 78 (1.000) 
0.000 
41 (1.000) 
0.000 1.000 NR1I3 AG 0 (0.000) 0 (0.000) 
 GG 0 (0.000) 0 (0.000) 
 
5’-upstream  rs1523130 5177T>C 
TT 61 (0.782) 
0.128 
31 (0.596) 
0.269 0.004 NR1I2 TC 14 (0.179) 14 (0.269) 
 CC 3 (0.038) 7 (0.135) 
 
5’-upstream  rs3814055 5705C>T 
CC 48 (0.640) 
0.220 
42 (0.824) 
0.088 0.018 NR1I2 CT 21 (0.280) 9 (0.176) 
 TT 6 (0.080) 0 (0.000) 
 
5’-upstream  rs1523128 6334A>G 
GG 41 (0.526) 
0.269 
33 (0.623) 
0.208 0.254 NR1I2 AG 32 (0.410) 18 (0.340) 
 AA 5 (0.064) 2 (0.038) 
 
5’-UTR  rs1523127 6709C>A 
CC 50 (0.649) 
0.201 
23 (0.442) 
0.365 0.003 NR1I2 CA 23 (0.299) 20 (0.385) 
 AA 4 (0.052) 9 (0.173) 
 
5’-UTR  rs38426892 
7070_7075del
GAGAAG 
+/+ 50 (0.641) 
0.212 
41 (0.774) 
0.132 0.100 NR1I2 +/- 23 (0.295) 10 (0.189) 
 -/- 5 (0.064) 2 (0.038) 
 
Intron 1  rs2472677 24087C>T 
CC 30 (0.385) 
0.391 
18 (0.360) 
0.370 0.806 NR1I2 CT 35 (0.449) 27 (0.540) 
 TT 13 (0.167) 5 (0.100) 
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Gene Location rs name 
Genomic 
identifier 
Genotype 
Xhosa n = 79 1 
Cape Mixed Ancestry 
n = 53 1 P-
value3 
n (frequency) MAF n (frequency) MAF 
 
Exon 2  rs12721613 31846C>T 
CC 63 (0.808) 
0.096 
49 (0.925) 
0.038 0.091 NR1I2 CT 15 (0.192) 4 (0.075) 
 TT 0 (0.000) 0 (0.000) 
 
Intron 2  rs1464603 32019G>A 
GG 51 (0.646) 
0.190 
32 (0.604) 
0.226 0.471 NR1I2 GA 26 (0.329) 18 (0.340) 
 AA 2 (0.025) 3 (0.057) 
 
Intron 2  rs1464602 32042G>A 
GG 36 (0.456) 
0.329 
21 (0.412) 
0.402 0.232 NR1I2 GA 34 (0.430) 19 (0.373) 
 AA 9 (0.114) 11 (0.216) 
 
Intron 6  rs2276707 39823C>T 
CC 23 (0.295) 
0.449 
23 (0.442) 
0.365 0.182 NR1I2 CT 40 (0.513) 20 (0.385) 
 TT 15 (0.192) 9 (0.173) 
Variants that differed significantly between the Xhosa and CMA cohort are indicated in bold. 
1
Due to problems with amplification, for some variants, the genotypes for some samples in the 
cohorts are not available. The true number of samples genotyped for each variant is stated in 
columns 6 and 8 for each separate genotype. 
2
The genotypes of the 6 bp-deletion are described as 
follows: “+”, one copy of the GAGAAG region is present; “-”, one copy of the GAGAAG region 
is deleted. 
3
A P-value of ≤ 0.05 is considered a significant difference in MAF. 
The MAFs of all variants in both the Xhosa and CMA cohorts were compared to the MAFs in 
five populations from the 1000 Genomes Project and one population from the HapMap Project. 
Population data was unavailable for SNP rs113800307 and deletion rs3842689. Frequency data 
for the HapMap GIH population were unavailable for nine of the variants. Figure 11 shows the 
MAFs for the abovementioned four SNPs (rs2307424, rs1523130, rs3814055 and rs1523127) in 
these six populations, as well as in the study cohorts. 
The range of variability in variant MAF among populations is demonstrated in Table 14 by the 
number of target SNPs that significantly differs in MAF between each population and the two 
genotyped cohorts (P ≤ 0.05). The CEU, CHB and GIH populations showed the highest 
percentage of SNPs that differed significantly from the Xhosa and CMA cohorts (Table 14). The 
number of SNPs in the CEU population that differed in MAF from the Xhosa cohort was 13 out 
of 17 (76.47%) and from the CMA cohort was 12 out of 17 (70.59%). The number of SNPs that 
differed between the CHB population and the Xhosa and CMA cohorts with regards to MAF was 
12 out of 17 (70.59). The percentage of SNPs that differed in MAF between the CIH population 
and the Xhosa and CMA cohorts cohorts was also high (75.00% and 63.50% respectively). The 
LWK and ASW populations showed the lowest percentage of SNPs that differed significantly 
from the Xhosa and CMA cohorts. The number of SNPs in the LWK population that differed in 
MAF from the Xhosa cohort was three out of 17 (17.65%), which is lower than the number for 
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the CMA cohort (eight out of 17, 47.06%). The number of SNPs in the ASW population that 
differed in MAF from the Xhosa cohort was three out of 17 (17.65%) and from the CMA cohort 
was four out of 17 (23.53%). Nine out of the total of 17 SNPs differed significantly in terms of 
MAF between the YRI population and both study cohorts (52.94%). 
 
Figure 11: MAFs for rs2307424, rs1523130, rs3814055 and rs1523127 in the study cohorts 
and populations from the 1000 Genomes and HapMap databases.  
CMA, Cape Mixed Ancestry cohort. LWK, Luhya in Webuye, Kenya. YRI, Yoruba in Ibadan, 
Nigeria. ASW, Americans of African Ancestry in South West, USA. CEU, Residents in Utah, 
USA, of Northern and Western European ancestry. CHB, Han Chinese in Bejing, China. GIH, 
Gujarati Indian from Houston, Texas.   
Table 14: Number of SNPs in six populations that differed significantly in MAF from the 
Xhosa and CMA cohorts 
Population 
(total) 
Xhosa CMA 
n % n % 
LWK (17) 3 17.65 8 47.06 
YRI (17) 9 52.94 9 52.94 
ASW (17) 3 17.65 4 23.53 
CEU (17) 13 76.47 12 70.59 
CHB (17) 12 70.59 12 70.59 
GIH (8) 6 75.00 5 62.50 
The numbers in brackets are the total number of SNPs for which frequency data are available. A 
P-value of ≤ 0.05 is considered a significant difference in MAF. LWK, Luhya in Webuye, Kenya. 
YRI, Yoruba in Ibadan, Nigeria. ASW, Americans of African Ancestry in South West, USA. 
CEU, residents in Utah, USA, of Northern and Western European ancestry. CHB, Han Chinese in 
Bejing, China. GIH, Gujarati Indians from Houston, Texas 
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4.5.2. Results of Hardy-Weinberg equilibrium analysis 
Eight variants in the Xhosa cohort and seven variants in the CMA cohort were tested for HWE 
using a χ2 test; the remaining variants were tested using an analogu to Fisher’s Exact test. In both 
the Xhosa and CMA cohorts, all variants fulfilled the criteria for HWE, therefore genotyping 
error and evolutionary forces could be ignored. 
4.5.3. Linkage disequilibrium analysis of variants  
Using Haploview v4.2 (Barrett et al., 2005), linkage disequilibrium analysis was performed for 
seven NR1I3 variants and nine NR1I2 variants. Variants that did not qualify for linkage 
disequilibrium analysis were rs113800307, which was non-polymorphic in both cohorts and 
rs35709078, which had a MAF of <0.01 in the CMA population. LD plots showed that no LD 
was found between any of the NR1I3 variants in both Xhosa and CMA cohorts (Appendix I). LD 
plots for NR1I2 variants in both cohorts are shown in Figure 12. In both cohorts, rs3814055 
(5705C>T) was found to be in LD with the deletion rs3842689 (r
2
 = 0.885 and 0.907 for Xhosa 
and CMA respectively; LOD score = 21.670 and 11.040 for Xhosa and CMA respectively) and 
rs1523130 (5177T>C) was found to be in LD with rs1523127 (6709C>A) (r
2
 = 0.411 and 0.587 
for Xhosa and CMA respectively; LOD score = 8.04 and 10.83 for Xhosa and CMA 
respectively).  
 
Figure 12: LD plots for NR1I2 variants in the Xhosa and CMA cohorts. 
LD values are represented in the blocks by correlation coefficient (r
2
) values. 
4.6. Analysing the effect of confounders 
All possible confounding factors were tested for significant effect on EFV hair levels, treatment 
outcome and occurrence of ADRs. The three confounding factors that had a significant effect on 
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the three outcomes were time using EFV, age at diagnosis and ethnicity. Subsequently, statistical 
analysis was adjusted for these three confounders. 
4.7. Correlations between genotype and EFV hair levels 
4.7.1. The effect of single variant genotype on EFV levels 
The preliminary effect of single variant genotype on EFV levels was analysed, in order to see if 
there are any trends that point to possible findings from the more detailed statistical analysis to 
follow. Table 15 shows the mean EFV levels for the genotype groups for each variant, separated 
by ethnicity. 
Figure 13 shows the mean EFV levels for variants rs3842689 (7070_7075delGAGAAG), 
rs35205211 (9892C>G), rs1523130 (5177T>C) and rs1523128 (6334A>G). The mean EFV 
levels for all variants are shown in Appendix J. The highest mean EFV levels (12.76 ng/ml) were 
recorded for CMA individuals homozygous for the deletion rs3842689 
(7070_7075delGAGAAG) (n = 2) (Table 15). The lowest mean EFV levels (1.15 ng/ml) were 
recorded for a CMA individual heterozygous for rs35205211 (9892C>G) (Table 15). There were 
no individuals homozygous for rs35205211 in the CMA cohort. For SNP rs1523130, individuals 
homozygous for the minor allele (CC) (n = 3) have the highest mean EFV level among the Xhosa 
cohort (10.42 ng/ml). Xhosa individuals homozygous for the minor alleles of rs1523128 and 
rs3814055 had the lowest EFV levels (3.53 ng/ml and 3.56 ng/ml respectively) among the Xhosa 
cohort, however, these levels were not as low as the lowest EFV levels for the CMA cohort. 
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Table 15: Genotype mean EFV levels for each variant for the Xhosa and CMA cohort 
Gene rs number 
Genomic 
identification 
Genotype 
Mean EFV hair 
levels 
Xhosa CMA 
 
rs2307420 10445A>G 
AA 5.96 6.28 
NR1I3 AG 9.28 5.37 
 GG n/a 5.07 
 
rs2307424 10396C>T 
CC 6.11 6.00 
NR1I3 CT 7.66 6.91 
 TT n/a 5.14 
 
rs34161743 9923C>T 
CC 6.34 6.14 
NR1I3 CT 6.36 10.00 
 TT n/a n/a 
 
rs35205211 9892C>G 
CC 6.31 6.32 
NR1I3 CG 8.15 1.15 
 GG n/a n/a 
 
rs2502815 9774C>T 
CC 6.27 6.20 
NR1I3 CT 6.66 5.64 
 TT 5.57 5.60 
 
rs35709078 7145C>T 
CC 6.37 6.22 
NR1I3 CT 5.60 3.98 
 TT n/a n/a 
 
rs55802895 258G>A 
GG 6.43 6.27 
NR1I3 GA 5.92 5.53 
 AA 5.37 n/a 
 
rs1523130 5177T>C 
TT 5.84 6.69 
NR1I2 TC 7.37 5.59 
 CC 10.42 4.57 
 
rs3814055 5705C>T 
CC 6.61 5.51 
NR1I2 CT 6.78 7.81 
 TT 3.56 4.62 
 
rs1523128 6334A>G 
GG 5.64 6.37 
NR1I2 GA 7.66 5.95 
 AA 3.53 4.93 
 
rs1523127 6709C>A 
CC 5.83 6.41 
NR1I2 CA 4.93 6.43 
 AA 7.66 4.97 
 
rs3842689 
7070_7075del
GAGAAG 
+/+ 6.47 5.39 
NR1I2 +/- 6.58 8.08 
 -/- 3.89 12.76 
 
rs2472677 24087C>T 
CC 5.91 6.92 
NR1I2 CT 7.00 5.86 
 TT 5.52 6.14 
 
rs12721613 31846C>T 
CC 5.87 6.22 
NR1I2 CT 8.32 5.61 
 TT n/a n/a 
 
rs1464603 32019G>A 
GG 5.93 6.80 
NR1I2 GA 7.32 5.09 
 AA 4.08 6.04 
 
rs1464602 32042G>A 
GG 5.22 5.58 
NR1I2 GA 7.05 7.40 
 AA 8.14 5.55 
 
rs2276707 39823C>T 
CC 6.90 6.06 
NR1I2 CT 6.43 5.09 
 TT 5.22 8.93 
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Figure 13: Mean EFV levels for rs35205211, rs1523130, rs1523128 and rs3842689 according 
to genotype. 
The effect of single NR1I3 and NR1I2 variant genotypes on EFV was analysed using linear 
regression models in R statistical software (The R Development Core Team, 2010). In both 
cohorts, the natural logarithm of EFV levels was used, as the distribution of EFV levels is 
positively skewed. The P-values obtained following linear regression analysis for all variants are 
shown in Table 16. For single variant analysis, one NR1I2 SNP, rs1523128 (6334A>G), was 
significantly associated with EFV levels (P = 0.0168), when correcting for time using EFV, age 
at diagnosis and ethnicity. In all individuals homozygous for the minor allele of rs1523128 (AA), 
EFV levels were 56% lower than for heterozygous patients (GA) (95%CI: 9% to 124%). 
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Table 16: Association analysis between single NR1I3 and NR1I2 variants and EFV levels 
using linear regression models 
Gene rs number 
Genomic 
identification 
P-Value Quantitative effect on EFV levels 
NR1I3 rs2307420 10445A>G 0.796 n/a 
NR1I3 rs2307424 10396C>T 0.154 n/a 
NR1I3 rs34161743 9923C>T 0.708 n/a 
NR1I3 rs35205211 9892C>G 0.549 n/a 
NR1I3 rs2502815 9774C>T 0.976 n/a 
NR1I3 rs3003596 8784T>C 0.579 n/a 
NR1I3 rs35709078 7145C>T 0.842 n/a 
NR1I3 rs55802895 258G>A 0.531 n/a 
NR1I2 rs1523130 5177T>C 0.336 n/a 
NR1I2 rs3814055 5705C>T 0.123 n/a 
NR1I2 rs1523128 6334G>A 0.017 56% ↑ from 6334AG to 6334AA 
NR1I2 rs1523127 6709C>A 0.278 n/a 
NR1I2 rs3842689 
7070_7075del
GAGAAG 
0.385 n/a 
NR1I2 rs2472677 24087C>T 0.446 n/a 
NR1I2 rs12721613 31846C>T 0.160 n/a 
NR1I2 rs1464603 32019G>A 0.868 n/a 
NR1I2 rs1464602 32042G>A 0.054 n/a 
NR1I2 rs2276707 39823C>T 0.956 n/a 
↑, increase in EFV levels. ↓, decrease in EFV levels. 
4.7.2. The effect of composite variant genotypes on EFV levels 
The impact of composite genotypes on EFV levels was examined.  Using R statistical software 
(The R Development Core Team, 2010), linear regression models were used to search for 
statistically significant composite genotypes that had an effect on EFV levels. Eight NR1I3 and 
ten NR1I2 variants were analysed in conjunction with CYP2B6*6 (Appendix L). Table 17 shows 
the mean EFV levels for the *6*6 and Non-*6*6 groups (as explained in Section 3.10.2) in the 
Xhosa and CMA cohorts. The NR1I2 and NR1I3 SNPs were also analysed in conjunction with six 
SNPs from CYP1A2, CYP2A6, CYP3A4 and CYP3A5 (Appendix L). A total of 12 composite 
variant pairs were significantly associated with EFV levels (P ≤ 0.05), which are listed in Table 
18. Additive allelic models were used to determine the effect size of these variant pairs on EFV 
levels.  
For CYP2B6*6, one composite NR1I3 SNP, rs55802895 (258G>A) was found to be significantly 
associated with EFV levels. The 258GG genotype causes an increase in 161% in individuals with 
two CYP2B6*6 alleles as opposed to individuals with one or no CYP2B6*6-alleles. 
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Four variants in combination with CYP1A2*1F (163C>A) was found to be significantly 
associated with EFV levels, namely rs2502815, rs3842689, rs12721613 and rs2276707. SNP 
rs2502815 was found to be associated with increased EFV levels in individuals with the 163CC 
genotype, however, the sample cohort was very small (n < 10 individuals). The 6-bp deletion 
(rs3842689) showed a compound effect where individuals heterozygous for CYP1A2*1F and 
negative for the deletion (+/+) (n = 17) showed an increase in EFV levels compared to 
individuals heterozygous for both CYP1A2*1F and the deletion (n = 41). In NR1I2 rs12721613 
(31846C>T), a decrease in EFV levels (86%) is found in individuals with the 31846CT genotype 
and the 163CC genotype (n = 6) as opposed to the 163AA genotype (n = 11). SNP rs2276707 
was also associated with EFV levels in conjunction with CYP1A2*1F, however, after the effect 
size analysis, no discernible pattern of change in EFV levels could be found. 
Three composite variants of CYP2A6*9B (48T>G) were found to be associated with EFV levels, 
rs2307420, rs1464603 and rs1464602. The heterozygous genotype for all three variants causes an 
increase in EFV levels in individuals heterozygous for CYP2A6*9B. However, the sample size 
for these groups was less than 10 individuals.  
NR1I2 SNP rs1464602 (32042G>A) was found to be significantly associated with a change in 
EFV levels in conjunction with CYP2A6*17 (5065G>A). However, no clear pattern was found 
when analysing this composite genotype for effect size. In CYP3A4*1B (392A>G), NR1I2 
rs1523130 (5177T>C) was found to be associated with decreased EFV levels.  
For CYP3A5*3 (6986A>G), two composite variants, NR1I2 rs3842689 (7070_7075del) and 
NR1I2 rs2276707 (39823C>T) were found to be associated with a change in EFV levels. The 
minor homozygous genotype for both variants were found to cause an increase in EFV levels for 
individuals heterozygous for CYP3A5*3. 
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Table 17: Mean EFV levels according to CYP2B6*6 genotype for each variant for the 
Xhosa and CMA cohort 
Gene rs number 
Genomic 
identification 
Genotype 
Xhosa CMA 
Non-*6*6 *6*6 Non-*6*6 *6*6 
 
rs2307420 10445A>G 
AA 5.26 13.52 6.80 8.49 
NR1I3 AG 7.64 15.00 5.37 n/a 
 GG n/a n/a 5.07 n/a 
 
rs2307424 10396C>T 
CC 5.65 10.71 5.71 9,32 
NR1I3 CT 4.5 23.45 6.91 n/a 
 TT n/a n/a 4.72 n/a 
 
rs34161743 9923C>T 
CC 5.45 13.89 5.93 8.49 
NR1I3 CT 6.36 n/a 10.00 n/a 
 TT n/a n/a n/a n/a 
 
rs35205211 9892C>G 
CC 5.39 13.89 6.13 8.49 
NR1I3 CG 8.15 n/a 1.15 n/a 
 GG n/a n/a n/a n/a 
 
rs2502815 9774C>T 
CC 5.79 12.75 5.81 10.46 
NR1I3 CT 4.94 14.58 5.62 6.00 
 TT 5.57 n/a 5.24 7.05 
 
rs35709078 7145C>T 
CC 5.50 14.96 6.03 8.49 
NR1I3 CT 5.21 6.39 3.98 n/a 
 TT n/a n/a n/a n/a 
 
rs55802895 258G>A 
GG 5.43 14.96 5.96 10.68 
NR1I3 GA 5.87 6.39 6.13 1.91 
 AA 5.37 n/a n/a n/a 
 
rs1523130 5177T>C 
TT 5.34 11.45 6.29 12.50 
NR1I2 TC 6.65 16.80 5.48 7.05 
 CC 2.12 27.00 5.01 1.91 
 
rs3814055 5705C>T 
CC 5.74 16.15 12.5 1,91 
NR1I2 CT 5.64 11.64 7.05 10.68 
 TT 3.56 n/a 1.91 n/a 
 
rs1523128 6334A>G 
GG 4.77 16.73 6.08 8.49 
NR1I2 GA 6.82 12.19 5.95 n/a 
 AA 3.53 n/a 4.93 n/a 
 
rs1523127 6709C>A 
CC 5.23 12.71 5.83 12.5 
NR1I2 CA 6.38 11.60 6.40 7.05 
 AA 2.87 27.00 5.35 1.91 
 
rs3842689 
7070_7075del
GAGAAG 
+/+ 5.63 16.15 5.47 1.91 
NR1I2 +/- 5.52 11.64 6.97 10.68 
 -/- 3.89 n/a 12.76 n/a 
 
rs2472677 24087C>T 
CC 4.61 14.34 6.97 6.00 
NR1I2 CT 6.31 14.36 5.81 7.05 
 TT 5.09 10.70 3.26 10.46 
 
rs12721613 31846C>T 
CC 4.96 16.41 6.02 8.49 
NR1I2 CT 7.97 9.70 5.61 n/a 
 TT n/a n/a n/a n/a 
 
rs1464603 32019G>A 
GG 5.23 12.41 6.42 12.50 
NR1I2 GA 6.14 16.37 5.17 4.48 
 AA 4.08 n/a n/a n/a 
 
rs1464602 32042G>A 
GG 4.70 14.08 5.75 3.96 
NR1I2 GA 5.77 14.46 6.74 13.03 
 AA 7.82 10.70 5.55 n/a 
 
rs2276707 39823C>T 
CC 5.79 18.55 6.02 6.53 
NR1I2 CT 5.42 13.53 5.26 1.91 
 TT 5.13 6.39 7.67 19.00 
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Table 18: The effect size (empirical influence on EFV levels) of single and composite NR1I3 
and NR1I2 variants that were significantly associated with EFV levels. 
Gene rs number 
Genomic 
identifier 
P-Value Effect of genotype on EFV levels 
Single variants 
NR1I2 rs1523128  6334A>G 0.017 56% ↑ from 6334AG to 6334AA 
Composite variants 
CYP2B6*6 (516G>T) 
NR1I3 rs55802895 258G>A  0.005 
161% ↑ from *6*6|258GG to Non-*6*6|258GG 
No significant difference from *6*6|258GA to Non-
*6*6|258GA 
CYP1A2*1F (163C>A) 
NR1I3 rs2502815 9774C>T  0.026 
436% ↑ from 163CC|9774CT to 163CC|977CC 
390% ↑ from 163CC|9774TT to 163CC|977CC 
NR1I2 rs3842689 7070_7075del  0.017 
36% ↑ from 163AC|+/- to 163AC|+/+ 
263% ↑ from 163AC|-/- to 163AC|+/+ 
NR1I2 rs12721613 31846C>T  0.026 86% ↓ from 163CC|31846CT to 163AA|31846CT 
NR1I2 rs2276707 39823C>T  0.030 No definable pattern detected 
CYP2A6*9B (48T>G) 
NR1I3 rs2307420 10445A>G  0.007 464% ↑ from 48 TG|10445AA to 48 TG|10445AG 
NR1I2 rs1464603 32019G>A  0.021 215% ↑ from 48TG|32019GG  to 48TG|32019AG 
NR1I2 rs1464602 32042G>A  0.046 465% ↑ from 48TG|32042GG to 48TG|32042GA 
CYP2A6*17 (5065G>A) 
NR1I2 rs1464602 32042G>A  0.003 No definable pattern detected 
CYP3A4*1B (392A>G) 
NR1I2 rs1523130 5177T>C  0.011 
64% ↑ from 392GG|5177TT to 392GG|5177TC  
66% ↓ from 392AG|5177TT to 392AG|5177CC 
CYP3A5*3 (6986A>G) 
NR1I2 rs3842689 7070_7075del  0.008 
105% ↑ from 6986AG|+/+ to 6986AG|+/-  
199% ↑ from 6986AG|+/+ to 6986AG|-/-  
NR1I2 rs2276707 39823C>T  0.023 126% ↑ from 6986AG|39823CC to 6986AG|39823TT 
↑, increase in EFV levels. ↓, decrease in EFV levels. 
4.7.3. The effect of haplotypes on EFV levels 
The two variants that were found to be in LD, SNP rs3814055 (5705C>T) and deletion 
rs3842689, were analysed for an additive haplotype effect on EFV levels. No association was 
found between any haplotypes for these two variants and EFV levels (P = 0.463). 
4.8. Correlations between genotype and treatment outcome or adverse 
reactions 
The effect of NR1I3 and NR1I2 variants on treatment response was investigated by comparing 
non-responders to responders in terms of MAFs of each variant. A total of five individuals in the 
Xhosa cohort and seven individuals in the CMA cohort correspond to criteria for “non-
responders” (VL of > 80 copies/ml on date of sample collection). Appendix K shows the MAF of 
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each variant in the Responder and Non-Responder groups. In the Xhosa cohort, rs3814055 
(5705C>T) genotype differed significantly between Responders and Non-Responders (P = 0.011) 
and in the CMA cohort, rs2472677 (24087C>T) genotype differed significantly between 
Responders and Non-Responders (P = 0.023).  
Figure 14 shows the genotypes for these two SNPs in the respective groups. For both SNPs, more 
than 50% of individuals in the responder group are homozygous for the major allele (CC), and no 
individuals in the non-responder group are homozygous for this allele. 
 
Figure 14: Responder and non-responder genotype frequencies for rs3814055 in the Xhosa 
cohort and rs2472677 in the CMA cohort 
The effect of NR1I3 and NR1I2 genotype on the advent of EFV-based ADRs was also analysed. 
EFV-based ADRs were reported for 11 patients in the Xhosa cohort and five patients in the CMA 
cohort. The genotype frequencies and MAFs for each variant in the ADR and Non-ADR groups 
are also shown in Appendix K. No variant differed significantly between the two groups. 
Logistic regression analysis of the effect of single variant genotype on treatment outcome and the 
occurrence of ADRs did not find any statistically significant associations. (Appendix M). 
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CHAPTER 5 
5. Discussion 
This study aimed to analyse the effect of NR1I3 and NR1I2 variant genotypes on long-term 
efavirenz levels, treatment outcome and the occurrence of adverse drug reactions. This was 
achieved through the genotyping of DNA samples collected from HIV-positive female patients of 
Xhosa and Mixed ancestry who were prescribed an antiretroviral regimen containing efavirenz 
during the timeframe of the study, and, along with the measured efavirenz levels and available 
clinical data of the patients, searching for statistically valid correlations. 
5.1. Characteristics of study participants and confounding effects 
Recruitment of patients for the current study was limited due to the stringent criteria used for the 
study, including that suitable candidates should be female, of Xhosa or CMA ethnicity, and 
prescribed an ARV regimen containing EFV for at least three months.  
Only female patients were included in the current study. Some studies found an association 
between gender and EFV levels in the body (Haas et al., 2004; Burger et al., 2005; Mukonzo et 
al., 2009;  Habtewold et al., 2011). In these studies female individuals were found to have 
significantly higher mean EFV plasma levels than male individuals (Burger et al., 2005; 
Mukonzo et al., 2009; Habtewold et al., 2011). Other studies did not find a significant 
association, despite specifically testing for the potential confounding effect of gender in the 
analysis of variants (Marzolini et al., 2001; Haas 2004). A possible explanation for the discrepant 
findings could be that different methods were used to measure EFV levels while time and 
frequency of measurements also differed between studies.  In the current study, the decision to 
select only female study participants was due to three reasons. Firstly, the current study 
collaborated with the Women’s Interagency HIV Study (WIHS) in the USA and therefore 
selected females study participants in order to comply with their criteria. Secondly, in order to 
eliminate variables that could potentially act as confounding effects on EFV levels in the body, 
only female individuals were selected for our study. Another reason for the exclusion of male 
individuals was that in the Xhosa population, females were more willing to donate hair samples 
than male individuals, due to cultural reasons. 
Patients participating in the current study were of either Xhosa or CMA ethnicity. One of the 
aims of this study was to focus specifically on populations relevant to South Africa and the 
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Western Cape, as HIV is highly prevalent in the country, therefore pharmacogenetic research on 
ARVs can directly impact this burden in the country. Both the CMA and Xhosa populations are 
relevant to South Africa, as they are indigenous to the country and constitute a significant portion 
of the country, especially in the Western Cape (Statistics South Africa, 2013). These two 
populations also harbour a unique genetic make-up which represents other African population 
groups as well as contains some European genetic influences, which can provide insight on the 
differences and similarities among the population groups. 
The median age of the Xhosa and CMA participants of the study was 39 and 41 respectively 
(IQR: 34 – 45 and 37 – 46 respectively). The effect of patient age had variable results in studies 
searching for confounders influencing EFV levels. Amoroso et al. (2012) found a significant 
association between older age and increased odds of viral suppression (decreased VL). Prosperi et 
al. (2012) found a significant association with older age and an increased risk of EFV-based 
ADRs. In other studies, however, no association was found between age and any EFV-linked 
outcome (Marzolini et al., 2001;  Motsinger et al., 2006; Ritchie et al., 2006; Gandhi et al., 2009; 
Wyen et al., 2011; Sukasem et al., 2013). A possible explanation for the discrepancy between 
different studies could be the difference in the intervals between VL measurements and the total  
number of measurements taken. In the current study, age was significantly associated with 
treatment outcome as indicated by VL (P = 0.0270) (Figure 15), correlating with the Amoroso et 
al., (2012) study.  
 
Figure 15: Box plot for age for Responders (VL < 80 copies/ml) and Non-responders (V > 80 
copies/ml). 
BMI and weight has previously been associated with EFV-related outcomes in HIV-positive 
patients. Evans et al. (2012) reported that a low BMI was significantly associated with negative 
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treatment outcome of EFV or NVP as indicated by a VL > 400 copies/ml. Other studies also 
found an association between weight and EFV plasma levels (Arab-Alameddine et al., 2009; Di 
Iulio et al., 2009). It was found that an increased weight was associated with higher EFV 
clearance, and, therefore, decreased EFV plasma levels (Arab-Alameddine et al., 2009; Di Iulio 
et al., 2009). The current study did not find an association with weight and EFV levels, or any 
other outcome. It is possible that BMI and weight effect are ethnic-specific. The individuals that 
participated in the three studies mentioned above were predominantly Caucasian, whereas the 
current study did not include any individuals of Caucasian ethnicity. It should also be mentioned 
that by using BMI instead of weight as a variable for this study, the effect of height on body mass 
would have been taken into account, and could have resulted in a different outcome. 
In the current study, time using EFV was found to be significantly associated with the occurrence 
of reported EFV-based ADRs. Individuals that reported one or more occurrences of EFV-based 
ADRs were prescribed EFV for a longer period than individuals with no reported occurrences of 
EFV-based ADRs (Figure 16). This could be due to the fact that the longer time an individual 
was prescribed EFV, the longer time is available to report the occurrence of ADRs. The reporting 
of ADRs is largely done verbally by the patients’ themselves, which creates the possibility that 
not all ADRs are reported and some instances may be overlooked by the clinician.  
 
Figure 16: Box plot for time using EFV for individuals with reported EFV-based ADRs and 
individuals with no reported EFV-based ADRs. 
5.2. Survey of sequence conservation in NR1I3 
In silico analysis was performed in order to find putative conserved regions in the NR1I3 gene 
and its orthologs in various species. From mVISTA results, three conserved regions were 
highlighted: a 260 bp region just upstream of exon 1, the exon 1-region and the exon 2-region 
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(Figure 10). Due to the occurrence of enzyme slippage, bi-directional sequencing results for the 
260 bp upstream region was unsuccessful.  
Sequencing results indicate that the exon 1- and exon 2-regions, also including the first 40 bp and 
last 56 bp of intron 1, were conserved within the 30-patient sequencing cohort, as bi-directional 
sequencing results identified no variants in these regions. This was expected, as the occurrence of 
base pair variants in this region can result in the alteration of transcription and translation of 
NR1I3, and therefore the genetic conservation of these areas are important. The 5’-UTR region of 
NR1I3, of which exon 1 forms part, plays a role in the transcriptional regulation of NR1I3, and a 
variant occurring in this region can result in the alteration of mRNA secondary structure, TFBS 
and ribosomal binding sites, potentially influencing the transcription rate of NR1I3. An exonic 
variant can result in an amino acid change when the gene is translated, potentially altering protein 
activity.  A variant occurring in the 50-bp intronic regions flanking the exons, could potentially 
disrupt an exonic splice site. 
The promoter area of NR1I3 was also analysed for the presence of putative TFBS as identified by 
prediction software, as well as functional TFBS reported by other studies. It was found that only 
one SNP from sequencing results (rs55802895, 258G>A) disrupted a putative TFBS as identified 
in AliBaba (RAR-α), and no SNPs disrupted any of the functionally identified TFBS (Table 10). 
This shows that the TFBS in conserved, emphasising the importance of transcriptional regulation 
of NR1I3, even though it is constitutively expressed. 
From bi-directional sequencing analysis, it was found that the NR1I3 exonic regions were well 
conserved among the 30 individuals sequenced. Only 12 SNPs were found in the sequenced 
amplicons, which consisted of 738 bp 5’-upstream region, 393 bp UTR (including exon 1), 1,080 
bp exonic region and 1,754 intronic region (Table 11). Only three SNPs out of the 12 occurred in 
the exonic regions, two SNPs in exon 4 and one SNP in exon 5. None of the SNPs caused an 
amino acid change. 
In most nuclear receptors, the DBD should be more conserved than the LBD, both in terms of 
protein and DNA contents, in order for CAR to recognise and bind to response elements in target 
genes (Maglich et al., 2001; Wang & LeCluyse, 2003; Lamba 2008). In terms of number of SNPs 
found in the sequencing results, the DBD was more conserved than the LBD of NR1I3 in the 
current study. The DBD is 682 bp in length, and was included entirely in the sequenced 
amplicons. The total length of the LBD is 3,458 bp, but only 1,646 bp was included in the 
sequenced amplicons. From sequencing results, only one SNP, rs35709078, was identified in the 
DBD region, which resulted in a SNP density for the DBD of 1 SNP per 682 bp. Five SNPs were 
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identified in the LBD, which resulted in a SNP density of one SNP per 329 bp, confirming that 
the LBD is less conserved than the DBD. However, the results obtained would be viewed with 
more confidence if the number of individuals sequenced is increased, and if the entire LBD 
region is sequenced. 
5.3. Comparison of variant genotype and allele frequency in the study 
cohort and large database populations 
From the in silico analysis, bi-directional sequencing results, and literature analysis, target NR1I3 
SNPs were selected and subsequently genotyped. For NR1I2, analysis of literature, as well as the 
1000 Genomes and HapMap databases, resulted in the identification of NR1I2 target variants for 
subsequent genotyping.  
One SNP, rs1523130 (5177T>C) was genotyped using a Taqman® Genotyping Assay. Two 
samples, EF141 and EF152, failed on the Taqman® genotyping assay. Sample EF141 showed no 
fluorescence at all and was therefore not genotyped. The lack of fluorescence could be explained 
by the presence of a possible novel mutation within the recognition site of the Taqman® probe, 
which would result in the inability for the probe to bind, or could be an indication of the presence 
of inhibitors of the PCR reaction. Sample EF152 showed some fluorescence for both probes, but 
the fluorescence was too low for genotyping. The low level of fluorescence could be explained by 
the presence of inhibitors of the PCR reaction, or a low sample DNA concentration. 
From genotyping results for both genes, it was found that NR1I3 SNPs generally occurred at a 
lower frequency than NR1I2 variants. Seven out of the nine NR1I3 SNPs in the Xhosa cohort and 
six out of nine NR1I3 SNPs in the CMA cohort had a MAF lower than 0.100 (Table 13). This 
concurs with other studies that also reported low MAFs for most NR1I3 SNPs (Ikeda et al., 2003; 
Thompson et al., 2005; Chew et al., 2013). Seven out of nine NR1I2 variants in both cohorts had 
a MAF of higher than 0.200 (Table 13). This is in accordance with the observation that NR1I3 is 
more genetically conserved than NR1I2. The high conservancy of NR1I3 as compared to NR1I2 
can be explained by the larger size of NR1I2, creating more opportunity for genetic variants to 
occur. 
The average MAF for intronic variants was 0.197 (n = 4) in NR1I3 and 0.340 (n = 4) in NR1I2, 
and for exonic SNPs was 0.038 (n = 3) in NR1I3 and 0.067 (n = 1) in NR1I2. For both NR1I3 and 
NR1I2 variants, it was observed that the intronic variants had a higher MAF than the exonic 
SNPs, which concurs with the observation that exons are genetically more conserved than 
introns. 
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When comparing the Xhosa and CMA cohorts in terms of frequency distribution of SNPs, it was 
found that the MAFs of one NR1I3 SNP (rs2307424) and three NR1I2 SNPs (rs1523130, 
rs3814055 and rs1523127) differed significantly between the two cohorts (P ≤ 0.05). For three of 
these SNPs (rs2307424, rs1523130 and rs1523127), the CMA cohort had a higher MAF than the 
Xhosa cohort, and for one SNP (rs3814055), the Xhosa MAF was higher. The occurrence of such 
a low number of variants of significantly different MAFs, could indicate that the Xhosa and CMA 
cohorts are closely related. This correlated with a study by Ikediobi et al. (2011), who analysed 
approximately 200 SNPs occurring in pharmacogenetically relevant genes in the Xhosa and CMA 
populations, and found eight SNPs that differed significantly with regards to MAF. This is 
expected, as the Xhosa and CMA populations share N-K ancestry (Tishkoff et al., 2009).  
Subsequently, the MAFs for all target SNPs in the two cohorts were compared to MAFs of five 
populations from the 1000 Genomes database and one population from the HapMap database. 
The results indicate that the CEU, CHB and GIH populations had the highest difference in MAFs 
from the Xhosa and CMA cohorts (Table 14). This is expected, as the two South African cohorts 
would share similar genetic information with geographically closer cohorts, like the African 
cohorts YRI and LWK. The ASW population is also expected to be similar in genetic structure to 
both the Xhosa and CMA cohorts, as this population shares N-K ancestry with both the Xhosa 
and CMA cohorts, as well as European Caucasian ancestry with the CMA cohort (Tishkoff et al., 
2009). The SNP MAFs for CEU and GIH populations were closer to the CMA frequency 
distribution than the Xhosa population, as they shared a higher percentage similar SNP MAFs 
(Table 14). This was also expected, as the CMA population contains some European Caucasian 
and Indian ancestry (Tishkoff et al., 2009). The Xhosa and CMA cohorts showed equal 
differences in MAFs to the CHB population, which is expected, as neither cohort contains a high 
amount of East Asian ancestry (Tishkoff et al., 2009). A high percentage of SNPs differed in 
MAF between the YRI population and the study cohorts. This is unexpected for the Xhosa 
cohort, as the genetic constituency of the Xhosa population shares some similarities with 
populations from Central and West Africa, of which the Yoruban population forms part 
(Tischkoff et al. 2009; Schuster et al. 2010). A possible explanation for this occurrence could be 
that the Xhosa study cohort might not be fully homogenous and could contain some admixture 
(Patterson et al., 2010). 
All variants except NR1I3 SNPs rs113800307 and rs35709078 were  submitted to LD analysis 
using Haploview v4.2 (Barrett et al., 2005). No LD was found among the NR1I3 SNPs. This was 
unexpected, because, in a previous study (Oliver et al., 2010), NR1I3 SNPs rs2307424 and 
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rs2502815 were found to be in LD. Only two instances of LD were found in NR1I2; rs3814055 in 
the 5’-upstream region was found to be in LD with rs3842689 in the 5’-UTR region and 
rs1523130 in the 5’-upstream region was found to be in LD with rs1523127 in the 5’-UTR 
region. In another study (Fanta et al., 2008), a haplotype was found consisting of five variants, 
rs3814055, rs1523127, rs3842689, rs6785049 and rs2276707, associated with cyclosporine 
availability. However, in the current study, rs6785049 was not genotyped and rs2276707 was not 
linked to the other variants. It can be suggested that the LD results in the current study differ from 
previous studies, because of differences in ethnicity of the study participants, as the studies 
mentioned above used mainly Caucasian participants. 
5.4. The effect of variant genotype on EFV levels 
The effect of genetic variation in NR1I3 and NR1I2 on EFV pharmacokinetics as measured by 
EFV levels in hair was analysed, first through preliminary analysis using Microsoft Office Excel 
2010, followed by linear regression analysis using R statistical software (The R Development 
Core Team, 2010). The variation in the two nuclear receptor genes were analysed independently, 
as well as in combination with variants in genes encoding for EFV-metabolising proteins. 
From the statistical analysis results, NR1I2 SNP rs1523128 (6334A>G) was found to be 
associated with EFV hair levels. Linear regression models predict the effect size of the SNP to be 
a decrease of 56% in EFV in individuals homozygous for the A-allele (AA) compared to 
heterozygotes (GA) (Table 17). This SNP was also important in the preliminary analysis, where 
minor homozygotes (AA) for this SNP had the lowest mean EFV levels in the Xhosa cohort 
(Table 15). SNP rs1523128 occurs in the 5’-upstream region of NR1I2, 893 bp from the start of 
exon 1. Previous in silico analyses found that the rs1523128 A-allele creates a putative C/EBP 
TFBS and disrupts a putative HNF-1α TFBS (Zhang et al., 2001; Lamba et al. 2008). The C/EBP 
TF has been found to cooperate with both CAR and PXR in transcriptional regulation of 
xenobiotic metabolising genes, including CYP-genes (Goodwin et al., 2002; Benet  et al., 2010). 
HNF-1α is also involved in the transcriptional regulation of CYP-genes as well as the NR 
farnesoid X receptor (FXR) (Gonzalez & Lee, 1996; Vacca et al., 2013). However, the 
transcriptional regulation of PXR by the two TFs has yet to be investigated. It can be 
hypothesised that the disruption of a TFBS and the creation of another alters the activation and 
subsequent rate of transcription of PXR. This could lead to an increase in the induction of 
CYP2B6 and other EFV-metabolising proteins by PXR, which in turn could lead to lower EFV 
levels. SNP rs1523128 was mentioned in two other studies, where it was associated with 
susceptibility to Crohn’s Disease (inflammatory bowel disorder) and periodontitis (inflammatory 
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oral cavity disorder) (Glas et al., 2011; Folwaczny et al., 2012). However, this SNP was not 
associated with EFV levels in any other study. 
5.4.1. The effect of composite genotype on EFV levels 
NR1I3 SNP rs55802895 (258G>A), in conjunction with CYP2B6*6, was significantly associated 
with EFV levels. Individuals with the *6*6|258GG composite genotype showed a 161% increase 
in EFV levels compared to individuals with the Non-*6*6|258GG composite genotype (Table 
17). Individuals with the 258GA or 258AA genotype showed no significant change in mean EFV 
levels between the *6*6 and Non-*6*6 groups (Table 17). SNP rs55802895 occurs in the 5’-
upstream region of NR1I3, and the A-allele disrupts a putative RAR-α TFBS, as predicted using 
the AliBaba in silico program (Grabe, 2002). Saito et al. (2010) found that the binding of RAR 
TF to a TFBS in intron 1 of NR1I3 increases the transcription of the gene. It can therefore be 
postulated that the disruption of the putative TFBS by the rs55802895 minor allele could result in 
decreased NR1I3 transcription, resulting in decreased CYP2B6 activation and subsequent 
increased EFV levels. However, the opposite is observed, namely that the presence of the 
rs5580295 minor allele (A-allele) reduces the effect of CYP2B6*6 on EFV levels, resulting in 
lower EFV levels. 
The genotyped NR1I3 and NR1I2 genes have also been analysed for their composite effect on 
variants in four other genes involved in EFV metabolism, CYP1A2, CYP2A6, CYP3A4 and 
CYP3A5. A range of significant associations of NR1I3 and NR1I2 variants were identified, that 
exerted either a reducing or an amplifying effect on the influence of their composite SNP on EFV 
levels (Table 17).  
SNP CYP1A2*1F induces increased activity of the CYP1A2 enzyme (Han et al., 2002), which 
could result in decreased drug levels. This SNP formed a compound genotype with one NR1I3 
SNP (rs2502815) and three NR1I2 SNPs (rs3842689, rs12721613 and rs2276707) which 
influenced EFV hair levels in the study cohort. NR1I3 SNP rs2502815 showed a trend in 
decreased EFV levels in a study by Swart et al. (2012), although not statistically significant. 
NR1I2 SNP was associated with decreased PXR activity (Zhang et al., 2001). CYP2A6*9B was 
associated with elevated EFV plasma levels in a previous study (Kwara et al., 2009). Compound 
genotypes were identified of this SNP along with one NR1I3 SNP (rs2307420) and two NR1I2 
SNPs (rs1464603 and rs1464602). Individuals with these compound genotypes had increased 
EFV levels, which indicates that the NR1I3 and NR1I2 SNPs had an amplifying effect on 
CYP2A6*9B. CYP2A6*17 was also associated with higher mean EFV plasma levels in a previous 
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study (Kwara et al., 2009). One NR1I2 SNP was found to influence EFV levels in conjunction 
with CYP2A6*9B, however, no discernible pattern could be detected. The impact of CYP3A4*1B 
on CYP3A4 expression is unclear, and varying results are produced by different studies 
(Wojnowski, 2004; Klein & Zanger, 2013), indicating the possible impact of other additional 
SNPs on CYP3A4*1B. In the current study, NR1I2 SNP rs1523130 was found to influence EFV 
levels in conjunction with CYP3A4*1B. CYP3A5*3 creates a splice error, which leads to a 
decrease in CYP3A5 expression. Two NR1I2 SNPs, rs3842689 and rs2276707, were found to 
have an influence on EFV levels in conjunction with CYP3A5*3. These results emphasise the 
complexity of EFV metabolism and the various effects of all the elements involved.  
5.5. The effect of variant genotype on treatment outcome and adverse 
drug reactions 
The effect of genetic variation in NR1I3 and NR1I2 and treatment outcome and the occurrence of 
ADRs were analysed, first through preliminary analysis, and secondly through logistic regression 
models using R statistical software (The R Development Core Team, 2010). No variants were 
associated with treatment outcome or the occurrence of ADRs. The number of non-responders in 
the study cohort was small (n = 5 and n = 7 for the Xhosa and CMA cohorts respectively). The 
number of individuals with reported ADRs was also small (n = 11 and n = 5 for the Xhosa and 
CMA cohorts respectively). This small sample size limits the validity and strength of the 
statistical analysis. Significant statistical findings may occur in a cohort with a larger portion of 
non-responders and individuals with reported ADRs. 
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CHAPTER 6 
6. Conclusions and future research 
This study aimed to investigate the genetic variants in two nuclear receptor genes in two South 
African populations, and to analyse the effect of these on EFV levels and treatment outcome. 
Based on this aim, the following conclusions were drawn: 
The analysis of the characteristics of the study participants identified statistically significant 
confounding effects, which were adjusted for in the analysis: 
 Age was significantly associated with treatment outcome, as the mean age for responders 
was higher than the mean age of non-responders. 
 BMI and weight was not significantly associated with any of the study outcomes. 
 Time on efavirenz was significantly associated with the occurrence of ADRs, as patients 
that were prescribed EFV for a longer period of time had a higher occurrence of reported 
ADRs. 
The focus on the two nuclear receptors highlighted the importance of transcriptional regulation, 
and showed the need for more in-depth investigation into the activation and de-activation of 
transcriptional regulators, and the downstream effects of this action:  
 In NR1I3, the DBD was more conserved than the LBD when analysing the sequencing 
results, which confirmed in silico analysis. 
 In NR1I3, exonic SNPs occurred at a lower MAF than intronic SNPs, which confirms 
selective constraint. 
 NR1I3 SNPs have a lower MAF in general than NR1I2 variants, which confirms in silico 
analysis and literature proclaiming that NR1I3 is more conserved. 
Through the investigation of two important South African populations, and the comparison of the 
genetic variants in these two cohorts with other populations, it was shown that these populations 
share some common genetic composition with each other, as well as with other African 
populations, but also showed some significant differences in genetic variation:  
 Only four out of the 19 genotyped variants in total differed significantly between the 
Xhosa and CMA cohorts, which confirm the suggestion that these two populations share 
some genetic patterns. 
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 When comparing the variant MAFs with five other populations form HapMap and 1000 
Genomes databases, it was found that the Xhosa cohort is most similar to the LWK and 
ASW population and the CMA cohort is most similar to the ASW population. The CEU, 
CHB and GIH populations are the least similar to both study cohorts. 
Through the analysis of genetic variation in two important nuclear receptor genes, their effect 
in conjunction with primary EFV-metabolizing gene variants and their influence on EFV 
levels, treatment outcome and the occurrence of adverse reactions, the complexity of EFV 
metabolism was emphasised. 
 After correcting for confounders, NR1I3 SNP rs1523128 was associated with decreased 
EFV levels (P = 0.0168) in both cohorts. In individuals homozygous for the minor allele 
of rs1523128, a decrease of 56% in EFV levels was observed. 
 Individuals with CYP2B6*6*6 genotype and NR1I3 SNP rs55802895 GG genotype 
showed significant increase in EFV levels, which leads to the conclusion that this 
genotype has the ability to enhance the effect of CYP2B6*6*6. 
 Following analysis of NR1I2 and NR1I3 SNPs, in combination with SNPs from CYP1A2, 
CYP2A6, CYP3A4 and CYP3A5, 11 composite genotypes were identified that were 
significantly associated with increased or decreased EFV levels (Table 17). 
 No variants showed a statistically significant effect on treatment outcome or the 
occurrence of adverse drug reactions. This can be explained by the small portion of the 
cohort that was identified as bad responders or that reported the occurrence of ADRs. 
 In the attempt to attribute significant effects on EFV treatment outcome and the 
occurrence of ADRs to genetic variance in the two nuclear receptor genes, it was 
concluded that more elaborate and standardised measurements of treatment outcome and 
reports of ADRs are needed in order to gain valid results. 
The findings of this study prompt the further examination of the EFV metabolism pathway, and 
some factors should be carefully considered: 
 In the current study, sample size was a limiting factor. The small sample size of the study 
lowers the statistical impact of the results, as it increases the odds of significant results 
occurring due to chance. By dividing the sample cohort into two groups based on 
ethnicity, further decreases the sample size. It should be a priority of future studies to 
collect a sample cohort with as high as possible cohort size, which would ensure that 
statistical results are trustworthy and have a high power. The participation of more clinics 
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in future studies can help to increase the sample size, however, due to the high risk of 
stratification in the CMA population, the possibility increases of inadvertently merging 
CMA subgroups together that are in fact genetically separate entities. 
 The fact that the current sample cohort was started on ART at different times, differed in 
terms of regimen history and the recording of VL-measurements and CD4 counts were 
not at standardised times, complicated the design of statistical assays. Therefore, future 
research studies should ensure that clinical history for each patient is uniform, complete, 
up to date and standardised. This is currently being addressed in a new study in our group. 
 In order to be able to analyse the genetic conservation in both nuclear receptor genes 
equally, it would have been favourable to sequence the exonic region of the NR1I2 gene 
as was done for the NR1I3, and is therefore recommended for further research. 
 It would be helpful to investigate the downstream effect of NR1I3 and NR1I2 regulation 
on a protein level, as an addition to genetic analysis, by looking at the inhibition or 
activation of protein activity. 
  Another aspect of EFV-metabolism is the transport of the ARV drug and its metabolites 
in and out of cells. The effect of genetic variation in transporters linked to EFV, for 
example ABCB1, should be further investigated. This forms part of another study in our 
group. 
Using, among others, the above suggestions, the mechanism of EFV metabolism could be fully 
unravelled, which would aid in optimisation and management of patient ARV regimen dosage. 
This could help reduce the occurrence of adverse effects, as well as increase the chances of 
treatment success in patients. 
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Appendices 
Appendix A: Protocols 
Laboratory Protocol for Manual Purification of DNA from 0.5 ml of 
Oragene®•DNA/saliva (DNA Genotek Inc., Kanata, Canada). 
DNA yield and stability in Oragene·DNA 
Oragene•DNA is designed to capture the large amount of DNA present in saliva. The median 
yield of DNA from 2 ml of saliva when captured in 2 ml of Oragene•DNA is 110 μg. 
The following step-by-step protocol describes how to purify DNA from a 500 μl aliquot of an 
Oragene•DNA/saliva sample. Volumes of less than 500 μl may be purified by adjusting the 
volumes of reagents accordingly. 
Equipment and reagents to be supplied by user 
• Microcentrifuge capable of running at 13,000 rpm (15,000 × g) 
• Air or water incubator at 50°C (Note: water incubator is not recommended for OG-500). 
• Ethanol (95 to 100%) at room temperature 
• DNA buffer: TE (10 mM Tris-HCl, 1mM EDTA, pH 8.0) or similar solution 
• (Optional) Glycogen (20 mg/ml) (e.g., Invitrogen Cat. No. 10814-010) 
• Ethanol (70%) at room temperature 
Procedure 
Purification Steps Notes 
1. Mix the Oragene•DNA/saliva sample in the 
Oragene•DNA vial by inversion and gentle 
shaking for a few seconds. 
• This is to ensure that viscous saliva samples are properly 
mixed with the Oragene•DNA solution. 
2. Incubate the sample at 50°C in a water 
incubator for a minimum of one hour or in an 
air incubator for a minimum of two hours. 
• DNA in Oragene•DNA is stable at room temperature even 
without the incubation step. 
• This heat-treatment step is essential to ensure that DNA is 
adequately released and that nucleases are permanently 
inactivated. 
• This incubation step may be performed at any time after 
saliva is collected and before it is purified. 
• Incubation of the entire sample is recommended to ensure 
that this step has been completed. However, if it is more 
convenient, a 500 μl aliquot can be heat-treated. 
• The sample can be incubated either in the original 
container or after transfer to another tube. 
• The sample may be incubated at 50°C overnight if it is 
more convenient. 
• A longer time is required in an air incubator because 
temperature equilibration is slower than in a water 
incubator. 
3. Transfer 500 μl of the mixed 
Oragene•DNA/saliva sample to a 1.5 ml 
microcentrifuge tube. 
• The remainder of the Oragene•DNA/saliva sample can be 
stored at room temperature or frozen (-15°C to -20°C). 
4. For 500 μl of Oragene•DNA/saliva, add 20 μl • The sample will become turbid as impurities and 
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(1/25th volume) of Oragene•DNA Purifier 
(OG-L2P, supplied) to the microcentrifuge 
tube and mix by vortexing for a few seconds. 
inhibitors are precipitated. 
5. Incubate on ice for 10 minutes. • Room temperature incubation can be substituted but will 
be slightly less effective in removing impurities. 
6. Centrifuge at room temperature for five 
minutes at 13,000 rpm (15,000 × g). 
• A longer period of centrifugation (up to 15 min) may be 
beneficial in reducing the turbidity (high A320) of the 
final DNA solution. 
7. Carefully transfer the clear supernatant with a 
pipet tip into a fresh microcentrifuge tube. 
Discard the pellet containing impurities. 
 
Optional: Addition of Glycogen 
• The pellet contains turbid impurities. If accidentally 
disturbed, the tube should be re-centrifuged. 
 
Optional: Addition of Glycogen 
Some users may prefer to add 5 μl (100 μg) of Glycogen to the 
supernatant to make the pellet more easily visible. 
8. To 500 μl of supernatant, add 500 μl (i.e., an 
equal volume) of room-temperature 95-100% 
ethanol. Mix gently by inversion 10 times. 
• During mixing with ethanol, the DNA will be 
precipitated. This may appear as a clot of DNA fibers or 
as a fi ne precipitate, depending upon the amount of DNA 
in the sample. 
• Even if no clot is seen, DNA will be recovered by 
carefully following the next steps. 
9. Allow the sample to stand at room temperature 
for 10 minutes to allow the DNA to fully 
precipitate. 
• Incubation at -20°C is not recommended because 
impurities may co-precipitate with the DNA. 
10. Place the tube in the microcentrifuge in a 
known orientation. Centrifuge at room 
temperature for two minutes at 13,000 rpm 
(15,000 × g). 
• For example, place each tube in the microcentrifuge with 
the hinge portion of the cap pointing away from the centre 
of the rotor. After centrifugation, the position of the pellet 
can be located (even if too tiny to be easily visible.): it 
will be at the tip of the tube below the hinge. 
11. Carefully remove the supernatant with a pipet 
tip and discard it. Take care to avoid disturbing 
the DNA pellet. 
• This pellet contains DNA. Loss of the pellet will result in 
loss of the DNA. 
• Rotating the tube such that the pellet is on the upper wall 
will allow you to safely move a pipet tip along the lower 
wall and remove all of the supernatant. 
• The supernatant may contain impurities and should be 
removed as completely as possible. 
• Excessive drying of the pellet can make the DNA more 
difficult to dissolve. 
12. Ethanol wash step. Carefully add 250 μl of 
70% ethanol. Let stand at room temperature 
for 1 minute. Completely remove the ethanol 
without disturbing the pellet. 
• Take care not to disturb the DNA pellet. 
• The DNA pellet may be small. Addition of a carrier such 
as glycogen at step #7 will increase the visibility of the 
pellet. 
• Should the pellet detach, cetrifuge the sample for five 
minutes at 13,000 rpm (15,000 x g). 
• The 70% ethanol wash helps to remove residual 
• inhibitors. 
13. Add 100 μl of DNA buffer to dissolve the 
DNA pellet. Vortex for at least five seconds. 
• The expected concentration of the fully hydrated DNA is 
20 to 200 ng/μl. 
• Note that large amounts of high molecular weight DNA 
can be slow to hydrate (dissolve) completely. 
• Incomplete hydration of the DNA is a cause of inaccuracy 
in estimating DNA concentration and of failure of 
downstream applications such as PCR. 
14. (Optional) Additional steps to ensure complete 
hydration of the DNA. 
a) Additional vigorous pipetting and vortexing, and/or 
b) Incubation at 50°C for 1 hour with occasional 
vortexing, and/or 
c) Incubation at room temperature for one to two days 
• For applications such as Southern blotting that require 
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very high molecular weight DNA, (c) is recommended. 
15. Storage of the fully rehydrated DNA. • In TE at 4°C for up to 1-2 months. 
• Recommended in TE in aliquots at -20°C for long-term 
storage. 
• Note that freezing of purified DNA in TE will cause DNA 
to precipitate. When thawing a sample of frozen purified 
DNA, pay careful attention to rehydration, as discussed in 
step 13. 
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Bioline SureClean protocol for PCR clean-up 
1. Add an equal volume of SureClean to nucleic acid solution and mix thoroughly. 
2. Incubate at room temperature for at least 10 min. 
3. Centrifuge at maximum speed (best results at 14,000x g) in a bench-top centrifuge for 10 
minutes and carefully remove supernatant by aspiration.  
(Note: Centrifuging for longer time leads to better DNA recovery) 
4. Add a volume of 70% Ethanol equal to 2x original sample volume and vortex for 10 
seconds.  
(Note: For sensitive applications an optional second ethanol wash can be performed) 
5. Centrifuge at maximum speed (best results at 14,000 x g) in a bench-top centrifuge for 10 
minutes, remove supernatant and air-dry to ensure complete removal of ethanol. (Note: 
Do not overdry the pellet) 
Resuspend pellet in desired volume of TE, water or any other appropriate buffer for downstream 
procedures. 
Notes: 
A. Apparent molecular weight of the DNA treated (agarose gel electrophoresis) may be higher if 
the washing-step with 70% ethanol step is omitted. For accurate MW assay, two washing steps 
are recommended after the cleaning procedure. 
B. Nucleic acids to be purified must be ≥ 100 bp. 
C. Easier visualisation of the pellet can be achieved with a pink co-precipitant which is supplied 
in the Bioline SureClean Plus (BIO-37047). 
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Appendix B: List of primers 
Table B-1: Primers for bi-directional sequencing of NR1I3 
Start of amplicon 
Amplicon 
name 
Amplicon 
length (bp) 
Primer Name Sequence (5’-3’) 
Size 
(bp) 
TM 
(°C) 
GC 
(%) 
Source 
4791 bp upstream 
from exon 1 
UA1 576 
NR1I3 Upstream Amplicon 1 F ATTAGGCTCACAGAGGTGATCTGC 24 58.8 50.0 PrimerQuest 
NR1I3 Upstream Amplicon 1 R CTCCCTCACTCCCTATAAATGACC 24 56.2 50.0 PrimerQuest 
1245 bp upstream 
from exon 1 
UA2 611 
NR1I3 Upstream Amplicon 2 F GCTATTATTACAGGTGCACGCC 22 56.1 50.0 PrimerQuest 
NR1I3 Upstream Amplicon 2 R AGAGCCCTCTCACTTCCTAAC 21 55.8 52.4 PrimerQuest 
695 bp upstream 
from exon 1 
UA3 791 
NR1I3 Upstream Amplicon 3 F TGCCCTGTGGTCACTCTGATTT 22 58.7 50.0 PrimerQuest 
NR1I3 Upstream Amplicon 3 R TTATGTGGCCTCCAGTTGCTCT 22 58.5 50.0 PrimerQuest 
142 bp upstream 
from exon 1 
Exon 1 520 
NR1I3 Exon 1 F primer TCCCAGCTTGTTCAGGATCT  20 55.8 50.0 Thompson et al., 2005 
NR1I3 Exon 1 R primer AAGTGCTGGAATGACACACG 20 55.7 50.0 Thompson et al., 2005 
338 bp upstream 
from exon 2 
Exon 2 636 
NR1I3 Exon 2 altF primer AACCTGGGCAACATGGCAAA 20 58.3 50.0 PrimerQuest 
NR1I3 Exon 2 R primer TGCCAGCCACAGGGTAGTTA 20 58.4 55.0 PrimerQuest 
138 bp upstream 
from exon 3 
Exon 3 379 
NR1I3 Exon 3 F primer GCTTGAGATGTGTTGGATAC 20 51.0 45.0 Ikeda et al., 2003 
NR1I3 Exon 3 R primer TGTGCCTGCTATGTAGAGAA 20 53.1 45.0 Ikeda et al., 2003 
138 bp upstream 
from exon 4 
Exon 4/5 814 
NR1I3 Exon 4/5 F primer AGCCAAGCCCAAGAAAGTCT 20 56.9 50.0 Thompson et al., 2005 
NR1I3 Exon 4/5 R primer CCAAAGCTGGGAATTCAAGA 20 53.0 45.0 Thompson et al., 2005 
9 bp upstream 
from exon 6 
Exon 6/7 519 
NR1I3 Exon 6/7 altF primer AAGTGTCCTTGTTTCCTGC 19 53.0 47.4 PrimerQuest 
NR1I3 Exon 6/7 R primer GACTGAGGCTGGGATAGACCT 21 57.9 57.1 PrimerQuest 
64 bp upstream 
from exon 8 
Exon 8 317 
NR1I3 Exon 8 F primer GTCTATCCCAGCCTCAGTCC 22 56.7 60.0 Ikeda et al., 2003 
NR1I3 Exon 8 R primer TAGACCCCACGATACCTGAA 20 54.7 50.0 Ikeda et al., 2003 
175 bp upstream 
from exon 9 
Exon 9 556 
NR1I3 Exon 9 F primer AGACAGTGTCAGACCGAGGC 20 59.0 60.0 Thompson et al., 2005 
NR1I3 Exon 9 R primer TTAGCCCTGAGGTTTCCTCC 20 56.4 55.0 Thompson et al., 2005 
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Table B-2: Primers for genotyping of NR1I3 SNPs 
Position SNP 
Genotyping 
Assay 
Amplicon 
length (bp) 
Primer Name Sequence (5’-3’) 
Size 
(bp) 
TM 
(°C) 
GC 
(%) 
Source 
Exon 7 rs113800307 PCR-RFLP 519 
NR1I3 Exon 6/7 altF primer AAGTGTCCTTGTTTCCTGC 19 53.0 47.4 PrimerQuest 
NR1I3 Exon 6/7 R primer GACTGAGGCTGGGATAGACCT 21 57.9 57.1 PrimerQuest 
Intron 5 rs2307420 PCR-RFLP 277 
CAR rs2307420 F CCTCATCTTTCAGGAGGCAAACACTgC 27 61.5 51.9 PrimerQuest 
CAR rs2307420 R CAAACTTCTGGACTCAAGCGATCTGCC 27 61.4 51.9 PrimerQuest 
Exon 5 rs2307424 TSP 
856 
NR1I3 TSP LS 1 F TGCAGTTCTTCACAGGTTGGTGGA 24 60.7 50.0 PrimerQuest 
NR1I3 TSP LS 1 R ATGCTTGGAAAGGCTGACGCATGT 24 61.7 50.0 PrimerQuest 
218 / 324 
NR1I3 rs2307424 NLS F GCCCAAGATAAGGCTGG 17 53.0 58.8 PrimerQuest 
NR1I3 rs2307424 NLS R CGTCACCGGAAGACG 15 52.7 66.7 PrimerQuest 
Exon 4 rs34161743 PCR-RFLP 814 
NR1I3 Exon 4/5 F primer AGCCAAGCCCAAGAAAGTCT 20 56.9 50.0 Thompson et al., 2005 
NR1I3 Exon 4/5 R primer CCAAAGCTGGGAATTCAAGA 20 53.0 45.0 Thompson et al., 2005 
Exon 4 rs35205211 PCR-RFLP 814 
NR1I3 Exon 4/5 F primer AGCCAAGCCCAAGAAAGTCT 20 56.9 50.0 Thompson et al., 2005 
NR1I3 Exon 4/5 R primer CCAAAGCTGGGAATTCAAGA 20 53.0 45.0 Thompson et al., 2005 
Intron 3 rs2502815 TSP 
733 
NR1I3 TSP LS 4 F TTGCAGTGAGCCGAGATTGCTCCATT 24 62.6 50.0 PrimerQuest 
NR1I3 TSP LS 4 R TGTCATGATCTCTTGCCTGGCACA 24 60.6 50.0 PrimerQuest 
229 / 315 
NR1I3 rs2502815 NLS F GCCCTCCCTCTACACTG 17 54.4 64.7 PrimerQuest 
NR1I3 rs2502815 NLS R CGCCCTGCACAACG 14 54.6 71.4 PrimerQuest 
Intron 4 rs3003596
1 
PCR-RFLP 204 
CAR rs3003596 F CTTGCTTTTTCCATATCACACGA 23 62.0 39.1 PrimerQuest 
CAR rs3003596 R AGAAATGTGGACAGGCTTAGAT 22 62.0 40.9 PrimerQuest 
Intron 2 rs35709078 PCR-RFLP 379 
NR1I3 Exon 3 F primer GCTTGAGATGTGTTGGATAC 20 51.0 45.0 Ikeda et al., 2003 
NR1I3 Exon 3 R primer TGTGCCTGCTATGTAGAGAA 20 53.1 45.0 Ikeda et al., 2003 
5’-upstream rs55802895 PCR-RFLP 538 
NR1I3 TSP LS 3 F AAATGACAGGTGCAGCCCTTGACT 24 61.1 50.0 PrimerQuest 
NR1I3 TSP LS 3 R TTCCAACCCATCCTCCATGCTGTT 24 60.8 50.0 PrimerQuest 
1
Primers were adapted from Swart et al., 2012. Bold lowercase letters are incorporated mutagenic nucleotides. Underlined letters are non-complementary 5’-tails. 
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Table B-3: Primers for genotyping of NR1I2 SNPs 
Position SNP 
Genotyping 
Assay 
Amplicon 
length (bp) 
Primer Name Sequence (5’-3’) 
Size 
(bp) 
TM 
(°C) 
GC 
(%) 
Source 
5’-upstream  rs3814055 PCR-RFLP 
504 
PXR TSP LS 1 F TCCCAGCCTCAAGTCTTTCTCATCCCTT 28 62.7 50 PrimerQuest 
PXR TSP LS 1 R AGTCCTCACTCTTCAGCCTCAACCTTCT 28 62.3 50 PrimerQuest 
221 
PXR rs3814055 F TTTTTTGGCAATCCCAGGaT 20 52.8 40 Andrews et al., 2010 
PXR rs3814055 R CGAATGTGGTGGATACCAG 19 52.9 52.6 Andrews et al., 2010 
5’-upstream rs1523128 PCR-RFLP 696 
PXR rs1523128 F TCCTGGTCAGCCTTCTGTTCTGAG 24 60.3 54.2 PrimerQuest 
PXR rs1523128 R AGGAGTAGCTTTACCAAGGAGCCG 24 60.3 54.2 PrimerQuest 
5’-UTR rs1523127 TSP 
450 
PXR TSP LS 2 F AGCCGCTTAGTGCCTACATCTGACTT 26 61.6 50 PrimerQuest 
PXR TSP LS 2 R AGCAGCAAGGCCAACATGATTCACGA 26 63 50 PrimerQuest 
233 / 420 
PXR rs1523127 NLS F GCTACTCCTGTCCTGAAC 18 52 55.6 PrimerQuest 
PXR rs1523127 NLS R CGCTATGATGCTGACCTC 18 52.8 55.6 PrimerQuest 
5’-UTR rs3842689 PCR-RFLP 112 / 106 
PXR rs3842689 3 F TACTGATGCTCTCTGGTCCTGCAC 24 60.3 54.2 PrimerQuest 
PXR new rs3842689 R CTGTAACAGGGAGCTGGTTGTATG 24 57.3 50 PrimerQuest 
Intron 1 rs2472677 PCR-RFLP 621 
PXR rs2472677 F TGCTAGCAGTGCATAAGGGCTCAG 24 61 54.2 PrimerQuest 
PXR rs2472677 R TCCTGACCTTAGGTGATCCATGCC 24 60.3 54.2 PrimerQuest 
Exon 2 
rs12721613 
(PXR*2) 
PCR-RFLP 408 
PXR TSP LS4 F CCGAGTTCACAGGCCCAAATGTGAGT 26 62.9 53.8 PrimerQuest 
PXR TSP LS4 R TCAAGCTGAGGCCCTGAGACGTTAC 25 62.2 56 PrimerQuest 
Intron 2 rs1464603 PCR-RFLP 522 
PXR Intron 2 F GTTCCTGGAAAGCCCAGTGTCAAC 24 60.2 54.2 PrimerQuest 
PXR Intron 2 R TCCCTTCGGTCTGTTTCTCTTCCC 24 60.3 54.2 PrimerQuest 
Intron 2 rs1464602 PCR-RFLP 522 
PXR Intron 2 F GTTCCTGGAAAGCCCAGTGTCAAC 24 60.2 54.2 PrimerQuest 
PXR Intron 2 R TCCCTTCGGTCTGTTTCTCTTCCC 24 60.3 54.2 PrimerQuest 
Intron 8 rs2276707 PCR-RFLP 291 
PXR rs2276707 F ACAGTGTTCAATGCGGAGACTGGA 24 60.4 50 PrimerQuest 
PXR rs2276707 R TCCAGTAGAAGTTGCTGGAAGCCA 24 60.1 50 PrimerQuest 
Bold lowercase letters are incorporated mutagenic nucleotides. Underlined letters are non-complementary 5’-tails. 
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Appendix C: List of reagents and buffers 
10 mg/ml Cresol stock solution 
0.1 g Cresol red (Sigma-Aldrich Co. LLC, St. Louis, USA) 
1000 μl Sabax water (Adcock Ingram Pty. Ltd., Midrand, ZA) 
Cresol loading dye 
200 μl Cresol stock solution (10 mg/ml) 
3.4 g sucrose (Merck KGaA, Darmstadt, Germany) 
9.5 ml Sabax water (Adcock Ingram Pty. Ltd., Midrand, ZA) 
TBE 10x buffer 
108 g Tris (Sigma-Aldrich Co. LLC, St. Louis, USA) 
55 g boric acid (Sigma-Aldrich Co. LLC, St. Louis, USA) 
12.445 g EDTA (Sigma-Aldrich Co. LLC, St. Louis, USA) 
Fill to 500 ml with distilled water (dH2O) or water subjected to reverse osmosis (RO-water) 
TBE 1x buffer 
200 ml TBE 10x buffer 
1.8 L distilled or RO-water 
TBE 5x buffer 
200 ml TBE 10x buffer 
200 ml distilled or RO-water 
10% (w/v) SDS solution 
10 g SDS (Merck KGaA, Darmstadt, Germany) 
100 ml distilled or RO-water 
0.6% (w/v) Agarose gel 
0.3 g agarose (Lonza Group Ltd., Rockland, USA) 
50 ml distilled or RO-water 
1.0% (w/v) Agarose gel 
0.5 g agarose (Lonza Group Ltd., Rockland, USA) 
50 ml distilled or RO-water 
1.5% Agarose gel 
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0.75 g agarose (Lonza Group Ltd., Rockland, USA) 
50 ml distilled or RO-water 
3% Agarose gel 
1.5 g agarose (Lonza Group Ltd., Rockland, USA) 
50 ml distilled or RO-water 
40% (w/v) Stock Polyacrylamide solution 
38 g acrylamide (Sigma-Aldrich Co. LLC, St. Louis, USA) 
2 g bisacrylamide (Promega Corporation, Fitchburg, USA) 
100 ml distilled or RO-water 
15% Polyacrylamide gel mix 
37.5 ml stock polyacrylamide solution 
20 ml 5x TBE buffer 
42.5 ml distilled or RO-water 
10% Ammonium persulphate solution (APS) 
0.1 g ammonium persulphate (Promega Corporation, Fitchburg, USA) 
100 μl distilled or RO-water 
Polyacrylamide gel mix 
10 ml 15% polyacrylamide gel mix 
100 μl APS 
20 μl TEMED (Sigma-Aldrich Co. LLC, St. Louis, USA) 
Bluejuice Loading dye (adapted from Barril & Nates, 2012) 
4 ml (0.25%) bromophenol blue (Merck KGaA, Darmstadt, Germany) 
4 ml (0.25%) xylene cyanol FF (Sigma-Aldrich Co. LLC, St. Louis, USA) 
30 ml (30%) glycerol (Merck KGaA, Darmstadt, Germany) 
62 ml TBE 1x buffer 
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Appendix D: List of patient characteristics 
 
Xhosa CMA 
Characteristic Median (IQR) Median (IQR) 
Age at sample collection (years) 39 (34 - 45) 41 (37 - 46) 
BMI Baseline 23.38 (34 - 45) 21.46 (37 - 46) 
CD4 Baseline (copies / ml) 159 (98 - 206) 147 (98 - 192) 
Time on EFV (months) 40.96 (24 - 57) 25.59 (10 - 41) 
Characteristic Number of pts (%) Number of pts (%) 
WHO Disease Stage: 
  
Stage 1 3 (3.80) 3 (5.66) 
Stage 2 16 (20.25) 12 (22.64) 
Stage 3 39 (49.37) 21 (39.62) 
Stage 4 18 (22.78) 14 (26.42) 
n/a 3 (3.80) 3 (5.66) 
Smoking: 
  
yes 2 (2.53) 10 (18.87) 
no 47 (59.49) 24 (45.28) 
n/a 30 (37.97) 19 (35.85) 
Alcohol: 
  
yes 5 (6.33) 9 (16.98) 
no 48 (60.76) 26 (49.06) 
n/a 26 (32.91) 18 (33.96) 
Adherence 
  
good 70 (87.5) 43 (81.13) 
acceptable 6 (7.5) 7 (13.21) 
bad 3 (3.75) 2 (3.77) 
n/a 1 (1.25) 1 (1.89) 
Default 5 (6.33) 6 (11.32) 
Change in regimen 
  
No change 42 (53.16) 27 (50.94) 
Change 37 (46.84) 26 (49.06) 
More than once 9 (11.39) 7 (13.21) 
Regimen during sampling 
  
EFV/3TC/d4T 46 (58.23) 33 (62.26) 
EFV/3TC/AZT 21 (26.58) 9 (16.98) 
EFV/3TC/TDF 12 (15.19) 10 (18.87) 
n/a 0 (0.00) 1 (1.89) 
Second-line therapy 
  
yes 6 (7.59) 1 (1.89) 
no 73 (92.41) 52 (98.11) 
n/a 0 (0.00) 1 (1.89) 
Additional medication 
  
yes 18 (22.78) 13 (24 53) 
no 61 (77.22) 40 (75.47) 
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Appendix E: Regions of STRs in Amplicons UA2 and UA3 
 
The red coloured text regions indicate sites of STRs, resulting in enzyme slippage in a sequencing reaction. Blue shaded regions 
indicate the UA2 primer set. Green shaded regions indicate the UA3 primer set. The region shaded grey indicates the forward 
primer for Exon 1. 
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Appendix F: Chromatograms of SNPs identified through bi-directional sequencing. 
 
  
rs55802895 (258G>A) rs2501870 (432C>T) rs11584174 (548G>A) rs35709078 (7145C>T) 
rs141260451 (7393C>G) rs2502815 (9774C>T) rs35205211 (9892C>G) rs2307424 (10396C>T) 
rs2307420 (10445A>G) rs34859188 (13196T>C) rs35103872 (13220G>A) rs36017137 (13297G>A) 
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Appendix G: Gel photos of SNP genotypes 
NR1I3 SNPs: 
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NR1I2 SNPs: 
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Appendix H: Taqman® analysis plots for rs1523130 (5177T>C) 
Allelic discrimination plots: 
Allelic discrimination plots for all samples showing the change in fluorescence for the T-allele probe on the 
y-axis and the C-allele probe on the x-axis. 
 
Amplification plots: 
Amplification plots for three samples showing the change in fluorescence per PCR cycle for the two 
fluorescent probes specific for each allele, normalised to baseline. 
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Appendix I: LD plots for NR1I3 variants in the Xhosa and CMA cohorts 
LD values are represented in the blocks by correlation coefficient (r2) values. 
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Appendix J: Mean EFV levels for all NR1I3 and NR1I2 variants 
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Appendix K: Tables of allele frequencies according to treatment outcome and the presence of adverse drug reactions. 
Table K-1: Genotype frequencies and MAFs for NR1I3 and NR1I2 variants in the Xhosa and CMA cohorts for responders and non-responders 
 
rs number 
Genomic 
identification 
Genotype 
Xhosa CMA 
Gene Responders Non-Responders Responders Non-Responders 
 n 
(frequency) 
MAF 
n 
(frequency) 
MAF 
n 
(frequency) 
MAF 
n 
(frequency) 
MAF 
 
rs2307420 10445A>G 
AA 64 (0.914) 
0.028 
3 (0.600) 
0.083 
31 (0.861) 
0.028 
6 (0.857) 
0.042 NR1I3 AG 6 (0.086) 2 (0.040) 4 (0.111) 1 (0.143) 
 GG 0 (0.000) 0 (0.000) 1 (0.028) 0 (0.000) 
 
rs2307424 10396C>T 
CC 60 (0.857) 
0.047 
4 (0.800) 
0.042 
27 (0.750) 
0.052 
4 (0.571) 
0.167 NR1I3 CT 10 (0.143) 1 (0.200) 7 (0.194) 2 (0.286) 
 TT 0 (0.000) 0 (0.000) 2 (0.056) 1 (0.143) 
 
rs34161743 9923C>T 
CC 67 (0.957) 
0.014 
5 (1.000) 
0.000 
35 (1.000) 
0.000 
6 (0.857) 
0.042 NR1I3 CT 3 (0.043) 0 (0.000) 0 (0.000) 1 (0.143) 
 TT 0 (0.000) 0 (0.000) 0 (0.000) 0 (0.000) 
 
rs35205211 9892C>G 
CC 66 (0.985) 
0.005 
5 (1.000) 
0.000 
35 (0.972) 
0.005 
7 (1.000) 
0.000 NR1I3 CG 1 (0.015) 0 (0.000) 1 (0.028) 0 (0.000) 
 GG 0 (0.000) 0 (0.000) 0 (0.000) 0 (0.000) 
 
rs2502815 9774C>T 
CC 41 (0.594) 
0.156 
1 (0.200) 
0.208 
17 (0.486) 
0.104 
3 (0.429) 
0.208 NR1I3 CT 23 (0.333) 3 (0.600) 14 (0.400) 3 (0.429) 
 TT 5 (0.072) 1 (0.200) 4 (0.114) 1 (0.143) 
 
rs35709078 7145C>T 
CC 68 (0.971) 
0.009 
4 (0.800) 
0.042 
35 (0.972) 
0.005 
7 (1.000) 
0.000 NR1I3 CT 2 (0.029) 1 (0.200) 1 (0.028) 0 (0.000) 
 TT 0 (0.000) 0 (0.000) 0 (0.000) 0 (0.000) 
 
rs55802895 258G>A 
GG 59 (0.843) 
0.057 
4 (0.800) 
0.042 
33 (0.917) 
0.014 
5 (0.714) 
0.083 NR1I3 GA 10 (0.143) 1 (0.200) 3 (0.083) 2 (0.286) 
 AA 1 (0.014) 0 (0.000) 0 (0.000) 0 (0.000) 
 
rs1523130 5177T>C 
TT 54 (0.783) 
0.087 
5 (1.000) 
0.000 
20 (0.571) 
0.096 
5 (0.714) 
0.125 
NR1I2 TC 12 (0.174) 0 (0.000) 10 (0.286) 1 (0.143) 
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rs number 
Genomic 
identification 
Genotype 
Xhosa CMA 
Gene Responders Non-Responders Responders Non-Responders 
 n 
(frequency) 
MAF 
n 
(frequency) 
MAF 
n 
(frequency) 
MAF 
n 
(frequency) 
MAF 
 CC 3 (0.043) 0 (0.000) 5 (0.143) 1 (0.143) 
 
rs3814055 5705C>T 
CC 47 (0.701) 
0.113 
0 (0.000) 
0.208 
27 (0.771) 
0.042 
5 (0.714) 
0.083 NR1I2 CT 16 (0.239) 3 (0.750) 7 (0.200) 2 (0.286) 
 TT 4 (0.060) 1 (0.250) 1 (0.029) 0 (0.000) 
 
rs1523128 6334G>A 
GG 34 (0.493) 
0.190 
4 (0.800) 
0.042 
24 (0.667) 
0.062 
3 (0.429) 
0.208 NR1I2 GA 30 (0.435) 1 (0.200) 11 (0.306) 3 (0.429) 
 AA 5 (0.072) 0 (0.000) 1 (0.028) 1 (0.143) 
 
rs1523127 6709C>A 
CC 46 (0.676) 
0.120 
2 (0.400) 
0.167 
15 (0.429) 
0.125 
3 (0.429) 
0.208 NR1I2 CA 19 (0.279) 2 (0.400) 14 (0.400) 3 (0.429) 
 AA 3 (0.044) 1 (0.200) 6 (0.171) 1 (0.143) 
 
rs3842689 
7070_7075delG
AGAAG 
+/+ 47 (0.681) 
0.123 
1 (0.429) 
0.208 
26 (0.722) 
0.057 
5 (0.714) 
0.083 NR1I2 +/- 18 (0.261) 3 (0.429) 8 (0.222) 2 (0.286) 
 -/- 4 (0.058) 1 (0.143) 2 (0.056) 0 (0.000) 
 
rs2472677 24087C>T 
CC 27 (0.391) 
0.260 
2 (0.400) 
0.125 
18 (0.514) 
0.101 
0 (0.000) 
0.333 NR1I2 CT 30 (0.435) 3 (0.600) 13 (0.371) 6 (0.857) 
 TT 12 (0.174) 0 (0.000) 4 (0.114) 1 (0.143 
 
rs12721613 31846C>T 
CC 55 (0.797) 
0.066 
4 (0.800) 
0.042 
33 (0.917) 
0.014 
7 (1.000) 
0.000 NR1I2 CT 14 (0.203) 1 (0.200) 3 (0.083) 0 (0.000) 
 TT 0 (0.000) 0 (0.000) 0 (0.000) 0 (0.000) 
 
rs1464603 32019G>A 
GG 45 (0.643) 
0.123 
3 (0.600) 
0.125 
20 (0.556) 
0.085 
4 (0.571) 
0.167 NR1I2 GA 24 (0.343) 1 (0.200) 14 (0.389) 2 (0.286) 
 AA 1 (0.014) 1 (0.200) 2 (0.056) 1 (0.143) 
 
rs1464602 32042G>A 
GG 31 (0.443) 
0.226 
2 (0.400) 
0.167 
12 (0.353) 
0.149 
4 (0.571) 
0.167 NR1I2 GA 31 (0.443) 2 (0.400) 13 (0.382) 2 (0.286) 
 AA 8 (0.114) 1 (0.200) 9 (0.265) 1 (0.143) 
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rs number 
Genomic 
identification 
Genotype 
Xhosa CMA 
Gene Responders Non-Responders Responders Non-Responders 
 n 
(frequency) 
MAF 
n 
(frequency) 
MAF 
n 
(frequency) 
MAF 
n 
(frequency) 
MAF 
 
rs2276707 39823C>T 
CC 21 (0.304) 
0.295 
1 (0.200) 
0.208 
18 (0.514) 
0.110 
2 (0.286) 
0.250 NR1I2 CT 34 (0.493) 3 (0.600) 11 (0.314) 4 (0.571) 
 TT 14 (0.203) 1 (0.200) 6 (0.171) 1 (0.143) 
Genotype frequencies that differ significantly between responders and non-responders are indicated in bold. 
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Table K-2: Genotype frequencies and MAFs for NR1I3 and NR1I2 variants in the Xhosa and CMA cohorts for ADR and Non-ADR groups 
rs number 
Genomic 
identification 
Genotype 
Xhosa    CMA    
Non-ADR  ADR  Non-ADR  ADR  
n 
(frequency) 
MAF n 
(frequency) 
MAF n 
(frequency) 
MAF n 
(frequency) 
MAF 
rs2307420 10445A>G 
AA 61 (0.897)  9 (0.818)  43 (0.896)  4 (0.800)  
AG 7 (0.103) 0.051 2 (0.182) 0.091 4 (0.083) 0.063 1 (0.200) 0.100 
GG 0 (0.000)  0 (0.000)  1 (0.021)  0 (0.000)  
rs2307424 10396C>T 
CC 58 (0.853)  9 (0.818)  35 (0.729)  2 (0.400)  
CT 10 (0.147) 0.074 2 (0.182) 0.091 11 (0.229) 0.156 2 (0.400) 0.400 
TT 0 (0.000)  0 (0.000)  2 (0.042)  1 (0.200)  
rs34161743 9923C>T 
CC 65 (0.956)  11 (1.000)  46 (0.979)  5 (1.000)  
CT 3 (0.044) 0.022 0 (0.000) 0.000 1 (0.021) 0.011 0 (0.000) 0.000 
TT 0 (0.000)  0 (0.000)  0 (0.000)  0 (0.000)  
rs35205211 9892C>G 
CC 64 (0.985)  10 (0.909)  46 (0.979)  5 (1.000)  
CG 1 (0.015) 0.008 1 (0.091) 0.045 1 (0.021) 0.011 0 (0.000) 0.000 
GG 0 (0.000)  0 (0.000)  0 (0.000)  0 (0.000)  
rs2502815 9774C>T 
CC 39 (0.574)  4 (0.400)  22 (0.468)  2 (0.400)  
CT 23 (0.338) 0.257 5 (0.500) 0.350 20 (0.426) 0.319 3 (0.600) 0.300 
TT 6 (0.088)  1 (0.100)  5 (0.106)  0 (0.000)  
rs35709078 7145C>T 
CC 65 (0.956)  11 (1.000)  47 (0.979)  5 (1.000)  
CT 3 (0.044) 0.022 0 (0.000) 0.000 1 (0.021) 0.010 0 (0.000) 0.000 
TT 0 (0.000)  0 (0.000)  0 (0.000)  0 (0.000)  
rs55802895 258G>A 
GG 57 (0.838)  10 (0.909)  42 (0.875)  4 (0.800)  
GA 10 (0.147) 0.088 1 (0.091 0.045 6 (0.125) 0.063 1 (0.200) 0.100 
AA 1 (0.015)  0 (0.000)  0 (0.000)  0 (0.000)  
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rs number 
Genomic 
identification 
Genotype 
Xhosa    CMA    
Non-ADR  ADR  Non-ADR  ADR  
n 
(frequency) 
MAF n 
(frequency) 
MAF n 
(frequency) 
MAF n 
(frequency) 
MAF 
rs1523130 5177T>C 
TT 53 (0.791)  8 (0.727)  28 (0.583)  3 (0.750)  
TC 12 (0.179) 0.119 2 (0.182) 0.182 13 (0.271) 0.281 1 (0.250) 0.125 
CC 2 (0.030)  1 (0.091)  7 (0.146)  0 (0.000)  
rs3814055 5705C>T 
CC 44 (0.677)  4 (0.404)  37 (0.787)  5 (1.000)  
CT 16 (0.246) 0.200 5 (0.500) 0.350 9 (0.191) 0.117 0 (0.000) 0.000 
TT 5 (0.077)  1 (0.100)  1 (0.021)  0 (0.000)  
rs1523128 6334G>A 
AA 33 (0.493)  8 (0.727)  31 (0.646)  2 (0.400)  
AG 29 (0.433) 0.291 3 (0.273) 0.136 15 (0.313) 0.198 3 (0.600) 0.300 
GG 5 (0.075)  0 (0.000)  2 (0.042)  0 (0.000)  
rs1523127 6709C>A 
CC 43 (0.652)  7 (0.198)  20 (0.426)  3 (0.600)  
CA 20 (0.303) 0.197 3 (0.273) 0.227 18 (0.383) 0.383 2 (0.400) 0.200 
AA 3 (0.045)  1 (0.091)  9 (0.191)  0 (0.000)  
rs3842689 
7070_7075del
GAGAAG 
+/+ 45 (0.672)  5 (0.455)  37 (0.771)  4 (0.800)  
+/- 18 (0.269) 0.194 5 (0.455) 0.318 9 (0.188) 0.135 1 (0.200) 0.100 
-/- 4 (0.060)  1 (0.091)  2 (0.042)  0 (0.000)  
rs2472677 24087C>T 
CC 28 (0.418)  2 (0.182)  15 (0.333)  3 (0.600)  
CT 30 (0.448) 0.358 5 (0.455) 0.591 25 (0.556) 0.389 2 (0.400) 0.200 
TT 9 (0.134)  4 (0.364)  5 (0.111)  0 (0.000)  
rs12721613 31846C>T 
CC 54 (0.806)  9 (0.818)  44 (0.917)  5 (1.000)  
CT 13 (0.194) 0.097 2 (0.182) 0.091 4 (0.083) 0.042 0 (0.000) 0.000 
TT 0 (0.000)  0 (0.000)  0 (0.000)  0 (0.000)  
rs1464603 32019G>A 
GG 46 (0.677)  5 (0.455)  29 (0.604)  3 (0.600)  
GA 20 (0.294) 0.176 6 (0.545) 0.273 16 (0.333) 0.229 2 (0.400) 0.200 
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rs number 
Genomic 
identification 
Genotype 
Xhosa    CMA    
Non-ADR  ADR  Non-ADR  ADR  
n 
(frequency) 
MAF n 
(frequency) 
MAF n 
(frequency) 
MAF n 
(frequency) 
MAF 
AA 2 (0.029)  0 (0.000)  3 (0.063)  0 (0.000)  
rs1464602 32042G>A 
GG 31 (0.456)  5 (0.455)  19 (0.413)  2 (0.400)  
GA 28 (0.412) 0.273 6 (0.545) 0.273 17 (0.370) 0.402 2 (0.400) 0.400 
AA 9 (0.132)  0 (0.000)  10 (0.217)  1 (0.200)  
rs2276707 39823C>T 
CC 17 (0.254)  6 (0.545)  21 (0.447)  2 (0.400)  
CT 37 (0.552) 0.470 3 (0.273) 0.318 17 (0.632) 0.372 3 (0.600) 0.300 
TT 13 (0.194)  2 (0.182)  9 (0.191)  0 (0.000)  
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Appendix L:  Association analysis between composite genotypes and efavirenz levels 
using logistic regression models 
Gene rs number 
Genotypic 
identification 
P-value Quantitative effect on EFV levels 
CYP2B6*6 (516G>T) 
NR1I3 rs2307420 10445A>G 0.393 n/a 
NR1I3 rs2307424 10396C>T 0.856 n/a 
NR1I3 rs34161743 9923C>T n/a n/a 
NR1I3 rs35205211 9892C>G n/a n/a 
NR1I3 rs2502815 9774C>T 0.945 n/a 
NR1I3 rs3003596 8784T>C 0.192 n/a 
NR1I3 rs35709078 7145C>T 0.617 n/a 
NR1I3 rs55802895 258G>A 0.005 
161% ↑ from *6*6|258GG to Non-*6*6|258GG 
No significant difference from *6*6|258GA to Non-
*6*6|258GA 
NR1I2 rs1523130 5177T>C 0.778 n/a 
NR1I2 rs3814055 5705C>T 0.783 n/a 
NR1I2 rs1523128 6334G>A 0.524 n/a 
NR1I2 rs1523127 6709C>A 0.401 n/a 
NR1I2 rs3842689 
7070_7075delG
AGAAG 
0.755 n/a 
NR1I2 rs2472677 24087C>T 0.634 n/a 
NR1I2 rs12721613 31846C>T 0.365 n/a 
NR1I2 rs1464603 32019G>A 0.331 n/a 
NR1I2 rs1464602 32042G>A 0.361 n/a 
NR1I2 rs2276707 39823C>T 0.877 n/a 
CYP1A2*1F (163C>A) 
NR1I3 rs2307420 10445A>G 0.681 n/a 
NR1I3 rs2307424 10396C>T 0.152 n/a 
NR1I3 rs34161743 9923C>T 0.648 n/a 
NR1I3 rs35205211 9892C>G 0.068 n/a 
NR1I3 rs2502815 9774C>T 0.026 
436% ↑ from 163CC|9774CT to 163CC|977CC 
390% ↑ from 163CC|9774TT to 163CC|977CC 
NR1I3 rs3003596 8784T>C 0.316 n/a 
NR1I3 rs35709078 7145C>T n/a n/a 
NR1I3 rs55802895 258G>A 0.269 n/a 
NR1I2 rs1523130 5177T>C 0.130 n/a 
NR1I2 rs3814055 5705C>T 0.122 n/a 
NR1I2 rs1523128 6334G>A 0.635 n/a 
NR1I2 rs1523127 6709C>A 0.153 n/a 
NR1I2 rs3842689 
7070_7075delG
AGAAG 
0.017 
36% ↑ from 163AC|+/- to 163AC|+/+ 
263% ↑ from 163|-/- to 163AC|+/+ 
NR1I2 rs2472677 24087C>T 0.354 n/a 
NR1I2 rs12721613 31846C>T 0.026 86% ↓ from 163CC|31846CT to 163AA|31846CT 
NR1I2 rs1464603 32019G>A 0.682 n/a 
NR1I2 rs1464602 32042G>A 0.210 n/a 
NR1I2 rs2276707 39823C>T 0.030 no definable pattern detected 
CYP2A6*9B (48T>G) 
NR1I3 rs2307420 10445A>G 0.007 464% ↑ from 48 TG|10445AA to 48 TG|10445AG 
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NR1I3 rs2307424 10396C>T n/a n/a 
NR1I3 rs34161743 9923C>T n/a n/a 
NR1I3 rs35205211 9892C>G n/a n/a 
NR1I3 rs2502815 9774C>T 0.470 n/a 
NR1I3 rs3003596 8784T>C 0.599 n/a 
NR1I3 rs35709078 7145C>T n/a n/a 
NR1I3 rs55802895 258G>A n/a n/a 
NR1I2 rs1523130 5177T>C 0.483 n/a 
NR1I2 rs3814055 5705C>T 0.605 n/a 
NR1I2 rs1523128 6334G>A 0.984 n/a 
NR1I2 rs1523127 6709C>A 0.121 n/a 
NR1I2 rs3842689 
7070_7075delG
AGAAG 
0.409 n/a 
NR1I2 rs2472677 24087C>T 0.872 n/a 
NR1I2 rs12721613 31846C>T n/a n/a 
NR1I2 rs1464603 32019G>A 0.021 215% ↑ from 48TG|32019GG  to 48TG|32019AG 
NR1I2 rs1464602 32042G>A 0.046 465% ↑ from 48TG|32042GG to 48TG|32042GA 
NR1I2 rs2276707 39823C>T 0.676 n/a 
CYP3A5*6 (14690G>A) 
NR1I3 rs2307420 10445A>G 0.207 n/a 
NR1I3 rs2307424 10396C>T 0.960 n/a 
NR1I3 rs34161743 9923C>T 0.650 n/a 
NR1I3 rs35205211 9892C>G n/a n/a 
NR1I3 rs2502815 9774C>T 0.911 n/a 
NR1I3 rs3003596 8784T>C 0.907 n/a 
NR1I3 rs35709078 7145C>T n/a n/a 
NR1I3 rs55802895 258G>A 0.590 n/a 
NR1I2 rs1523130 5177T>C 0.247 n/a 
NR1I2 rs3814055 5705C>T 0.639 n/a 
NR1I2 rs1523128 6334G>A 0.312 n/a 
NR1I2 rs1523127 6709C>A 0.118 n/a 
NR1I2 rs3842689 
7070_7075delG
AGAAG 
0.426 n/a 
NR1I2 rs2472677 24087C>T 0.289 n/a 
NR1I2 rs12721613 31846C>T 0.353 n/a 
NR1I2 rs1464603 32019G>A 0.888 n/a 
NR1I2 rs1464602 32042G>A 0.907 n/a 
NR1I2 rs2276707 39823C>T 0.825 n/a 
CYP2A6*17 (5065G>A) 
NR1I3 rs2307420 10445A>G 0.172 n/a 
NR1I3 rs2307424 10396C>T 0.688 n/a 
NR1I3 rs34161743 9923C>T n/a n/a 
NR1I3 rs35205211 9892C>G n/a n/a 
NR1I3 rs2502815 9774C>T 0.442 n/a 
NR1I3 rs3003596 8784T>C 0.700 n/a 
NR1I3 rs35709078 7145C>T 0.424 n/a 
NR1I3 rs55802895 258G>A 0.266 n/a 
NR1I2 rs1523130 5177T>C 0.971 n/a 
NR1I2 rs3814055 5705C>T 0.832 n/a 
NR1I2 rs1523128 6334G>A 0.904 n/a 
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NR1I2 rs1523127 6709C>A 0.990 n/a 
NR1I2 rs3842689 
7070_7075delG
AGAAG 
0.723 n/a 
NR1I2 rs2472677 24087C>T 0.516 n/a 
NR1I2 rs12721613 31846C>T 0.090 n/a 
NR1I2 rs1464603 32019G>A 0.743 n/a 
NR1I2 rs1464602 32042G>A 0.003 no definable pattern detected 
NR1I2 rs2276707 39823C>T 0.813 n/a 
CYP3A4*1B (392A>G) 
NR1I3 rs2307420 10445A>G 0.664 n/a 
NR1I3 rs2307424 10396C>T 0.975 n/a 
NR1I3 rs34161743 9923C>T 0.673 n/a 
NR1I3 rs35205211 9892C>G 0.809 n/a 
NR1I3 rs2502815 9774C>T 0.587 n/a 
NR1I3 rs3003596 8784T>C 0.569 n/a 
NR1I3 rs35709078 7145C>T 0.602 n/a 
NR1I3 rs55802895 258G>A 0.665 n/a 
NR1I2 rs1523130 5177T>C 0.011 
64% ↑ from 392GG|5177TT to 392GG|5177TC  
66% ↓ from 392AG|5177TT to 392AG|5177CC 
NR1I2 rs3814055 5705C>T 0.246 n/a 
NR1I2 rs1523128 6334G>A 0.686 n/a 
NR1I2 rs1523127 6709C>A 0.093 n/a 
NR1I2 rs3842689 
7070_7075delG
AGAAG 
0.084 n/a 
NR1I2 rs2472677 24087C>T 0.658 n/a 
NR1I2 rs12721613 31846C>T 0.686 n/a 
NR1I2 rs1464603 32019G>A 0.961 n/a 
NR1I2 rs1464602 32042G>A 0.963 n/a 
NR1I2 rs2276707 39823C>T 0.125 n/a 
CYP3A5*3 (6986A>G) 
NR1I3 rs2307420 10445A>G 0.077 n/a 
NR1I3 rs2307424 10396C>T 0.495 n/a 
NR1I3 rs34161743 9923C>T 0.641 n/a 
NR1I3 rs35205211 9892C>G 0.060 n/a 
NR1I3 rs2502815 9774C>T 0.572 n/a 
NR1I3 rs3003596 8784T>C 0.436 n/a 
NR1I3 rs35709078 7145C>T n/a n/a 
NR1I3 rs55802895 258G>A 0.461 n/a 
NR1I2 rs1523130 5177T>C 0.669 n/a 
NR1I2 rs3814055 5705C>T 0.056 n/a 
NR1I2 rs1523128 6334G>A 0.265 n/a 
NR1I2 rs1523127 6709C>A 0.649 n/a 
NR1I2 rs3842689 
7070_7075delG
AGAAG 
0.008 
105% ↑ from 6986AG|+/+ to 6986AG|+/-  
199% ↑ from 6986AG|+/+ to 6986AG|-/-  
NR1I2 rs2472677 24087C>T 0.834 n/a 
NR1I2 rs12721613 31846C>T n/a n/a 
NR1I2 rs1464603 32019G>A 0.068 n/a 
NR1I2 rs1464602 32042G>A 0.229 n/a 
NR1I2 rs2276707 39823C>T 0.023 126% ↑ from 6986AG|39823CC to 6986AG|39823TT 
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Appendix M: Analysis of the effect of genotype on treatment outcome and adverse 
reactions 
Gene rs number 
Genomic  
identification 
P-Value  
   
Treatment 
Outcome 
ADRs 
NR1I3 rs2307420 10445A>G 0.2893 0.4724 
NR1I3 rs2307424 10396C>T 0.4911 0.2902 
NR1I3 rs34161743 9923C>T 0.5136 0.3292 
NR1I3 rs35205211 9892C>G 0.6674 0.3244 
NR1I3 rs2502815 9774C>T 0.1831 0.2244 
NR1I3 rs3003596 8784T>C 0.7856 0.2845 
NR1I3 rs35709078 7145C>T 0.0631 0.5152 
NR1I3 rs55802895 258G>A 0.3011 0.9351 
NR1I2 rs1523130 5177T>C 0.1842 0.9486 
NR1I2 rs3814055 5705C>T 0.3843 0.6089 
NR1I2 rs1523128 6334G>A 0.9342 0.0675 
NR1I2 rs1523127 6709C>A 0.8016 0.9903 
NR1I2 rs3842689 7070_7075delGAGAAG 0.4283 0.4756 
NR1I2 rs2472677 24087C>T 0.1180 0.3833 
NR1I2 rs12721613 31846C>T 0.9555 0.4012 
NR1I2 rs1464603 32019G>A 0.7220 0.0958 
NR1I2 rs1464602 32042G>A 0.1260 0.3809 
NR1I2 rs2276707 39823C>T 0.2316 0.5780 
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